Drug, bio-affecting and body treating compositions inventions 04/09

20090110632 - Biological materials and uses thereof: There is provided by the invention a modified antibody molecule which selectively binds to a specific target, the antibody molecule being modified at, at least one amino acid residue that forms part of a glycosylation site in the variable region of an unmodified parent antibody molecule, characterised in that the... Agent: Jaeckle Fleischmann & Mugel, LLP

20090110633 - Nanocells for diagnosis and treatment of diseases and disorders: The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells... Agent: Sutherland Asbill & Brennan LLP

20090110634 - Radiolabelled nanoparticles: The present invention relates to radiolabelled nanoparticles having a radioisotope non-covalently bonded thereto. The radiolabelled nanoparticles are useful as radiopharmaceuticals. Kits and methods of preparation of the radiolabelled nanoparticles are also disclosed.... Agent: Ge Healthcare, Inc.

20090110635 - Methods for imaging dopamine transporter level: Presented is a method for assessing dopamine transporter levels in a selected area of a subject's central nervous system by SPECT imaging comprising administering an injection of a labeled dopamine transporter ligand at approximately the time the subject is positioned for SPECT imaging and initiating a SPECT acquisition for a... Agent: Seyfarth Shaw LLP

20090110636 - Fluorinated dihydrotetrabenazine ether imaging agents and probes: wherein R1 is a C2-C10 fluorinated aliphatic radical; R2 is a C1-C10 aliphatic radical, or a C3-C10 cycloaliphatic radical; R3 is hydrogen or a C1-C10 aliphatic radical; and R4 is hydrogen or a C1-C10 aliphatic radical. The fluorinated ether compounds are provided in both racemic and enantiomerically enriched forms and... Agent: General Electric Company Global Research

20090110637 - Lmp and regulation of tissue growth: Novel methods are provided for changing cell phenotype, comprising a method of changing a phenotype of a target cell comprising: increasing an amount of an amino acid sequence in a source cell, wherein the source cell is located within a volume of a media and wherein the amino acid sequence... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090110638 - Methods using the grueneberg ganglion chemosensory system: The present invention relates to physical and pharmaceutical methods of increasing or decreasing the activity of the Grueneberg Ganglion (GG) in a subject. In one embodiment, the method comprising administering a compound to the GG, wherein the compound is an agonist or antagonist, respectively, for at least one guanylyl cyclase... Agent: Morgan Lewis & Bockius LLP

20090110639 - Predicting vaccine efficacy: The present invention provides methods for evaluating a vaccine, combinations of tests and reaction mixtures that can be used as part of such methods, and collections of results comprising results obtained from such methods. The methods, combinations, and collections are useful for determining whether a vaccine is effective and, for... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090110640 - Contrast agents for magnetic resonance imaging and spectroscopy consisting of a cyclic oligoamid core of 3 to 4 identicial monomer units with 3 to 4 paramagnetic chelate side chains: The present invention relates to: Compounds of formula (I) consisting of a cyclic polymer core A and groups -L-X attached to said core A-(L-X)n (I) wherein A denotes a cyclic polymer which is comprised of 3 or 4 identical monomers which are connected by amide bonds; L may be present... Agent: Ge Healthcare, Inc.

20090110642 - Method for the production of bio-imaging nanoparticles with high yield by early introduction of irregular structure: Methods of preparing bio-imaging nanoparticles having high dispersibility in an aqueous solution, biocompatibility, and targetability with high yield, by early introduction of an irregular structure are disclosed.... Agent: Jones Day

20090110644 - Polymer nanoparticles coated by magnetic metal oxide and uses thereof: The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the polymer, said nanoparticles may optionally further comprise at least one active agent physically or covalently bound to the outer... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090110643 - Method of producing liposomes containing gas enclosed therein: Gas-filled liposomes that are useful for ultrasonography and ultrasound therapy are provided. A method of producing the gas-filled liposomes, including filling the void space in a sealed container containing a liposome suspension in a volume amounting to 20 to 80% of the inner capacity thereof with a fluoride gas or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090110641 - Method and apparatus for non-invasive measurement of skin tissue cholesterol: The present invention provides a method and apparatus for non-invasive measurement of skin cholesterol. More particularly, one aspect of the invention provides for a device to apply a detector reagent to a selected area of skin. Another an indicator device to produce a visual change corresponding to the amount of... Agent: Bereskin And Parr

20090110645 - Use of metal astringents for the treatment and prevention of hairy heel warts: A system and method for treating hoof related diseases, particularly hairy heel warts (papillomatus digital dermatitis), includes an aqueous solution having a metal astringent at a therapeutically effective concentration. The metal astringent includes aluminum, iron, and mixtures thereof. In preferred embodiments, the metal may include a mixture of monomeric and... Agent: Ecolab Inc.

20090110646 - Product for treating the skin and mucous membranes, and relative method of preparation: A method for preparing a product for treating the skin and mucous membranes comprises the steps of making available a suitable quantity of trichloracetic acid, making available a suitable quantity of hydrogen peroxide, making a first mixture of the trichloracetic acid and the hydrogen peroxide, making available a determinate quantity... Agent: Flaster/greenberg P.C. 8 Penn Center

20090110647 - Method of preventing adverse effects by glp-1: A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as... Agent: K&l Gates LLP

20090110648 - Chocolate flavored dentifrice with new visuals: A multi-phase dentifrice composition is provided, comprising an orally acceptable carrier and a chocolate flavoring, wherein, using the CIE L*a*b* color scale, a first phase of the composition has an L* value of at least about 75, an a* value from about −8 to about 8, and a b* value... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090110649 - Antipruritic cosmetic and dermatological preparations: A topical cosmetic or dermatological preparation which is effective for treating a pruritic condition, is present as a non-ionic O/W emulsion, and comprises water, one or more oil phases, PEG 12 cetearylether and/or PEG 40 monostearate, polidocanol, menthol, and one or more O/W emulsifiers or co-emulsifiers.... Agent: Greenblum & Bernstein, P.L.C

20090110650 - Photoprotective composition and screening agents for said composition: The present invention concerns a photoprotective composition comprising at least one interferential screening agent screening UVA and/or UVB.... Agent: Oliff & Berridge, PLC

20090110651 - Cosmetic composition comprising a combination of a sugar fatty acid ester with a plant extract of waltheria indica or pisum sativum for skin whitening: The invention is directed to a skin-whitening active comprising at least one sugar fatty acid ester and at least one plant extract selected from the group consisting of extracts of Waltheria indica, extracts of Pisum sativum and mixtures thereof. The invention is further directed to cosmetic compositions comprising such a... Agent: Fox Rothschild LLP

20090110652 - Polyglycerol dimer polyester resins: The present invention relates to a series of novel polyesters that are prepared by crosslinking polyglycerol and dimer acid. The nature of the water loving polyglycerol group as well as the fact that a C-36 fatty diacid is used in preparation of the products results in unique products.... Agent: Anthony J O'lenick Jr

20090110653 - Fluoro silicone polyester resins: The present invention relates to a series of novel silicone polyesters which are prepared by crosslinking an fluoro dimethicone copolyol with a dimer acid. The reaction of the fluoro dimethicone copolyol and dimer acid results in a polyester having affinity to oils and that is highly lubricious on hair, skin... Agent: Anthony J O'lenick Jr

20090110654 - Bio-plastic composite material, method of making same, and method of using same: A bio-plastic composite comprises at least one biological material and one plastic material. The biological material in the bio-plastic composite is hydrolyzed, classified, or cryogenically ground for enhanced integration with the plastic material. A bio-odor generated during process of making bio-plastic composites is counter acted or masked by integrating odor... Agent: Buchanan Ingersoll & Rooney P.C. One Oxford Centre

20090110655 - Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis: The present invention provides a method for the treatment of nonalcoholic steatohepatitis with a pharmaceutically acceptable anion exchange resin such as, for example, colestimide.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090110656 - Skin cooling composition: A cooling composition for application to the skin of a mammal, such as a human. The base of the composition is an interpenetrating polymer network, which may contain a thermo-responsive polymer. Having a Critical Temperature above an average core body temperature, the material may undergo a phase change as the... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20090110657 - Skin care compositions: Provided are compositions which are suitable for topical application to mammalian skin for cleansing and anti-microbial properties. In one embodiment, the compositions include an ester of polyalkylene glycol monoazelate monolaurate. It is postulated that bacteria on or in the skin may cleave the ester linkage of a compound according to... Agent: Christopher J. Whewell

20090110658 - Antifouling condensation curing organopolysiloxane composition, making method, and underwater structure: An antifouling condensation curing organopolysiloxane composition is prepared by premixing a part or all of (A) a diorganopolysiloxane free of a reactive group with a part or all of (B) silica to form a premix, then mixing the premix with the remainder of (A) and (B), (C) a base diorganopolysiloxane,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090110659 - Human chemotactic cytokine: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a... Agent: Mcdermott Will & Emery LLP

20090110660 - Combination of an anti-ed - b fibronectin domain antibody - il-2 fusion protein and gemcitabine: The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognising the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.... Agent: Millen, White, Zelano & Branigan, P.C.

20090110661 - Novel gene therapy approach for treating the metabolic disorder obesity: The present application relates to novel methods for treating obesity. Some aspects pertain to the use of gene therapy to treat diseases related to metabolic dysfunction, such as diabetes, obesity, high blood pressure, and atherogenic dyslipidemia. The present application also pertains to the use of vectors such as a recombinant... Agent: Nutter Mcclennen & Fish LLP

20090110662 - Modification of biological targeting groups for the treatment of cancer: The present invention relates to the field of polymer chemistry and more particularly to click-functionalized targeting compounds and methods for using the same.... Agent: Choate, Hall & Stewart LLP

20090110663 - Method for treatment of bowel disorders: A composition and method for treatment for bowel disorders is described. The composition consists of two parts. First, highly purified, insoluble, chemically unmodified fiber from plants is mixed with an aqueous solution such as water. The second component of the composition is a commercially available probiotic preparation. These commercially probiotic... Agent: David G. Moore Strasburger & Price, LLP

20090110664 - Probiotic compositions and methods for inducing and supporting weight loss: A probiotic composition for inducing or supporting weight loss in a subject, the probiotic composition including an effective amount of a bacteria selected from the genus Bacteroides and a carrier for delivering the bacteria to the subject.... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090110670 - Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter: Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the... Agent: Lynn E Barber

20090110665 - Reovirus for the treatment of neoplasia: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type... Agent: Fish & Richardson P.C.

20090110667 - Detection and treatment of autoimmune disorders: Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing the involving a PD1 ligand.... Agent: Knobbe Martens Olson & Bear LLP

20090110666 - Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours: The invention described herein refers to derivatives of the long pentraxin PTX3 with the sequence indicated in the text, capable of binding to the membranes of inactivated tumour cells. The inactivated tumour cells, bearing on their surface a derivative of PTX3 are used to prepare an autologous vaccine for the... Agent: Nixon & Vanderhye, PC

20090110669 - Methods for improving cell line activity in immunoisolation devices: Methods for maintaining and improving the secretory activity of cells housed in immunoisolation devices.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090110668 - Subpopulations of bone marrow-derived adherent stem cells and methods of use therefor: The presently disclosed subject matter provides an isolated subpopulation of bone marrow-derived adherent stem cells that are purified from bone marrow-derived adherent cells. Also provided are methods for isolating the subpopulation of bone marrow-derived adherent stem cells from bone marrow-derived adherent cells and for using the isolated subpopulation of bone... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090110671 - Agent for enhanching the production of collagen and it's use: The present invention has an object to provide a means for durably exerting an action of enhancing collagen-production, and the object is attained by providing a collagen-production enhancer which contains, as an effective ingredient, α,α-trehalose and/or a saccharide derivative thereof, and by a composition incorporated with the collagen-production enhancer to... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090110672 - Angiogenic tyrosyl trna synthetase compositions and methods: The present invention provides an isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant which comprises (a) a Rossmann fold region or a portion thereof, preferably including an 5 coil; and (b) an anticodon recognition domain or portion thereof, preferably including an 14 coil. Preferably, the 5 coil and the 14 coil... Agent: Olson & Cepuritis, Ltd.

20090110673 - Methods of reducing cell death following hypoxia / reoxygenation: Provided are methods of reducing cell death, attenuating a burst of reactive oxygen species, reducing cytotoxicity, reducing intracellular oxidant stress due species in a population of cells following hypoxia by reoxygenating the cells in the presence of a reversible electron transport chain inhibitor or under hypercarbic conditions. Also provided is... Agent: Michael Best & Friedrich LLP

20090110674 - Health supplement: A health supplement consisting of numerous ingredients from several general groups including: anti-aging, anti-oxidant, vitamins, minerals, and elemental substances including metals. The supplement is specifically formulated for maximizing synergistic interaction of the ingredients while eliminating harmful interaction among the ingredients. A holistic approach to health is followed with ingredients to... Agent: Williams G. Sykes

20090110675 - Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis: A method for determining a patient's susceptibility to anaphylaxis comprises assaying the activity of platelet activating factor acetylhydrolase (PAF-AH) activity and comparing the measured activity to a reference value, wherein the level of PAF-AH activity inversely correlates with the susceptibility to anaphylaxis. The method further comprises determining the severity of... Agent: Blake, Cassels & Graydon LLP

20090110676 - Baff, inhibitors thereof and their use in the modulation of b-cell response and treatment of autoimmune disorders: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.... Agent: Biogen Idec / Finnegan Henderson, LLP

20090110677 - Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same: e

20090110679 - Methods and compositions for pulmonary administration of a tnfa inhibitor: The invention describes methods of pulmonary delivery of a TNFα inhibitor to a subject having a disorder in which TNFα is detrimental, such that the disorder is treated. Also included is a method of achieving systemic circulation of a TNFα inhibitor in a subject comprising administering the TNFα inhibitor to... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090110678 - Receptor antagonists for treatment of metastatic bone cancer: The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090110680 - Combination of an anti ed-b fibronectin domain antibody and gemcitabine: Disclosed is a combination of an anti edb fibronectin domain antibody and gemcitabine.... Agent: Millen, White, Zelano & Branigan, P.C.

20090110681 - Anti-m-csf antibody compositions: The present invention provides for compositions of anti-M-CSF antibodies comprising a chelating agent and/or histidine. Also provided are methods of treating M-CSF-mediated disorders with pharmaceutical formulations of anti-M-CSF anti-bodies, including inflammatory diseases and neoplasia disorders.... Agent: Pharmacia Corporation Global Patent Department

20090110682 - Antibody having inhibitory effect on amyloid fibril formation: Disclosed is an antibody having a high inhibitor effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation... Agent: Edwards Angell Palmer & Dodge LLP

20090110683 - Monoclonal antibodies against activated protein c: The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening... Agent: Fulbright & Jaworski L.L.P.

20090110684 - Neutralizing monoclonal antibodies to respiratory syncytial virus: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated... Agent: Dickstein Shapiro LLP

20090110685 - Treatment and prevention of viral infections: Disclosed is polynucleotide encoding a polypeptide comprising an antibody binding site, the polypeptide being able to bind to HCV E2 samples representative of each of HCV genotypes 1-6, as well as polypeptides having such properties and uses of such polypeptides in detecting and treating HCV infection.... Agent: Morrison & Foerster LLP

20090110686 - Antibodies against ccr5 and uses thereof: An antibody binding to CCR5 characterized in that the heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 1, and has advantageous properties for the treatment of immunosuppressive diseases.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090110687 - Compositions and methods related to tim 3, a th1-specific cell surface molecule: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed... Agent: David S. Resnick

20090110688 - Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor: e

20090110689 - Immunosuppression compound and treatment method: A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID... Agent: King & Spalding LLP

20090110690 - Hiv gp120 crystal structure and its use to identify immunogens: The present disclosure relates to stabilized forms of the HIV gp120 envelope protein in complex with the broadly neutralizing CD4-binding site antibody b12, to crystalline forms of the stabilized forms of the HIV gp120 envelope protein in complex with the broadly neutralizing CD4-binding site antibody b12, and to the high... Agent: Klarquist Sparkman, LLP

20090110691 - Ehrlichia canis diva (differentiate infected from vaccinated animals): The invention provides Ehrlichia canis antigens that can be used to detect E. canis infected animals regardless of whether the animals have been vaccinated for E. canis. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090110692 - Isolated complexes of endotoxin and modified md-2: Applicants have produced and isolated water soluble complexes of endotoxin and modified MD-2.... Agent: Viksnins Harris & Padys Pllp

20090110693 - Multimeric complexes of antigens and an adjuvant: The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ... Agent: Banner & Witcoff, Ltd.

20090110694 - Anti-inflammatory proteins and improved vaccines: A recombinant poxvirus lacking a functional gene corresponding to BI4R in the WR strain of VACV for use as a medicament especially as a vaccine against a disease caused by a poxvirus or another pathogenic agent or for use as a medicament against a disease associated with aberrant cells. An... Agent: Leon R. Yankwich

20090110695 - Compositions comprising a recombinant adenovirus and an adjuvant: The invention relates to pharmaceutical compositions comprising replication-defective adenoviruses, said adenoviruses generally comprising an adenoviral genome wherein a heterologous nucleic acid of interest is incorporated, and wherein said nucleic acid typically encodes an antigen. Such compositions are suitable for vaccination purposes. The pharmaceutical compositions of the present invention further comprise... Agent: Trask Britt

20090110696 - Mycobacterial seca2 mutants: Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that... Agent: Amster, Rothstein & Ebenstein LLP

20090110697 - Inactivated bovine herpes virus-1 and methods: This invention related to a method of immunizing cattle to reduce the effects of infection by bovine herpes virus 1, including abortion and stillbirth, by administering inactivated bovine herpes virus 1 prior to breeding.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090110698 - Method of determining vaccine compliance: A protein (xylanase) has been identified that produces a strong immune response in pigs when added to a vaccine. The protein is added to vaccines at a particular concentration. The protein is delivered to the animal as part of the vaccine and elicits an immune reaction (antibodies are generated by... Agent: Briggs And Morgan P.A.

20090110699 - Antigen-adjuvant compositions and methods: Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine compositions, and kits containing the vitreous compositions. Also disclosed are devices for administering the vitreous compositions to... Agent: Sanofi Pasteur, Inc.

20090110700 - Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis: The invention concerns an acellular immunogenic or vaccine composition for producing antibodies against Bacillus anthracis comprising a protective antigen (PA) and killed and optionally purified spores, obtained from mutating strains of Bacillus anthracis and their uses.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090110701 - T-cell modulation: The invention provides methods and materials for use in modulating T cell activation, based on the production and secretion of soluble cytotoxic T-lymphocyte antigen-4 (sCTLA-4) by cells of the immune system. The method involves stimulating secretion of endogenous sCTLA-4 by T cells, which have preferably previously been exposed to an... Agent: Speckman Law Group PLLC

20090110702 - Mesothelin vaccines and model systems and control of tumors: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and... Agent: Banner & Witcoff, Ltd.

20090110704 - Cosmetic composition based on a magnetic or magnetisable material, the preparation thereof and use thereof for cleansing the epidermis: The present invention relates to a cosmetic composition based on a magnetic or magnetisable material, the preparation thereof and use thereof for surface and deep cleansing of the epidermis. Said cosmetic composition has revealed to be particularly useful for preparing a mask for cleansing the epidermis of the face, breast,... Agent: Pearne & Gordon LLP

20090110703 - Cosmetic composition comprising polyorganosiloxane and uses thereof: The invention relates to a cosmetic composition comprising a cosmetically acceptable vector and polyorganosiloxane. The polyorganosiloxane comprises a group that includes a sterically hindered amine.... Agent: Hunton & Williams LLP Intellectual Property Department

20090110705 - Moisturizers comprising one or more of gamma-polyglutamic acid (gamma-pga, h form), gamma-polyglutamates and gamma-polyglutamate hydrogels for use in cosmetic or personal care products: The present invention relates to a moisturizer comprising γ-polyglutamic acid (γ-PGA, H form), and/or one or more of its salts (i.e., γ-polyglutamate in Na+ form, γ-polyglutamate in K+ form, γ-polyglutamate in NH4+ form, γ-polyglutamate in Mg++ form, γ-polyglutamate in Ca++ form) and/or γ-polyglutamate hydrogel, wherein said moisturizer is used in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090110706 - Pain relief composition and utilization thereof: A titanium-impregnated tape uses a material treated by fine dispersion water containing citric acid or its salt in which fine metal titanium particles are dispersed. The titanium-impregnated tape provides a physiological structure that acts upon the function to interfere with the pain memory system affecting neurons.... Agent: Knobbe Martens Olson & Bear LLP

20090110708 - Animate tissue antisepsis: A method and device provide for inactivating microorganisms on tissue exposed through a surgical incision. The method includes the steps of: applying a coating of a solution comprising hydrogen peroxide to the tissue; and force drying the solution on the tissue so as to concentrate the solution on the tissue.... Agent: K&l Gates LLP

20090110707 - Methods for producing pesticide compositions: Disclosed are compositions and methods related to powder and granular emulsifiable concentrate pesticide formulations. As disclosed, emulsions from non-aqueous based liquid or solvent soluble pesticide actives may be prepared using a high purity, high molecular weight sulfonated lignin as the emulsion stabilizer. The resulting emulsions may then be dried to... Agent: M. Scott Mcbride, Ph.d. Andrus, Sceales, Starke & Sawall, LLP

20090110709 - Elastin protective polyphenolics and methods of using the same: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for... Agent: Pepper Hamilton LLP

20090110713 - Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices: The present invention is directed to polymeric materials (e.g., coatings) comprising biodegradable copolymers and implantable devices (e.g., drug-delivery stents) formed of such materials. The biodegradable copolymers are derived from at least two relatively polar monomers and at least one relatively nonpolar monomer. Incorporation of at least one relatively nonpolar monomer... Agent: Squire, Sanders & Dempsey LLP

20090110710 - Devices and methods for treating defects in the tissue of a living being: An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery. Additionally, the implant may be “matched” to provide the implant with similar physical and/or chemical... Agent: Jeffrey C. Kelly

20090110711 - Implantable device having a slow dissolving polymer: The present invention provides an implantable device having a coating including a slow dissolving polymer or material and the methods of making and using the same.... Agent: Squire, Sanders & Dempsey LLP

20090110712 - Methods and systems for use of photolyzable nitric oxide donors: The present disclosure relates to methods and systems for use of photolyzable nitric oxide donors for the treatment of sexual dysfunction.... Agent: Searete LLC Clarence T. Tegreene

20090110714 - Medical or veterinary digestive tract utilization systems and methods: Systems and methods are described for implementing or deploying medical or veterinary utility modules comprising a first module operable in a digestive or respiratory tract to engage a second module, optionally by a magnetic field. Alternatively or additionally, systems may be operable to remain in situ and also operable to... Agent: Searete LLC Clarence T. Tegreene

20090110715 - Edible film package having product for oral intake enclosed therein: This invention provides an edible film packaging 1 containing an edible film material 10 which has adhesion properties and is softened upon contact with moisture. The edible film packaging 1 is taken or had-or-swallowed while an oral material being encapsulated. Moreover, this invention provides an oral-material taking method, including taking... Agent: Reed Smith LLP

20090110716 - Orally disintegrative dosage form: The present invention features an orally disintegrating dosage form including from about 5% to about 40%, by weight, of at least one hydrated salt and a pharmaceutically active agent, wherein the at least hydrated salt has a dehydration temperature of from about 20 to about 120° C.... Agent: Philip S. Johnson Johnson & Johnson

20090110717 - Transmucosal composition: The invention provides a composition for delivering active agents through transmucosal administration, more particularly through the buccal mucosa. The composition is a unique transmucosal disk (10) which has two compartments (14) and (18); the compartments consist of at least one active agent and at least one mucoadhesive agent and both... Agent: Ladas & Parry LLP

20090110718 - Derivatives of tiacumicin b as anti-cancer agents: e

20090110719 - Polyamine modified particles: A particle composition comprising a graft copolymer formed from a biocompatible polymer and a plurality of polyamine moieties, wherein the polyamine moieties are bound to the biocompatible polymer, and a combinatorial delivery polymer comprising a plurality of particles that comprises a graft copolymer formed from a biocompatible polymer and a... Agent: Baker Botts L.L.P. Patent Department

20090110720 - Use of compounds for the prevention of drug-induced cell toxicity: The present invention relates to the use of compounds for the manufacture of a medicament for the prophylaxis and/or treatment of induced cell toxicity, such as nephewrotoxicity and ototoxicity, in particular where the cell toxicity is induced by a medical treatment. In a preferred embodiment, the compounds have at least... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090110721 - Paneled capsule shells for release of pharmaceutical compositions: Capsule shells for use in multi-part dosage forms have generally cylindrical shell members with a snap fit component on an interior surface adjacent an open end, for connection to a linker part of the dosage form. The shell member also has a plurality of spaced apart integrally formed thin (relative... Agent: Glaxo Smith Kline/finnegan, Henderson LLP

20090110722 - Composition: A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.... Agent: Conley Rose, P.C.

20090110723 - Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms: A linker for multicomponent dosage form has a preformed drug substance tablet and an injection molded jacket including one or both axial jacket ends open for dispensing the preformed drug substances. The jacket has snap-fit connection elements on the outer surface adjacent each end for engagement with complementary snap-fit element... Agent: Glaxo Smith Kline/finnegan, Henderson LLP

20090110724 - Compositions and methods for treatment of pain: The present invention relates to compositions and methods for treatment of various forms of pain. Specifically, the method involves administering to a patient a composition comprising butalbital, acetaminophen and caffeine in the gelcap dosage form, to treat and/or alleviate the occurrence or negative effects of various forms of headaches.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090110725 - Solid, orodispersible and/or dispersible composition, without an excipient of known effect and its process of preparation: The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size not exceeding 50 μm; (b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble; (c)... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090110726 - Formulation having accurate dose-dividing function: In addition, the present invention provides a method of manufacturing a tablet, wherein a column comprising a plurality of columnar pharmaceutical composition layers having the same cross-section and laminated in the axial direction of the column is compression molded and then compression molded in a direction different from the axial... Agent: Sughrue Mion, PLLC

20090110727 - Extended release compositions of proton pump inhibitors: The invention provides extended release compositions comprising at least one proton pump inhibitor. The invention also provides methods for treating gastrointestinal disorders by administering the compositions of the invention to patients in need of gastrointestinal therapy.... Agent: Lahive & Cockfield, LLP/eisai Floor 30, Suite 3000

20090110728 - Zero-order modified release solid dosage forms: The invention comprises a solid dosage form for delivery of water soluble pharmaceutical agents. The solid dosage form comprises a matrix core containing the pharmaceutical agent and a hydrophobic material, and a coating containing a hydrophilic pore-forming agent and a hydrophobic polymer. The dosage form exhibits a zero-order release profile... Agent: Mallinckrodt Inc.

20090110729 - Solid oral compositions based on s-adenosyl methionine and/or nadh and process for obtaining them: e

20090110730 - Loadable polymeric particles for marking or masking individuals and methods of preparing and using the same: The present invention relates to the use of certain microspheres, nanospheres, and other structures to provide a method of marking or masking identifying marks in individual biological hosts. Biological hosts for the present invention may include humans, other animals, or plants. Such methods may be used to sense, signal, track,... Agent: Sutherland Asbill & Brennan LLP

20090110732 - Bioresorbable composition for repairing skeletal tissue: Bioresorbable compositions for treating skeletal tissue are disclosed. The biomedical compositions are formed from a polylactide polymer, a polyglycolide polymer, or a poly(lactic-co-glycolic acid) polymer having a relatively low molecular weight. For instance, the average number molecular weight of the polymer is generally less than 10,000, such as from about... Agent: Dority & Manning, P.A.

20090110733 - Delivery means: A delivery means for delivering a deliverable material to a wound bed comprises a hydrogel (preferably an optionally cross-linked polyvinylalcohol) and a deliverable material comprising: (i) a decomposable material which in the absence of said hydrogel decomposes and/or is permanently denatured if sterilised using heat, electron beam radiation or gamma... Agent: Michael Best & Friedrich LLP

20090110731 - Loadable polymeric microparticles for therapeutic use in alopecia and methods of preparing and using the same: Particles are provided for use in restorative procedures to treat and/or retard alopecia The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based... Agent: Sutherland Asbill & Brennan LLP

20090110734 - Quaternised ammonium cyclodextrin compounds: r

20090110735 - Controlled release formulations: The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.... Agent: Dla Piper LLP (us)

20090110736 - Alloplastic injectable dermal filler and methods of use thereof: A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material... Agent: Hunton & Williams LLP Intellectual Property Department

20090110737 - Orally disintegrating powder comprising cilostazol and mannitol: The present invention provides an orally disintegrating powder comprising cilostazol as an active ingredient and mannitol in an amount of 70% by weight or more, which can be taken without water and can be disintegrated in oral cavity. Said powder is suitable for patients to whom cilostazol is applied, especially... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090110738 - Loadable polymeric particles for cosmetic and reconstructive tissue augmentation applications and methods of preparing and using the same: Particles are provided for use in therapeutic cosmetic and/or reconstructive procedures to augment defects in tissue to restore contours and/or function. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a... Agent: Sutherland Asbill & Brennan LLP

20090110739 - Targeted cancer chemotherapy using synthetic nanoparticles: Compositions and methods for delivery of a pharmaceutical to an individual. Delivery vehicles are provided in a formulation of a pharmaceutical that is encapsulated in a synthetic self assembled nanoparticle that includes a lipid binding protein and a lipid monolayer. The interior of the particle represents a hydrophobic core region... Agent: Jackson Walker LLP

20090110740 - Materials and methods for modulating metabolism: The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090110741 - Method and compositions for polymer nanocarriers containing therapeutic molecules: A method of controlling a physical characteristic of polymeric nanocarrier-encapsulated protein particles includes altering or selecting a weight percentage of a hydrophobic polymer block in a total amphiphilic diblock copolymer of a primary emulsion of a double emulsion, freeze-thaw technique. The primary emulsion is formed using a freeze-thaw cycle of... Agent: Howson & Howson LLP

20090110742 - Long-acting colloidal insulin formulation and its preparation: m

20090110743 - Porous beta-tricalcium phosphate granules and methods for producing same: A porous β-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 μm, preferably 50-125 μm. The porous β-TCP material provides a carrier matrix for bioactive... Agent: Ropes & Gray LLP

20090110744 - Sustained release pharmaceutical compositions: p

20090110745 - Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging: The present invention provides methods for improving cognitive function, improving mood, and decreasing aggression in a normal adult subject, and in a subject having symptoms characteristic of a neurological disorder, by administration of a nutriceutical formulation of the invention to the subject. The invention additionally features methods of treating neurological... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090110747 - Drug and/or food supplement containing nisylen r, cepa, euphrasia, belladona and/or mercurius solubilis: The present disclosure relates to a drug and/or food supplement with antiviral effects, in particular for the preventive and/or therapeutic treatment of herpes labialis and/or herpes genitalis, and/or with antibacterial and/or immunomodulating and/or antiphlogistic effects and/or for the preventive and/or therapeutic treatment of affections of the prostate, containing NISYLEN® and/or... Agent: Alleman Hall Mccoy Russell & Tuttle LLP

20090110746 - New class of therapeutics that enhance small modecule diffusion: The subject invention relates to novel compositions containing a diffusion enhancing compound and their use in treating a variety of disorders.... Agent: Nixon & Vanderhye, PC

20090110748 - Biocompatible material and process for manufacturing the same: In order to provide a biocompatible material consisting mainly of a fish scale-derived hydroxyapatite and a fish scale-derived collagen, which is adjusted so that easily digested and absorbed in a human body, the material contains a composite consisting mainly of a fish scale-derived hydroxyapatite and a fish scale-derived collagen.... Agent: Notaro & Michalos P.C.

20090110749 - Method and apparatus for producing a stabilized antimicrobial non-toxic electrolyzed saline solution exhibiting potential as a therapeutic: An improved method and apparatus is disclosed for producing a stable, non-toxic, antimicrobial electrolyzed saline solution with a broad range of anti-infective and therapeutic applications. The resulting solution is balanced to normal and hypertonic saline and has been shown to exhibit remarkable antimicrobial, antiviral and therapeutic characteristics. The nature of... Agent: Marcus G Theodore, PC

20090110750 - Antimicrobial materials: A material for the treatment or prophylaxis of microbial, including bacterial, infections, comprising a metal species and a polymer, wherein the polymer stabilises the metal species. Compositions and devices comprising the material. A method for the treatment or prophylaxis of microbial, including bacterial, infections, comprising the use of such a... Agent: Chief Patent Counsel Smith & Nephew, Inc.

20090110751 - Compositions and methods for treatment of diseases of the foot of an animal: The present invention is directed to an activator composition comprising copper sulfate, zinc sulfate, sodium chloride, and ammonium sulfate, for the activation of an anti-microbial composition. The resulting activated anti-microbial composition is used for the treatment of an infectious disease of a foot of an animal, particularly for the use... Agent: Whyte Hirschboeck Dudek S C Intellectual Property Department

20090110752 - Composition for controlling blood glucose and method thereof: A composition for controlling a blood glucose and a method thereof are provided. The composition comprises a far-infrared ray releasing substance, wherein the composition reduces the blood glucose of a subject via an irradiation of the far-infrared ray releasing substance. In another aspect, the method comprises the steps of providing... Agent: Volpe And Koenig, P.C.

20090110753 - Enzyme-cleavable prodrug compounds: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences... Agent: Lahive & Cockfield, LLP/medarex Floor 30, Suite 3000

20090110754 - Stabilized chlorine dioxide and hypochlorous acid in a liquid biocide: A liquid biocide containing stabilized chlorine dioxide and hypochlorous acid for various uses, including use as a teat dip or dairy animals. The stable, prophylactic biocide consists essentially of 0.10-20.0% by weight of a chlorite salt, 0.1-3.0% by weight of an acid, 0.10-2.0% by weight of an alkaline agent, and... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090110755 - Compositions and methods for preventing migraines: The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of... Agent: Morgan, Lewis & Bockius LLP

20090110756 - Methods and compositions related to plunc surfactant polypeptides: Embodiments include compositions and methods for lower the surface tension of a liquid-air interface by contacting such interface with all or part of a PLUNC polypeptide.... Agent: Fulbright & Jaworski L.L.P.

20090110757 - Methods for modulating eicosanoid metabolism: The inventive subject matter relates to methods for treating prostate cancer, comprising administration of a composition comprising therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, huzhang, Chinese goldthread, and... Agent: The Nath Law Group

20090110758 - Compositions and methods for promoting weight loss: Compositions, which include psyllium and polyethylene glycol in a weight ratio of psyllium to polyethylene glycol of from about 1:3 to about 2:1, a gum, and one or more additional ingredients selected from the group consisting of water, salt, sweeteners, flavoring agents, and preservatives are presented.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090110759 - Pharmaceutical composition for use as a laxative: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by... Agent: Alston & Bird LLP

20090110760 - Lipometabolism improver containing pine bark extract: As a lipid metabolism improving agent for allowing lipids in the body to be metabolized efficiently, a lipid metabolism improving agent containing a pine bark extract as an active component is provided. The lipid metabolism improving agent of the present invention has abilities to promote cholesterol excretion, inhibit lipid absorption,... Agent: Amin, Turocy & Calvin, LLP

20090104113 - Ionizing-radiation-responsive compositions, methods, and systems: A method, composition and system respond to ionizing, radiation to adjust biological activity. In some approaches the ionizing radiation is X-ray or extreme ultraviolet radiation that produces luminescent responses that induce biologically active responses.... Agent: Searete LLC Clarence T. Tegreene

20090104114 - Nanotherapeutic colloidal metal compositions and methods: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, the nanotherapeutic compositions of the present invention comprise a platform comprising a colloidal metal, a targeting ligand such a tumor necrosis factor,... Agent: King & Spalding

20090104115 - Cancerous disease modifying antibodies: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.

20090104116 - Compounds for the inhibition of integrins and use thereof: The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene; Ψ is a radical of formula (II), R2 is a hydrophobic moiety; and G is a radical containing one or more moieties selected from the group... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090104117 - Compositions and methods of use of targeting peptides against placenta and adipose tissues: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents... Agent: Fulbright & Jaworski L.L.P.

20090104118 - Contrast agents for myocardial perfusion imaging: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.... Agent: Wolf Greenfield & Sacks, P.C.

20090104119 - Dendrimer based compositions and methods of using the same: The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based multifunctional compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or... Agent: Casimir Jones, S.c.

20090104122 - Detection of membrane androgen receptor (mar) agents: Disclosed are methods to detect agents that modulate a membrane androgen receptor (mAR). In one embodiment, the invention provides a method to detect and optionally identify mAR binding ligands. One assay according to the invention detects agents that selectively bind the mAR relative to binding to the classical intracellular androgen... Agent: Edwards Angell Palmer & Dodge LLP

20090104120 - Dlx1 cancer markers: This invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, this invention relates to DLX1 cancer markers that are useful as diagnostic markers and clinical targets for prostate cancer.... Agent: Casimir Jones, S.c.

20090104121 - Multi-subunit biological complexes for treatment of plaque-associated diseases: Provided herein are methods and compositions for the in vitro formation of multi subunit biological platforms. The biological platforms may be used to screen chemical or biological compounds, in particular compounds that may disrupt or otherwise affect the formation of the multi subunit complexes, or disrupt already-formed in vitro assembled... Agent: Wilson Sonsini Goodrich & Rosati

20090104123 - Targeted contrast agents and methods for targeting contrast agents: A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.... Agent: Christopher B. Linder Thomas, Kayden, Horetemeyer & Risley, L.l.p

20090104124 - Paramagnetic complexes with pendant crown compounds showing improved targeting- specificity as mri contrast agents: Potential magnetic resonance imaging (MRI) contrast agents that are functionalized with crown compounds have been synthesized, and show target-specificity to the kidney and liver, along with excellent water solubility, high MR intensity enhancement efficiency, long resident lifetime, low dosage requirement, low cytotoxicity and prolonged excretion rate.... Agent: Cooper & Dunham, LLP

20090104125 - Stable liquid desoximethasone compositions with reduced oxidized impurity: The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C2-C4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt %... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20090104126 - Sulfamate compounds and uses thereof: wherein R1 to R3 and n have defined meanings, pharmaceutical compositions comprising these compounds; a process for preparing these compounds, and the use of such compounds or compositions to treat or inhibit various disorders or disease states in patients in need thereof by administering to such a patient a therapeutically... Agent: Crowell & Moring LLP Intellectual Property Group

20090104127 - Suspension aerosol formulations of pharmaceutical products: Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090104128 - Denture adhesive compositions with anti-ucler agents: The present invention relates to methods and compositions for reducing, inhibiting, and/or preventing denture sores, comprising a denture adhesive component and an effective amount of an anti-ulcer agent selected from the group consisting of Glycyrrhiza extract (GX), xylitol, and cobalamin. A denture wearer in need thereof applies the composition to... Agent: Jeffrey T. Haley

20090104130 - Compositions comprising organic and inorganic phosphors for converting electromagnetic radiation and methods for using the same: There is disclosed a topical composition comprising at least one organic and/or inorganic phosphor in a physiologically acceptable medium, wherein the phosphor(s) is present in an amount effective to convert electromagnetic radiation of an initial frequency to a different frequency. In one embodiment, the phosphors convert the initial radiation frequency,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090104133 - Methods of moisturizing the skin and killing microorganisms thereon: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer and bound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing... Agent: Bozicevic, Field & Francis LLP

20090104134 - Organophilic clay for thickening organic solvents: An organophilic clay for thickening hydrophobic liquids comprising a layered silicate material, surfaces of said layered silicate material modified by an amphipathic copolymer prepared from a first comonomer that generates a hydrophilic homopolymer that is essentially insoluble in a hydrophobic liquid and a second comonomer that generates a hydrophobic homopolymer... Agent: Marshall, Gerstein & Borun LLP

20090104129 - Skin care compositions: The present invention relates to a skin care composition comprising at least two oil phases dispersed in a continuous aqueous phase comprising a thickening agent, wherein a first oil phase of the oil phases has different composition from the other oil phase, and wherein the composition contains an emulsifier no... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090104131 - Topical anti-inflammatory compositions comprising o/w emulsions containing pro-penetrating glycols: Topically applicable compositions in the form of oil-in-water (O/W) emulsions contain a pro-penetrating system including at least one glycol and at least one additional pro-penetrating agent, a suitable emulsifying system and at least one active agent of the family of steroidal anti-inflammatory agents, and are useful e.g., for the treatment... Agent: Buchanan, Ingersoll & Rooney PC

20090104132 - Topical anti-inflammatory compositions comprising o/w emulsions containing pro-penetrating glycols: Topically applicable compositions in the form of oil-in-water emulsions contain a pro-penetrating system including at least one glycol and at least one additional pro-penetrating agent, a suitable gelling agent and at least one active agent of the family of steroidal anti-inflammatory agents and are useful, e.g., for the treatment of... Agent: Buchanan, Ingersoll & Rooney PC

20090104135 - Use of mineral/organic composite material in the form of an ultraviolet radiation protective agent: The invention relates to the use of composite material which comprises nanoparticles of a least one metal derivative and at least one organic sunscreen agent which is chemically bound with said particles in a covalent manner in the form of an ultraviolet radiation protective agent containing the inventive composite material.... Agent: Oliff & Berridge, PLC

20090104138 - Aerosol hairspray composition: A hair spray composition comprising at least one hair setting polymer comprising pendant carboxyl groups, a solvent for the setting polymer and a neutraliser for the polymer wherein the level of neutraliser present is such that at least 170% of the total carboxyl groups on the polymer could be neutralised.... Agent: Unilever Patent Group

20090104139 - Hair treatment compositions comprising particles and hydrophobic oil: A hair treatment composition comprising studded particles, the studded particles comprising liquid hydrophobic oil droplets studded by particulate material, the mean diameter (D3.2) of the studded particles being from 0.01 to 100 microns, and a hair treatment composition obtainable by the process of: (i) forming a pre-mix of a dispersion... Agent: Unilever Patent Group

20090104137 - Cosmetic composition: The present invention is related to enhance deposition of UV filters especially anionic water soluble ones onto hair from conditioning composition comprising UV filter, especially anionic water soluble ones, at least one conditioning agent and having a pH below 4.5.... Agent: Norris, Mclaughlin & Marcus, P.A.

20090104136 - Hair care compositions and methods of treating hair using same: The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions.... Agent: Fitzpatrick Cella Harper & Scinto

20090104140 - 1-oxaspiro (4, 5) dec-3-ene derivatives as perfuming ingredients: The present invention relates to a spiroheterocycle derivative which is a useful perfuming ingredient. Furthermore, the present invention concerns also the compositions or articles containing this compound.... Agent: Winston & Strawn LLP Patent Department

20090104141 - Isothermal preparation of heat-resistant gellan gels with reduced syneresis: A gel comprising a deacylated gellan gum, an effective amount of a sequestrant, an effective amount of a syneresis control agent, and a gelation inducer is described. Also methods for making the gel are disclosed including a method for forming heat-resistant gels comprising mixing deacylated gellan gum and xyloglucan; hydrating... Agent: Cp Kelco Us, Inc

20090104142 - Compositions for treating multiple sclerosis: The present invention relates to compositions comprising Tr1 cells directed to a multiple sclerosis associated antigen and methods for treating multiple sclerosis.... Agent: Young & Thompson

20090104143 - Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells: A cell-targeted polymeric drug delivery system was designed based on the specific interaction between hyaluronic acid (HA) and its cell surface receptors overexpressed on cancer cell surface. The invention relates to compounds composed of a carrier molecule, wherein the carrier molecule contains at least one residue of an anti-cancer agent... Agent: King & Spalding LLP

20090104144 - Gypsum board with a fluorine-containing antifungal agent: A novel gypsum board having improved antifungal properties is disclosed. The board comprises a gypsum core, front and back paper facings, and a polymeric antifungal agent effective at inhibiting fungal growth. A preferred polymeric antifungal agent is polyDADMAC or polyTMMC. The novel gypsum board further comprises a non-polymeric antifungal agent... Agent: Elman Technology Law, P.C.

20090104145 - Mixtures of anthranilamide invertebrate pest control agents: Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, an N-oxide, or a salt thereof, Formula (1) and (b) at least one invertebrate pest control agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090104146 - Compositions for enhancing keratinocyte migration and epidermal repair via a receptor containing osmrbeta as a subunit, and applications thereof: The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to activate a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for activating in vitro and/or in vivo keratinocyte migration and/or the expression of... Agent: Alston & Bird LLP

20090104147 - Sialoadhesin-related compositions and methods: Methods of delivering a cargo moiety to a cell is provided according to embodiments of the present invention which includes contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and... Agent: Trask Britt

20090104148 - Treatment and prevention of joint disease: The invention provides compositions and methods for preserving, prolonging, or augmenting joint lubrication by contacting a tissue of a joint such as a knee, elbow, or other articulating joint, with a tribonectin and an inhibitor of a proinflammatory mediator.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090104149 - Compositions for hcv treatment: The present invention concerns a pharmaceutical combination comprising a) a first agent which is a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I and b) a co-agent.... Agent: Novartis Corporate Intellectual Property

20090104150 - Polymer conjugates of interferon beta-1a and uses: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as... Agent: Steptoe & Johnson LLP

20090104151 - Smac mimetic dimers and trimers useful as anti-cancer agents: The invention provides small molecule mimics of the Smac peptide that are dimer-like or trimer-like compounds having two or three amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including... Agent: Morrison & Foerster LLP

20090104152 - Glycosylated interferon alpha: The invention relates to interferon-α molecules having certain O-linked oligosaccharide structures.... Agent: Synageva Biopharma Corp.

20090104154 - Composition and method for killing of tumours: The present invention provides a method of treating a solid tumour in a subject, the method comprising the following steps (i) delivering to the solid tumour a composition comprising an engineered ovine atadenovirus; and (ii) administering a prodrug to the subject, wherein the engineered ovine atadenovirus comprises a promoter and... Agent: Mcdermott Will & Emery LLP

20090104153 - Method of eliciting immune response: The present invention relates to methods of eliciting an immune response by use of a prime-boost schedule for delivering a polynucleotide encoding a heterologous non-self antigen. In particular, the invention relates to a prime-boost schedule wherein the priming polynucleotide composition is delivered by an adenoviral vector, and the boosting polynucleotide... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090104156 - Pharmaceutical compositions for treating papillomavirus tumors and infection: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region... Agent: Buchanan, Ingersoll & Rooney PC

20090104155 - Treatment of connective tissue disorders: The present invention relates to methods of delivering nucleic acids to connective tissue cells and to methods of treating connective tissue disorders; in particular, the invention provides methods of delivering nucleic acids to connective tissue cells and methods of treating connective tissue disorders using parvovirus vectors.... Agent: Myers Bigel Sibley & Sajovec

20090104166 - Stimulating neurite outgrowth using tctex-1-related polypeptides: A method of stimulating neurite outgrowth in a subject may include administering to the subject a formulation that includes a tctex-1-related polypeptide that stimulates neurite outgrowth in vitro.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090104165 - Transgenic strains of trichoderma and their use in biocontrol: The present invention relates to a transgenic Trichoderma spp. having a recombinant nucleic acid molecule encoding a bioactive molecule. The present invention also relates to methods for controlling plant disease that involve applying a transgenic strain of Trichoderma spp. plants or plants seeds, where the transgenic strain of Trichoderma spp.... Agent: Nixon Peabody LLP - Patent Group

20090104169 - Pet food composition for skin photoprotection: An ingestable composition for the photoprotection of the skin of pets which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one yeast and/or a carotenoid or derivative, included into an ingestable carrier.... Agent: Bell, Boyd & Lloyd LLP

20090104167 - Prophylactic/ameliorating agent for menopausal disorder and functional beverage/food: Disclosed is a method for producing an estrogen-like active intermediate (e.g., secoisolariciresinol) by culturing a lignan (e.g., a lignan derived from Eucommia ulmoides) together with a bacterium Lactobacillus acidophilus. Also disclosed a prophylactic/ameliorating agent for menopausal disorder and a functional beverage/food for preventing/ameliorating menopausal disorder comprising a lignan cultured together... Agent: Birch Stewart Kolasch & Birch

20090104168 - Use of specific lactic bacteria for the preparation of immunomodulating compositions: The invention concerns the use of two lactobacteria for the preparation of immunomodulating compositions, in particular for the treatment and/or prevention of allergies and immunodeficiencies, and specifically use of the following two strains Lactobacillus salivarius I 1794 and Lactobacillus paracasei I 1688, alone or in combination, in the treatments indicated... Agent: Nixon & Vanderhye, PC

20090104157 - Utilization of bacteriophage to control bacterial contamination in fermentation processes: A fermentation process for the production of ethanol from natural sources, such as corn, comprising introducing a fermentable sugar and an inoculant, and a bacteriophage cocktail into a fermentation system and introducing a cocktail comprising one or more lytic bacteriophage is added to one or more of the fermentable sugar,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090104164 - Angiogenic cells from human placental perfusate: Provided herein are the production of vasculogenic or angiogenic cells from placental perfusate. Also provided are methods of treating an individual having a cardiac or vascular insufficiency, disease, disorder or condition comprising administering to said individual placental perfusate, placental perfusate cells, or combinations of placental perfusate or perfusate cells with... Agent: Jones Day

20090104162 - Attenuated reoviruses for selection of cell populations: The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells... Agent: Fulbright & Jaworski L.L.P.

20090104163 - Immunomodulatory properties of multipotent adult progenitor cells and uses thereof: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response.... Agent: Larry S. Millstein Holland & Knight LLP

20090104161 - Method for activation treatment of antigen-presenting cell: Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or γδ T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090104160 - Mobilization of stem cells after trauma and methods therefor: Methods are presented in which release of stem cells from skeletal muscle is quantitated and correlated with severity of a disease or trauma, a future treatment option, prognosis, and/or anticipated time to recovery. Most preferably, the stem cell is a BLSC and/or an ELSC, and the stem cell isolation for... Agent: Fish & Associates, PC Robert D. Fish

20090104158 - Non-embryonic totipotent blastomere-like stem cells and methods therefor: Non-embryonic blastomere-like totipotent stem cells are disclosed. Most preferably, such cells are obtained from various tissues of postnatal mammals (e.g., using tissue biopsied from the mammal), are smaller than 1 μm, have normal karyotype, and do not spontaneously differentiate in serum-free medium without differentiation inhibitors. These non-embryonic blastomere-like totipotent stem... Agent: Rutan & Tucker, LLP.

20090104159 - Vascular/lymphatic endothelial cells: The present invention provides methods to culture and use vascular endothelial cells, including lymphatic, venous and arterial endothelial cells.... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090104170 - Compositions and methods for treating hyperproliferative disorders: The invention generally relates to a composition comprising an enriched NK cell population. The invention further relates to a method of treating a solid tumor or a hyperproliferative disorder by administering the enriched NK cell population to a mammalian subject in need thereof.... Agent: Woodcock Washburn LLP

20090104171 - Metabolic enhancement therapy: A Metabolic Enhancement Therapy nutritional supplement for treating symptoms and conditions such as acute anxiety, hyperactivity, panic attacks, confusion, involuntary movements, sleep disorders, mood disorders, depression, anger, seizures, obsessive-compulsive behavior, unregulated fear, panic, neuronal disorders, autism, schizophrenia, attention deficit disorder (ADD), attention deficit hyperactive disorder (ADHD) and neuronally based immunologic... Agent: Fox Rothschild LLP

20090104172 - Methods for killing spores and disinfecting or sterilizing devices: The present invention provides a method for killing or inactivating spores, by contacting the spores with a haloperoxidase, hydrogen peroxide, chloride or bromide ions, and ammonium ions.... Agent: Novozymes North America, Inc.

20090104173 - Novel process for solubilizing protein from a proteinaceous material and compositions thereof: The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis... Agent: Mckee, Voorhees & Sease, P.L.C

20090104176 - Compositions and methods of using chondroitinase abci mutants: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.... Agent: Pepper Hamilton LLP

20090104174 - Methods and compositions for reducing the appearance of dynamic facial wrinkles: The present invention relates to methods and compositions for reducing the appearance of dynamic facial wrinkles by administering oral and/or topical compositions comprising therapeutically-effective amounts of extracts of one or more relaxing herbal agents (“RHAs”) alone or in combination with one or more extracts of an edible solanaceous glycoalkaloid-containing plant... Agent: Louis C. Paul

20090104175 - Use of caspases for the preparation of medicaments: The invention relates to caspases and to extracellular use of caspases for regulating cell functions.... Agent: David S. Resnick

20090104181 - Antibodies for discrimination of prions: In the present invention, we described the use of anti-DNA antibody for the detection of prions and diagnosis of Transmissible Spongiform Encephalopathies (TSE) diseases in animals and humans.... Agent: Philip S. Johnson Johnson & Johnson

20090104178 - Chemokine binding activity of viral tnf receptors and related proteins: Chemokine binding activity of viral TNF receptors and related proteins. The invention relates to a C-terminal domain (CTD) of viral tumour necrosis factor receptors (vTNFRs) CrmB or CrmD or CTD homologues (CTD1, CTD2 and CTD3) from poxvirus and their functional homologues, including derivatives, and fragments, for use in binding chemokines... Agent: Darby & Darby P.C.

20090104183 - Glue composition for lung volume reduction: The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The... Agent: Townsend And Townsend And Crew, LLP

20090104182 - Inhibition of tristetraproline for protection of the heart from cardiac injuries: The present invention relates to compounds suitable for the treatment of conditions which may be improved, at least in part, by increasing TNF α production. The invention further relates to assays for the identification of an individual at increased risk for or suffering front such conditions and to methods of... Agent: Millen, White, Zelano & Branigan, P.C.

20090104179 - Ionizing-radiation-responsive compositions, methods, and systems: A method, composition and system respond to ionizing radiation to adjust biological activity. In some approaches the ionizing radiation is X-ray or extreme ultraviolet radiation that produces luminescent responses that induce biologically active responses.... Agent: Searete LLC Clarence T. Tegreene

20090104180 - Novel p-selectin ligand protein: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the... Agent: Wyeth/finnegan Henderson, LLP

20090104177 - Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins: The invention relates to a nucleic acid sequence encoding peptides which inhibit the interaction of protein kinase A (PKA) and protein kinase A anchor proteins (AKAP), to a host organism comprising said nucleic acid sequence and optionally expressing said peptides, to the use of said peptides and of said host... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090104184 - Pharmaceutical compositions containing monoclonal anti idiotypic anti-ca-125 antibody and aluminium: The present invention refers to a pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative.... Agent: Abelman, Frayne & Schwab

20090104188 - Anti-hepatitis c virus antibody and uses thereof: Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable of neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors... Agent: Bell, Boyd, & Lloyd LLP

20090104190 - Humanized anti-cd4 antibody with immunosuppressive properties: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.... Agent: Cermak Kenealy Vaidya & Nakajima LLP

20090104186 - Melanoma-associated mhc class i associated oligopeptides and the uses thereof: The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090104185 - Methods and compositions for mycoplasma toxins: The present invention provides Mycoplasma toxins, biologically active fragments/domains of the toxins, antibodies to the toxins, therapeutic fusion proteins comprising the toxins and/or biologically active fragments/domains of the toxins and nucleic acids encoding the toxins and fusion proteins. Also provided are methods of treating and/or preventing diseases and disorders using... Agent: Myers Bigel Sibley & Sajovec

20090104192 - Monoclonal antibodies to hepatocyte growth factor: The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Townsend And Townsend And Crew, LLP

20090104189 - Neutrokine-alpha and neutrokine-alpha splice variant: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically... Agent: Leydig, Voit & Mayer Ltd.

20090104187 - Novel rabbit antibody humanization methods and humanized rabbit antibodies: The present invention is directed to novel and improved methods for humanizing rabbit heavy and light variable regions. The resulting humanized rabbit heavy and light chains and antibodies and antibody fragments containing are well suited for use in immunotherapy and immunodiagnosis as they retain the antigen binding affinity of the... Agent: Hunton & Williams LLP Intellectual Property Department

20090104191 - Prevention of tumors with monoclonal antibodies against neu: Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its... Agent: Cooper & Dunham, LLP

20090104193 - Sema4d in cancer diagnosis, detection and treatment: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or... Agent: Novartis Vaccines And Diagnostics Inc.

20090104194 - Bi-directional antibody for treatment of ocular disorders: A system and method for treating ocular disorders are disclosed. Specifically, the system and method administer bi-directional antibodies to treat a retina. Structurally, each bi-directional antibody has a first receptor arm and a second receptor arm. Further, each first receptor arm possesses binding affinity for retinal cells and each second... Agent: Neil K. Nydegger

20090104195 - Targeted ligands: The invention contemplates a composition containing a multispecific ligand containing at least a first ligand binding moiety and a second ligand binding moiety. The first ligand binding moiety specifically binds with a pre-selected first affinity to at least a first ligand. The first ligand has a first biodistribution. The second... Agent: Cheryl H Agris Phd

20090104196 - Antibodies for use in identifying and/or scoring prostate cancer and androgen receptor-dependent gene expression control: The invention relates to antibodies for use for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical and diagnostical compositions comprising such antibodies. The invention also relates to a method for identifying and/or scoring prostate carcinomas. Furthermore, the invention relates to the use of at... Agent: Greenblum & Bernstein, P.L.C

20090104199 - Breast cancer resistance protein (bcrp) and the dna which encodes it: The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs.... Agent: Merchant & Gould PC

20090104202 - Cd44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain capable of specifically binding a CD44 polypeptide as set forth in SEQ ID NO: 2 and incapable of binding a CD44 polypeptide selected from the group consisting of: SEQ ID NO: 4 or 6.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090104203 - Compositions and methods for regulating osteoclast differentiation, activation and bone resorption: Provided is a purified, negative regulator of osteoclast differentiation and bone resorption, specifically LRRc17. Further provided are methods and compositions for treating degenerative bone disorders, and treatments and prophylactic approaches for regulating bone resorption, and for decreasing or inhibiting the excessive bone loss associated with abnormal or excessive generation of... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090104201 - Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis: The present disclosure provides innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX and an inhibitor of a LOXL, or... Agent: Wilson Sonsini Goodrich & Rosati

20090104200 - Modulating inflammasome activity and inflammation in the central nervous system: Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and... Agent: Akerman Senterfitt

20090104198 - Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and... Agent: Marshall, Gerstein & Borun LLP

20090104197 - Vwfa and/or ant_ig domain containing proteins: This invention relates to novel proteins (herein termed INSP141, INSP142, INSP143, and INSP144), herein identified as anthrax receptor-like proteins containing von Willebrand factor A (vWFA) and Anthrax receptor extracellular (ANT_IG) domains and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090104204 - Human binding molecules having killing activity against staphylococci and uses thereof: The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the... Agent: Trask Britt

20090104205 - Human-murine chimeric antibodies against respiratory syncytial virus: This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or treatment of RSV infection.... Agent: Medimmune, LLC Jonathan Klein-evans

20090104206 - Bone microenvironment modulated migraine treatments: Novel etiology and pathogenesis of premenstrual headache and premenstrual migraine are presented and novel treatment methods are provided. Present invention identifies how declining estrogen results in a transient elevation in extracellular calcium concentrations via osteoclast upregulation. The elevated extracellular calcium pathogenesis is then traced, from bone to brain, and includes... Agent: Mark Zamoyski

20090104207 - Hepatitis c virus neutralizing antibodies: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions,... Agent: Nixon & Vanderhye, PC

20090104208 - House dust mite allergen: A polypeptide comprising an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or comprising at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity... Agent: Chalker Flores, LLP

20090104209 - Methods of reducing a viral infection and kits therefore: A method for treating and/or preventing a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9)-susceptible viral infection comprising increasing a PCSK9 activity and/or expression in a biological system infected by the virus, whereby the increased PCSK9 activity and/or expression treats and/or prevents the viral infection in the biological system. Methods of... Agent: Goudreau Gage Dubuc

20090104210 - Peptide compounds for treating obesity and insulin resistance: Compounds comprising an angiopoietin-like protein 6 (Angptl6) peptide for use in the treatment of metabolic syndrome, in particular, obesity and insulin resistance are described.... Agent: Merck And Co., Inc

20090104212 - Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption: m

20090104211 - Treatment of atherosclerosis: The invention relates to a method and a device for commissioning articles from a first number of pick-up sections (16) into a corresponding number of order placement sections (18), by means of a second number of commissioners (20). Thus, only one commissioner (20) carries out commissioning in a commissioning zone... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090104213 - Vaccine for house dust mite allergen using naked dna: Vaccination with the DNA encoding T-cell epitopes to the house dust mite Dermatophagoides pteronyssimus (Der p) and Dermatophagoides farinae (Der f were effective in the inhibition of the allergen induced IgE synthesis. Gene therapy using T-cell epitope encoding DNA is useful in combating allergic disease.... Agent: Foley & Lardner LLP

20090104215 - Methods and compositions for modulating tumor cell activity: Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding to clusterin.... Agent: Cassan Maclean

20090104214 - Synthetic peptides containing the motif \"ywwlxp\" as anthrax toxin antidotes: Specific inhibitors, in Multiple Antigen Peptide form, which inhibit the interaction between protective antigen and lethal factor and neutralize anthrax toxin in vivo. Anti protective antigen peptides were selected from a phage library by competitive panning with lethal factor. Selected 12mer peptides were synthesized in tetra-branched form and systematically modified... Agent: Juneau Partners

20090104216 - Peptide-based influenza vaccine formulation: Peptide-based anti-influenza formulations against influenza A and B are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza in human, avian,... Agent: Edwards Angell Palmer & Dodge LLP

20090104217 - Pharmaceutical composition comprising an antigen: The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected from neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.... Agent: Fulbright & Jaworski L.L.P.

20090104218 - Group b streptococcus: Polypeptides and nucleic acids from Streptococcus agalactiae which can be used in the development of vaccines, for diagnostic purposes, and as targets for antibiotics.... Agent: Novartis Vaccines And Diagnostics Inc.

20090104219 - Antigenic polypeptide se36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen: The present invention provides a polypeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasonodium falciparum, at the erythrocyte stage, a process for purifying said polypeptide, and a malaria vaccine and diagnostic agent using as an active component said purified antigen obtained... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090104220 - Method to make a peptide-carrier conjugate with a high immunogenicity: The present invention provides a method for making a peptide-carrier conjugate. The method comprises modifying a first peptide to produce a second peptide so that the pI of the second peptide is in a favorable range or closer to the range than the pI of the first peptide, and conjugating... Agent: Merck And Co., Inc

20090104221 - Rapid generation of t cell-independent antibody responses to t cell-dependent antigens: The present invention comprises the use of follicular dendritic cells (FDCs) or FDC-like cells to generate FDC-dependent, but T cell-independent, B cell responses to T cell-dependent antigens, with antigen-specific and polyclonal antibody production in ˜48 h. In another embodiment, a germinal center (GC) lymphoid tissue equivalent (LTE) was used to... Agent: Merchant & Gould PC

20090104222 - Composition comprising a glucan or a glucan derivative and a pesticide and methods for improving plant health: The present invention relates to a method for improving the health of an agricultural plant by applying to the plant, the locus where the plant is growing or is expected to grow, and/or the seeds from which the plant grows a non-phytotoxic effective amount of active ingredient mixtures, comprising component... Agent: Birch Stewart Kolasch & Birch

20090104223 - Method for obtaining antigenic aggregates and the use thereof in formulations: The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and... Agent: Hoffmann & Baron, LLP

20090104224 - Modified vaccinia virus ankara for the vaccination of neonates: In particular, the invention concerns the vaccination of neonates against infections with viruses belonging to the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen... Agent: Law Office Of Salvatore Arrigo

20090104225 - Use of mva to treat prostate cancer: The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or... Agent: Law Office Of Salvatore Arrigo

20090104226 - Alphavirus vectors for respiratory pathogen vaccines: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as... Agent: Novartis Vaccines And Diagnostics Inc.

20090104227 - Vaccine composition for the prevention of cmv infection: The invention relates to a method for preventing HCMV infection in HCMV seronegative human subjects and for preventing HCMV congenital infection in newborns, which method comprises administering an effective amount of a vaccine composition containing the gB antigen of HCMV in an O/W emulsion to the seronegative human subjects.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090104228 - Influenza virus vaccine: The invention relates to influenza virus vaccines, and in particular to a reassortant influenza virus which has at least its hemagglutinin gene derived from a non-pathogenic or low pathogenic influenza virus, and its other genes derived from a donor strain. In one embodiment the influenza virus is a 7:1 reassortant,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090104229 - Novel use: The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gp120 protein or polynucleotide in the manufacture of a... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090104230 - Compositions and methods of using capsid protein from flaviviruses and pestiviruses: This invention provides methods of inducing cell death with Flavivirus or Pestivirus capsid protein, such as West Nile virus (WNV) capsid protein, and functional fragments thereof. The invention also provides methods of treating patients suffering from diseases characterized by hyperproliferating cells by administering pharmaceutical compositions comprising WNV or other virus... Agent: Pepper Hamilton LLP

20090104231 - Vaccine: The present invention relates to methods and compositions useful in the treatment and prevention of Hepatitis C virus (HCV) infections and the symptoms and diseases associated therewith. In particular the present invention relates to DNA vaccines comprising polynucleotide sequences encoding HCV proteins, and methods of treatment of individuals infected with... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090104232 - Compositions and methods for inducing an immune response against yersinia pestis: The invention provides a gene transfer vector for inducing an immune response against Yersinia pestis in a mammal. The gene transfer vector comprises a nucleic acid sequence encoding an immunogenic portion of one or more proteins of Yersinia pestis and/or a nucleic acid sequence encoding a monoclonal antibody directed against... Agent: Leydig Voit & Mayer, Ltd

20090104233 - Identification of residues critical for the function of the vibrio cholerae virulence regulator toxt by scanning alanine mutagenesis: Disclosed are Vibrio cholerae comprising a mutated transcriptional regulatory protein (ToxT) amino acid sequence, wherein the mutation results in a reduction in the expression of cholera toxin by the Vibrio cholerae. Also disclosed are Vibrio cholerae comprising a mutated transcriptional regulatory protein (ToxT) amino acid sequence, wherein the mutation results... Agent: Fulbright & Jaworski L.L.P.

20090104234 - Methods of treating chronic neurogenic inflammation using modified clostridial toxins: The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such modified Clostridial toxins and compositions.... Agent: Allergan, Inc.

20090104237 - Method for increasing tissue oxygenation: Disclosed are methods and compositions for increasing tissue oxygen levels by administration of superoxygenated compositions of tissue surfaces. The methods are applicable to treatment of a wide variety of conditions including burns, bedsores, ulcers, necrosis and anaerobic infections.... Agent: Akerman Senterfitt

20090104235 - Method for producing of a preparation of a solid dmso-containing silicone oil emulsion for the binding of reactive oxygen compounds in human and animal bodies: The invention relates to a method for production of an oral, rectal or vaginal preparation comprising a solid silicone oil emulsion, characterized in that said preparation comprises 0.01-85 wt. % dimethicone and 0.01-45 wt. % dimethylsulphoxide, whereby the preparation dissolves after application and the emulsion is released. The dimethylsulphoxide is... Agent: Patent Central LLC Stephan A. Pendorf

20090104236 - Pharmaceutical solid hybrids: The invention provides solid pharmaceutical hybrids that are useful in the treatment or diagnosis of diseases, as well as methods of producing the solid pharmaceutical hybrids.... Agent: Leydig Voit & Mayer, Ltd

20090104238 - Method for producing polymers modified by silicone: e

20090104239 - Method, material and system for controlled release of anti-microbial agents: There is provided a method for treating a fluid with an anti-microbial agent comprising the steps of: (a) contacting the fluid with a solid material containing an anti-microbial agent; and, (b) abrading an interface of the solid material and removing particles therefrom and exposing an underlying surface of the solid... Agent: Docketing Specialist Sullivan & Worcester LLP

20090104246 - local administration of a combination of rapamycin and panzem for the treatment of vulnerable plaque: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20090104245 - Biodegradable carrier and method for preparation thereof: A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where said biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in said biodegradable carrier are infecting and/or transfecting viruses.... Agent: James C. Lydon

20090104243 - Drug cores for sustained release of therapeutic agents: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid... Agent: Schwegman, Lundberg & Woessner, P.A.

20090104240 - Dual drug formulations for implantable medical devices for treatment of vascular diseases: The present invention relates to implantable medical devices coated with the polymer containing at least an olimus and a corticosteroid for the treatment of vascular diseases.... Agent: Squire, Sanders & Dempsey LLP

20090104242 - Niobium oxide compositions, nanostructures, bioactive forms and uses thereof: Self-organized niobium oxide nanocones with nano-sized tips are prepared by anodization of niobium in the presence of an electrolyte such as hydrofluoric acid (HF) (aq.). Dimensions and integrity of the bulk nanostructures formed are strongly dependent on potential, temperature, electrolyte composition, and anodization times. Accordingly, the morphology, topology, uniformity and... Agent: Bose Mckinney & Evans LLP

20090104241 - Random amorphous terpolymer containing lactide and glycolide: The present invention provides an amorphous terpolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same... Agent: Squire, Sanders & Dempsey LLP

20090104244 - Therapeutic agent-eluting medical devices having textured polymeric surfaces: A medical device comprising: (a) a substrate having first and second surfaces, (b) a therapeutic-agent-eluting polymeric layer disposed over the first substrate surface and (c) a textured polymeric layer that is textured to promote cell attachment, cell growth, or both, disposed over the second surface.... Agent: Mayer & Williams PC

20090104247 - Coating designs for the tailored release of dual drugs from polymeric coatings: Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same.... Agent: Squire, Sanders & Dempsey LLP

20090104248 - Lacrimal implants and related methods: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090104249 - Exotoxin inhibitory factor: The invention provides an exotoxin inhibitory factor, compositions containing the factor, methods of using the compositions.... Agent: Fish & Richardson P.C.

20090104250 - Medical or veterinary digestive tract utilization systems and methods: Systems and methods are described for implementing or deploying medical or veterinary utility modules (a) operable for mooring at least partly within a digestive tract, (b) small enough to pass through the tract per vias naturales and including a wireless-control component, (c) having one or more attachment protrusions positionable adjacent... Agent: Searete LLC Clarence T. Tegreene

20090104251 - Heat stable microcapsules and methods for making and using the same: A method of manufacturing a microcapsule that may include complex coacervating a protein and a polyanionic polymer to form a coacervate, the coacervate being at least a portion of the microcapsule, and wherein a cross-linking reagent is not used during the coacervation.... Agent: Michael Best & Friedrich LLP

20090104252 - Wound dressing for improving scarring: An occlusive wound dressing for application to wound sites to accelerate the healing process and improve the appearance of the final mature scar including a silicone gel sheet and antimicrobial silver disposed in the silicone gel sheet where the silver may be present in the form of particles or wires... Agent: Drinker Biddle & Reath LLP Attn: Patent Docket Dept.

20090104253 - Hemostatic biocidal dressing: A hemostatic biocidal dressing includes pro-coagulant and biocidal agents providing a physical barrier to bleeding as well as chemical action to promote blood coagulation and thereby arrest coverage. At the same time, biocidal properties of the dressing prevent the introduction of infected agents and the establishment of infection within wounded... Agent: Bergman & Song, LLP

20090104259 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent: Pepper Hamilton LLP

20090104260 - Compositions and methods for sirna inhibition of icam-1: RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can... Agent: Pepper Hamilton LLP

20090104254 - Controlled release hydrogels: Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.... Agent: Davidson, Davidson & Kappel, LLC

20090104257 - Liposomal vancomycin formulations: The present disclosure relates in part to liposomal vancomycin compositions having low lipid to drug ratios and high concentration of vancomycin. The present disclosure also relates in part to methods of making such compositions.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090104255 - Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds: This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, antioxidant or anti-inflammatory compounds to the gastrointestinal tract after oral administration.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090104256 - Methods of treating pulmonary disorders with liposomal amikacin formulations: Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090104258 - Use of tocopheryl phosphate as an agent for preventing or slowing down the appearance of the effects of skin ageing: The invention relates to a cosmetic composition of a tocopheryl phosphate, especially in its dl or d form, or in the form of a cosmetically acceptable salt or ester thereof, as a cosmetic agent for preventing or slowing down the appearance of the effects of skin ageing, in particular of... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090104261 - Treatment for attention-deficit hyperactivity disorder: A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and related compounds is provided.... Agent: King & Spalding

20090104263 - 5-ht4 partial agonist pharmaceutical compositions: A solid pharmaceutical composition for oral administration comprising tegaserod in base or salt form in an amount of up to 10% by weight a bulking agent in an amount of 70 to 90% by weight a disintegrant in an amount of less than 15% by weight a glidant and a... Agent: Novartis Corporate Intellectual Property

20090104262 - Chlorthalidone combinations: The invention relates to favourable combinations of the thiazide diuretic chlorthalidone with Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090104264 - Controlled release solid preparation: The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing a combination of (1) an... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090104265 - Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl) 2-[2-methyl-4,5-(methylenedioxy)phenylacetyl] thiophene-3-sulfonamide, sodium salt: N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenyl-acetyl]thiophene-3-sulfonamide, sodium salt, is provided herein in the form of three polymorphs (Forms A, B and C). Forms A, B and C are specified by the peaks in their X-ray powder diffraction patterns, their absorption peaks in their infrared absorption spectra, their peaks in their Raman spectra and their melting... Agent: Jones Day

20090104266 - 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation: (

20090104267 - Soft tablet containing high molecular weight cellulosics: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional tastemasking coating, and a matrix comprising hydroxyalkylcellulose having a weight average molecular weight of from about 60,000 to about 5,000,000. The tablet possesses... Agent: Philip S. Johnson Johnson & Johnson

20090104270 - Film delivery system for tetrahydrolipstatin: The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including tetrahydrolipstatin, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided.... Agent: Hoffmann & Baron, LLP

20090104272 - Inhaled hypertonic saline delivered by a heated nasal cannula: The invention described herein is directed to method of treating chronic obstructive pulmonary disease, comprising administering an effective amount of an osmolyte by at least one nasal cannula to a subject in need thereof. Also provided is a nasal cannula system for delivering an osmolyte, comprising a nebulizer and tubing... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090104269 - Nanoformulations: Methods, and the products thereof, for producing nanoparticles that in some embodiments are at least partially encapsulated by an encapsulant; and methods, and products thereof, for producing nanoformulations that are suspensions of nanoparticles in a liquid formulation. Typically the nanoparticles include agrochemicals, pharmaceuticals, catalysts, and other active ingredients.... Agent: Battelle Memorial Institute

20090104268 - Nanoparticles comprising antigens and adjuvants, and immunogenic structures: Nanoparticles comprising adjuvants and antigens, such as tumour and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and... Agent: Dann, Dorfman, Herrell & Skillman

20090104273 - Novel nifedipine compositions: The present invention is directed to nanoparticulate compositions comprising nifedipine. The nifedipine particles of the composition have an effective average particle size of less than about 2 microns.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090104271 - Use of microparticles combined with submicron oil-in-water emulsions: Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submicron oil-in-water emulsion, and (b) a therapeutically effective amount of a selected antigen entrapped in a microparticle.... Agent: Novartis Vaccines And Diagnostics Inc.

20090104274 - Process of making microspheres: A process for the manufacture of free-flowing uniformly sized micro spheres for the sustained release of therapeutically active ingredient comprising: a) preparing a first dispersed phase comprising a therapeutically active ingredient, a biodegradable polymer and an organic solvent; b) mixing the first dispersed phase with a aqueous phase to form... Agent: Sughrue Mion, PLLC

20090104276 - Absorbable copolyesters of poly(ethoxyethylene diglycolate) and glycolide: A semi-crystalline, absorbable copolyester composition comprising the reaction product of a polycondensation polyester and at least one lactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and diethylene glycol; and the copolyester comprises about 30 to 60% by weight of the polycondensation polyester... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20090104275 - Nanoencapsulation of proteins: The protein encapsulation via entrapping protein in CaCO3 microparticles followed by polymeric shell deposition can be used for vaccination based on protein antigen, and in particular rPA 102.... Agent: Alexander Grinberg Md

20090104277 - preparation of molecular imprinted polymers: One aspect is a method for improved preparation of molecular imprinted polymer (MIP) particles, where initial compositions comprising insoluble MIP particles are enriched for those MIP particles that bind a particular target molecule, thus excluding non-binding and weakly binding particles from the final composition. Enrichment is typically accomplished via use... Agent: Harness, Dickey & Pierce, P.L.C

20090104278 - Food composition for recovery from fatigue: In the present application are disclosed a food composition for recovery from fatigue, comprising, as an effective ingredient, an extract of migratory fish such as a Perciformes Scombrina, or a composition of the make-up similar to the extract, according to which food composition can be provided a food composition for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090104279 - Use of pak inhibitor for the treatment of a joint disease: The invention refers to the use of a p21-activated kinase (PAK) inhibitor as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090104280 - Pharmaceutical compositions for treating/preventing motor organ diseases: Fullerene inhibited the decrease in cell proliferation ability of chondrocytes which is observed when cultured chondrocytes are treated with a cartilage degenerating factor (IL-1β or H2O2). Fullerene inhibited production of cartilage matrix-degrading enzymes (matrix metalloprotease (MMP)-1, 3 and 13) which is induced in cultured chondrocytes by cartilage degenerating factors. Fullerene... Agent: Townsend And Townsend And Crew, LLP

20090104281 - Compositions having a high antiviral and antibacterial efficacy: A method of providing a rapid, broad spectrum bacterial control, and a rapid persistent antiviral control on a surface, and particularly a mammalian skin surface, is disclosed. In the method, a compound or composition capable of lowering skin pH to less than about 4 is applied to the skin, and... Agent: Marshall, Gerstein & Borun LLP (dial)

20090104282 - Method for the treatment of nail disease: A treatment for diseased nails comprises treating the diseased nail after thorough cleaning with a peroxide solution, and thereafter applying an iodine solution until the diseased nail has recovered.... Agent: Ursula B. Day, Esq.

20090104283 - Method for reducing the severity of neurological disorders: t

20090104284 - Topically applied chitosan composition for pain relief and boosting immune system: A composition of matter that when applied topically relieves pain in the area where it is applied (i.e. knees, back, elbows, heels, etc.). The composition contains chitosan, canola oil, sea salt minerals (chloride ion, sulfate ion, calcium, potassium, zinc, sodium, magnesium and nickel), and water. To make the composition, the... Agent: Berenato, White & Stavish, LLC

20090104285 - Methods and compositions for use in treating cancer: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.... Agent: Clark & Elbing LLP

20090104286 - Regulation of allergic reaction: After the analysis of 21 genes which are involved in the inflammatory processes of a mouse, it was shown that, among other things, the featured preparations strongly activate NFkB and its translocation from cytoplasm into the nucleus in spleen cells. Besides that, by activation of relb genes, the featured preparations... Agent: Ratnerprestia

20090104287 - Protocol for aids prevention and treatment by nutritional methods: HIV-1 is a slow virus that has a genome that requires the removal of glutathione, glutathione peroxidase and of selenium, cysteine, glutamine and tryptophan from its host as it is replicated. Although various clinical trials have improved the health of AIDS patients by correcting one or more of these nutritional... Agent: Robert H. Barrigar Barrigar Intellectual Property Law

20090104288 - Compositions and methods for inhibiting a honey bee pathogen infection or controlling a hive infestation: The present invention is directed to methods and compositions to prevent or treat a honey bee pathogen infection (e.g., Melissococcus plutonis, Paenibacillus larvae, Ascosphaera apis). Specifically, the invention provides for the treatment or prevention of European or American foulbrood or chalkbrood. In addition, the invention provides methods for controlling Varroa... Agent: Edwards Angell Palmer & Dodge LLP

20090104290 - Energizing formulation: The present invention relates to a pre-mix and a pharmaceutical composition for oxygenating a subject's tissues, uses and methods of treatment thereof.... Agent: Bereskin And Parr

20090104289 - Formulation of antimicrobial film, coatings and/or sprays containing portulaca oleracea extract and film prepared therefrom: An antimicrobial film formulation is prepared by extracting Portulaca oleracea using chloroform, petroleum ether or hot water, filtering and concentrating the extract, processing the concentrated extract into a liquid or powder state, and completely dissolving 0.25-0.5% (w/v) of the Portulaca oleracea extract, 1.5-2% (w/v) of chitosan and 0.5-2% (w/v) of... Agent: Lowe Hauptman Ham & Berner, LLP

20090104292 - Topical arnica treatment for reducing bruising: A method of preventing post-surgery, post-laser treatment or post-traumatic bruising of the skin comprising applying topically to the affected area of the skin a treatment comprising at least 15% by weight Arnica Montana and preferably 30-40% by weight Arnica Montana.... Agent: Drinker Biddle & Reath LLP Attn: Patent Docket Dept.

20090104291 - Water-dispersible nanoparticle which contains blood circulation promoter: It is an object of the present invention to provide a nanoparticle which comprises a blood circulation promoter and a biodegradable polymer, which is safe and excellent in terms of dispersion stability and has high transparency and good absorbability due to its small particle size. The present invention provides a... Agent: Sughrue Mion, PLLC

20090104294 - Bioactive composition for cosmetic applications: The invention relates to a process for the preparation of a plant extract from Curcuma plants, characterized by the process steps process step A) liquid extraction of Curcuma rhizomes, process step B) optionally, separation of a curcuminoid-containing solid obtained by precipitation from the extraction mixture obtained in process step A),... Agent: Scully Scott Murphy & Presser, PC

20090104293 - Use of a potent product extracted from rhizomes of zingiber officinale in treating a disease associated with helicobacter pylori: The present invention discloses a new use of a potent product extracted from rhizomes of Zingiber officinale in treating a disease associated with Helicobacter pylori such as gastritis, gastric ulcer or duodenal ulcer in a patient. The potent product is prepared by a process including the steps of a) preparing... Agent: Bacon & Thomas, PLLC

20090104295 - Agent for hair growth: The aim of this invention is to offer a novel agent for hair growth, which has excellent hair growth effects but not side effects. The agent for hair growth of the present invention is characterized by comprising a processed semi-mature soybean and/or a processed semi-mature soybean extracts and at least... Agent: The Webb Law Firm, P.C.

20090104296 - Discovery of the ability of an effective natural plant product-peeled apple pips (seeds), taken internally-to affect very significantly a human organism delaying the onset of factors associated with ageing: e

20090104297 - Herbal composition for treatment of infections caused by dermatophytes: The present invention relates to a novel herbal composition comprising extract of roots of the plant Murraya koenigii for the treatment of infections caused by dermatophytes, particularly tinea infections, and method of manufacture of said composition. The said herbal composition comprises 2-methoxy-3-methyl-9H-carbazole (compound 1) as a bioactive ingredient. Invention also... Agent: Merchant & Gould PC

20090104298 - Use of rooibos extract for protecting hair colour: The invention relates to the use of an extract of fermented and/or unfermented rooibos leaves and/or stems for reducing or slowing the loss of the natural or artificial colour of hair.... Agent: Connolly Bove Lodge & Hutz LLP

20090098044 - Solid particles from controlled destabilisation of microemulsions: The present invention relates to a process for making a particulate substance. The process comprises providing an emulsion, optionally a microemulsion, comprising droplets dispersed in a continuous liquid phase. At least some of the droplets of the emulsion comprise nuclei. The droplets are then at least partially destabilised to form... Agent: Foley And Lardner LLP Suite 500

20090098045 - Cytotoxicity mediation of cells evidencing surface expression of mcsp: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.A.

20090098046 - Combination cancer therapy with anti-psma antibodies: This invention includes compositions and methods for combination cancer treatments, particularly involving at least one cytotoxic agent used in combination with an anti-PSMA monoclonal antibody.... Agent: Morgan Lewis & Bockius LLP

20090098047 - Bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands: i

20090098051 - Bacillus thuringiensis toxin: A new Bt Cry toxin, Cry1M is able to exert insecticidal effects on insects and/or nematodes in general, and in addition, on insects that have acquired resistance to alternative Cry proteins.... Agent: Morrison & Foerster LLP

20090098050 - Calcium binding peptides: Disclosed herein are a class of compounds comprising peptides of the sequence (X-Y-Z)n, wherein X is an amino acid selected from aspartic acid, glutamic acid, asparagine, alanine and glutamine, and Y and Z are amino acids selected from alanine, serine, threonine, phosphoserine, phosphothreonine, and their derivatives. These compounds have the... Agent: Townsend And Townsend And Crew, LLP

20090098053 - La1 - the genome of a lactobacillus strain: The present invention pertains to the use of the DNA sequence of a Lactobacillus johnsonii strain, in particular to its genomic sequence for elucidating interactions of micro-organism with hosts they colonize, and moreover for elucidating the basis of probiotic properties exhibited by such strain. In addition, the present invention also... Agent: Bell, Boyd & Lloyd LLP

20090098049 - Targeting transducible molecules to specific cell types: The disclosure provides fusion polypeptides and constructs useful in targeting molecules including diagnostics and therapeutics to a cell type of interest. The fusion constructs include a protein transduction domain, a ligand domain and a cargo domain. Also provided are methods of treating disease and disorders such as cell proliferative disorders.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090098052 - Transgenic mice: A transgenic non-human animal, in particular a transgenic mouse encoding Aβ peptide proteins, which have been implicated in Aβ peptide-related diseases. Cells and cell lines comprising transgenes encoding for Aβ peptide. Methods and compositions for evaluating agents that affect Aβ peptide, for use in compositions for the treatment of Aβ... Agent: Sonnenschein Nath & Rosenthal LLP

20090098056 - Alpk1 gene variants in diagnosis risk of gout: The present invention relates to a method of identifying a human subject having an elevated risk of gout and/or hyperuricemia by detecting the occurrence of at least one SNP associated with an elevated risk of gout in an ALPK1 gene in a biological sample from the subject, or by determining... Agent: Alston & Bird LLP

20090098055 - Methods and compositions for diagnosing disease: The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090098054 - Methods and compositions relating to promoter regulation by muc1 and klf proteins: This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or inflammatory cell growth and/or activation. The invention provides methods of, and compositions useful for, inhibiting interactions between MUC1 and a kruppel-like factor (KLF), method of inhibiting interactions between a KLF protein... Agent: Fulbright & Jaworski L.L.P.

20090098059 - Contrast agents: The present invention relates to iodine containing compounds containing a central optionally substituted cyclohexane central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging... Agent: Ge Healthcare, Inc.

20090098058 - Method of injecting liquid agents at acupuncture points to arrive internal organs and method of visualizing arrival of liquid agents: Provided are a method of injecting a visualizing material into a point in the vicinity of the Jung-Wan and a method of visualizing arrival of liquid agent in order to verify that the visualizing material injected arrives at internal organs. A point having the lowest electric resistance is found in... Agent: Ipla P.A.

20090098057 - Silica-cored carrier particle: A nanoparticulate imaging probe with an oxide core, a biocompatible polymeric shell covalently attached to the oxide core, a dye, and a cleavable spacer that covalently binds the dye to the probe. When the spacer is cleaved, the dye is liberated from the probe. The emissions of the dye are... Agent: Susan L. Parulski, Patent Legal Staff Carestream Health, Inc.

20090098060 - Aerosol compositions: An aerosol composition comprising: 0.01 wt % to 1.00 wt % sodium borate; 0.01 wt % to 1.50 wt % polyglycerol ester surfactant; <30 wt % propellant; and 67.5 wt % to 85.0 wt % water. Methods of manufacture of an aerosol air freshener are also described wherein the aerosol... Agent: Norris, Mclaughlin & Marcus

20090098062 - Activated peroxide solutions and a process for the preparation thereof: The present invention discloses an activated biocidal aqueous solution containing hydrogen peroxide (activated peroxide solution) obtainable by subjecting an initial solution of hydrogen peroxide in water to a non-thermal electrical discharge process, such as a glow discharge plasma or a corona discharge. The resulting activated peroxide solution containing 0.05 to... Agent: Oliff & Berridge, PLC

20090098063 - Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response: The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus.... Agent: Keown & Zucchero, LLP

20090098064 - Method of treating pulmonary edema or pulmonary inflammation: The invention provides a method for preventing or treating pulmonary edema and/or pulmonary inflammation in a subject by the administration of at least one nucleotidase. The subject is preferably a human subject. The nucleotidase is preferably of a mammalian origin, such as a human origin. The NTPDase and NPP families... Agent: Howery LLP

20090098061 - Solution for tissue adhesion prevention and method for tissue adhesion prevention: The objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and convenient. The invention is the solution for tissue adhesion prevention of which the... Agent: Sughrue Mion, PLLC

20090098065 - Composition and methods for the treatment of skin disorders: Methods and pharmaceutical compositions for use in the treatment of benign or malignant proliferative pathologies are disclosed. The methods involve the topical administration of nicotinamide or a nicotinamide derivative in combination with a vitamin D compound. The combination is shown to act in synergy and is especially useful for treatment... Agent: Winston & Strawn LLP Patent Department

20090098066 - Substituted bicyclo [2.2.2] oct/5-ene compounds and their use as cooling agents: t

20090098072 - Antioxidants: The invention relates to the use of compounds of formula (X—Ar—Y), in which X and Y respectively are selected independently of one another from the groups H, C-1-8 alkyl and groups as per formulae (Ia), (Ib) or (Ic), together with other groups that are defined as cited in the description,... Agent: Millen, White, Zelano & Branigan, P.C.

20090098071 - Cosmetic and dermatological light protection formulations in the form of o/w macroemulsions or o/w microemulsions, with a content of dihydroxyacetone: A process for preparing a sprayable self-tanning oil-in-water microemulsion having an oil droplet diameter in a range of from about 10−1 μm to about 10−2 μm. The process comprises changing a pH of a mixture comprising an aqueous phase, an oil phase, from 0.5% to 6% by weight of dihydroxyacetone... Agent: Greenblum & Bernstein, P.L.C

20090098067 - Foamable sanitizing compositions: Foamable sanitizing compositions are disclosed. The compositions contain alcohol, water, a foaming agent, and a foam strengthening agent. The foaming agent which may comprise a derivatized dimethicone has been found to cause the alcohol solution to foam even though alcohol has various defoaming properties. The foam strengthening agent may comprise,... Agent: Dority & Manning, P.A.

20090098068 - Self-tanning cosmetic: a

20090098070 - Sunscreen compositions with low eye-sting and high spf: Sunscreen compositions that prevent, reduce or minimize eye-stinging while maintaining a high level of SPF protection.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090098069 - Transdermal, alcohol-free, pharmaceutical compositions: An alcohol-free, transdermal drug delivery composition administered via a metered spray drug delivery device is described herein. The non-occlusive transdermal drug delivery composition includes a therapeutically effective amount of at least one physiologically active agent or prodrug thereof, an effective amount of at least one dermal penetration enhancer; and at... Agent: Kv Pharmaceutical Company

20090098074 - Keratin-binding effector molecules containing reactive dyes: The invention relates to keratin-binding effector molecules comprising reactive dyes and keratin-binding polypeptides and to their use in hair-dyeing preparations. The present invention further relates to a method of dyeing hair.... Agent: Connolly Bove Lodge & Hutz, LLP

20090098073 - Phase change visual indicating composition: A skin sealant composition of a film former and a plasticizer and having various color changing dyes may be used to indicate that the composition has dried. The dyes change color in response to the phase change, i.e., drying of the film former. The dye may be added either directly... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20090098075 - Hops-based deodorant: The present invention relates to deodorants and other body care products comprising a CO2 extract of the hops plant having bacteriocide/bacteriostat properties wherein the CO2 extract has a very low level of essential hops oils.... Agent: Kevin Farrell Pierce Atwood

20090098076 - Method for the production of a keratin-binding effector molecule: The invention relates to a method of producing keratin-binding effector molecules, and to intermediates and end-products of the method according to the invention and to the use of the keratin-binding effector molecules produced according to the invention in dermocosmetics. In addition, the invention relates to a method of applying dermocosmetically... Agent: Connolly Bove Lodge & Hutz, LLP

20090098079 - Product release system for atomizing cosmetic hair compositions containing cationic polymers: A product release system for atomizing cosmetic hair compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition, which contains at least one film-forming, hair-setting, or hair-conditioning cationic polymer. The atomization is done using the capillary. The capillary preferably has a... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090098078 - Water-in-oil microemulsions for hair treatment: The present invention provides a water-in-oil microemulsion for hair treatment comprising: (a) an oil phase comprising: (i) a first oily component which is one or more glyceride fatty esters, and (ii) a second oily component which is one or more hydrocarbon oils of average carbon chain length less than 20... Agent: Unilever Patent Group

20090098077 - Two-phase composition for improving curl retention: The present invention is related to a composition for conditioning and improving curl retention of permanently shaped and/or natural curly hair comprising two optically separated phases at zero shear rate which becomes homogeneous upon shaking and returns to optically separated phases. Specifically, present invention is on two phase composition for... Agent: Norris, Mclaughlin & Marcus, P.A.

20090098080 - Method of controlling oil-absorbing properties of a silicone rubber powder: A method of controlling oil-absorbing properties of a silicone rubber powder characterized by keeping a silicone rubber powder in hot storage at a temperature in the range of 40° C. to 150° C. or in cold storage at a temperature in the range of 0° C. to 10° C.... Agent: Howard & Howard Attorneys PLLC

20090098081 - System for providing a method for applying a skin sealant having a phase change visual indicating component: A system for providing a method of sealing skin with a film forming polymer is provided. The system includes providing an at least two part applicator containing a sealant composition in one or more frangible containers, providing instructions for using the applicator associated therewith, where the method including moving at... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20090098082 - Substiuted organopolysiloxanes and use thereof: The compounds are useful as scavengers for the removal of unwanted organic and inorganic compounds, for solid phase extraction, for solid phase synthesis, for catalysis, for metal ion abstraction and for the immobilisation of bio-molecules. In addition, the compounds have high chemical and thermal stability, fixed and rigid structures, are... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090098083 - Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds: The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.... Agent: Clark & Elbing LLP

20090098084 - Parp inhibitor compounds, compositions and methods of use: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or... Agent: Connolly Bove Lodge & Hutz LLP

20090098085 - Tetrazolyl acyclic hepatitis c serine protease inhibitors: which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the... Agent: Elmore Patent Law Group, PC

20090098086 - Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors: i

20090098087 - Method of treating lactose intolerance using genetically engineered bacteria: The present invention relates to genetically engineered bacteria that are able to colonize the mammalian intestine and actively produce mammalian lactase (lactose-phlorizin hydrolase or LPH). This lactose-digesting enzyme is stable and active under the conditions normally found in the mammalian small intestine. Experimental subjects colonized with the genetically engineered bacteria... Agent: Trojan Law Offices

20090098088 - Methods and kits for the treatment of diverticular conditions: The present invention relates to methods and kits that are useful for the treatment of diverticular disease, diverticulitis, and combinations thereof. The methods comprise administering to a mammal in need of treatment a composition comprising a probiotic, either alone or in combination with an anti-inflammatory or an antibiotic.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090098089 - Reovirus for the treatment of neoplasia: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type... Agent: Fish & Richardson P.C.

20090098092 - Composite bone material and method of making and using same: Bone composite implants and the method of constructing bone composite implants are disclosed which may be used in the repair, replacement, and/or augmentation of various portions of animal or human skeletal systems. Furthermore, the bone composite implants of the present invention may be considered load-bearing implants which are incorporated into... Agent: Waddey & Patterson, P.C.

20090098091 - Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis: The present disclosure teaches analogs of human chemokines and methods of using them in the prevention, treatment, and ameliorization of diseases that can benefit from therapeutic angiogenesis. The teachings are generally directed to compositions comprising SDF-1 mimetics, as well as methods that include the use of SDF-1 mimetics to induce... Agent: Tips Group C/o Intellevate LLC

20090098093 - Generation of inner ear cells: Methods for generating cells of the inner ear, e.g., hair cells and supporting cells, from stem cells, e.g., mesenchymal stem cells, are provided, as well as compositions including the inner ear cells. Methods for the therapeutic use of the inner ear cells for the treatment of hearing loss are also... Agent: Fish & Richardson PC

20090098094 - Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090098090 - Vitro immunization: The present invention relates generally to a method of generating lymphocytes specific for particular antigens. More particularly, the present invention provides a method for generating antigen-reactive T- cells and even more particularly cytotoxic (CD8+) T-cells in 10 vitro specific for antigens such as peptide antigens. The method of the present... Agent: Knobbe Martens Olson & Bear LLP

20090098095 - Method of expanding double negative t cells: A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8+ and CD4+ T cells from the starting sample; (c) culturing the sample from step (b) with an immobilized T... Agent: Bereskin And Parr

20090098096 - Agent for correcting stress-inducing neuro-mediator, neuro-endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions: The invention relates to medicine, in particular to pharmacology, and is embodied in the form of an agent for limiting neuro-mediator, neuro-endocrine and metabolic disturbances generating the disorders of a central nervous system and functional somatic disorders. The inventive agent is based on a DSIP (delta sleep inducing peptide) or... Agent: Borden Ladner Gervais LLP Gail C. Silver

20090098098 - Anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) a mixture of a coenzyme having reducing ability and quinones,... Agent: Occhiuti Rohlicek & Tsao, LLP

20090098097 - Composition for normalizing blood pressure: The present inventors have found that coenzyme Q has a superior effect for normalizing the blood pressure and completed the present invention. That is, the present invention provides a composition for normalizing the blood pressure, which contains reduced coenzyme Q as an active ingredient, and a composition for normalizing the... Agent: Sughrue Mion, PLLC

20090098099 - Plant transformed with polynucleotide encoding lepidopteran-active bacillus thuringiensis delta-endotoxin: Disclosed are Bacillus thuringiensis strains comprising novel crystal proteins which exhibit insecticidal activity against lepidopteran insects. Also disclosed are novel B. thuringiensis genes and their encoded crystal proteins, as well as methods of making and using transgenic cells comprising the novel nucleic acid sequences of the invention.... Agent: Howrey LLP

20090098100 - Hormonally up-regulated, neu-tumor-associated kinase: This invention relates generally to a novel serine/threonine protein kinase, specifically to hormonally up-regulated, neu-tumor-associated kinase (HUNK); and to the nucleotide sequence encoding it. The kinase is temporally expressed during postnatal mammary development in a spatially heterogeneous manner in certain subsets of cells, and overexpressed in a subset of primary... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090098101 - Compositions and methods for ribonuclease-based therapeutics: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in... Agent: Casimir Jones, S.c.

20090098102 - Cosmetic composition containing enzyme and amino acid: The present invention relates to a skin cosmetic composition containing enzyme and amino acid. More particularly, the skin cosmetic composition according to the invention contains enzyme and amino acid, and thus safely improves stratum corneum thickening resulting from the progression of skin aging, improves skin drying occurring during keratin removal,... Agent: Nixon & Vanderhye, PC

20090098104 - Method for diagnosing cardiovascular diseases: Method for diagnosing a cardiovascular disease in an individual comprising the steps of: providing a sample of an individual; determining the amount of cytokeratin-18 (CK-18) or fragments thereof and/or interleukin-1β precursor (IL-1β precursor) in said sample; comparing the amount of CK-18 or fragments thereof and/or IL-1β precursor in said sample... Agent: Fulbright & Jaworski L.L.P.

20090098103 - Modified factor vii polypeptides and uses thereof: Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.... Agent: Bell, Boyd & Lloyd LLP

20090098048 - Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor: d

20090098113 - Activin-actriia antagonists and uses for promoting bone growth: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.... Agent: Ropes & Gray LLP

20090098114 - Alk7 and myostatin inhibitors and uses thereof: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke,... Agent: Ropes & Gray LLP

20090098109 - Compositions and methods for enhancing neuronal plasticity and regeneration: The present invention relates PirB expression and function in nervous tissue. PirB expressed in neurons acts to restrict plasticity of neural circuits, and/or, restrict competition between circuits with different activity patterns or levels, for cortical representation. Thus, the present invention relates to methods of increasing nervous system plasticity and associated... Agent: Edwards Angell Palmer & Dodge LLP

20090098110 - Injectable forms of solid-forming crosslinked bioelastic biopolymers for local drug delivery: A method for delivering a compound of interest to a selected region in a subject is carried out by administering a composition to the region of interest, the composition comprising a cross-linked bioelastomer in combination with the compound of interest non-covalently combined with the cross-linked bioelastomer. In some embodiments, the... Agent: Myers Bigel Sibley & Sajovec

20090098107 - Method of detecting relative risk for the onset of atopic dermatitis by gene single nucleotide polymorphism analysis: The present invention provides a method of discriminating a relative risk for the morbidity of atopic dermatitis of a test subject comprising: analyzing gene polymorphism of two or more of genes related to onset of atopic dermatitis using a sample isolated from a statistically significant number of normal persons and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090098111 - Methods for modulating checkpoint activation through topbp1: ATR kinase is a key regulator of checkpoint responses to incompletely replicated and damaged DNA. Without this checkpoint, cells will enter mitosis prematurely, likely resulting in cell death. The invention provides methods and reagents to either block or activate the activation of the ATR kinase checkpoint, through, for example, either... Agent: Ropes & Gray LLP

20090098112 - Novel antibodies: The present invention relates to the use of VEGF antagonists and a novel anti-α5β1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-α5β1 antibodies and methods of making and using them.... Agent: Genentech, Inc.

20090098106 - Pharmaceutical compositions for treating diseases associated with nf-kb activity: A method of treating a disease associated with NF-κB activity. The method is effected by providing to a subject in need thereof a therapeutically effective amount of an agent capable of modulating NIK-HC8 binding.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090098105 - Treatment of neurodegenerative diseases by the use of scd4 inhibitors: The present invention relates to the use of SCD4 interacting molecules, especially SCD4 inhibitors, for the preparation of a medicament for the treatment of neurodegenerative diseases, particularly Alzheimer's disease.... Agent: Clark & Elbing LLP

20090098108 - Use of long-acting glp-1 receptor agonists to improve insulin sensitivity and lipid profiles: The present invention provides to at least one novel human GLP-1 receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 receptor agonist, or specified portion or variant, GLP-1 receptor agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants,... Agent: Philip S. Johnson Johnson & Johnson

20090098119 - Antidotes for factor xa inhibitors and methods of using the same: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are... Agent: Foley & Lardner LLP

20090098115 - Cell lines and animal models of her2 expressing tumors: The present invention concerns cell lines and animal models of HER2-expressing tumors. In particular, the invention concerns cell lines and animal models of HER2-expressing tumors not responding or responding poorly to treatment with trastuzumab (HERCEPTIN®, Genentech, Inc.). The animal models and cell lines of the invention are useful for evaluating... Agent: Goodwin Procter LLP

20090098118 - Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent: e

20090098117 - Composition comprising and method of using angiopoietin-like protein 3 angptl3: The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are... Agent: Morrison & Foerster LLP

20090098120 - Compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090098116 - Immunogenic compositions for induction of anti-tumor immunity: for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel... Agent: Winston & Strawn LLP Patent Department

20090098121 - Immunoglobulin directed biocides: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate... Agent: Casimir Jones, S.c.

20090098123 - Hcv coreceptor and methods of use thereof: The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are... Agent: Thompson Coburn LLP

20090098122 - Srage mimetibody, compositions, methods and uses: Mammalian sRAGE mimetibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to reduce or inhibit the binding of RAGE and its ligands and to treat RAGE-related diseases are also disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090098124 - Identification and engineering of antibodies with variant heavy chains and methods of using same: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant heavy chain, which variant heavy chain comprises constant domains from more than one IgG isotype. The variant heavy chain of the invention may further comprise at least one amino acid modification relative to the... Agent: Edell, Shapiro & Finnan, LLC

20090098125 - Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease: The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform... Agent: Stites & Harbison PLLC

20090098127 - Agents capable of downregulating an msf-a dependent hif-1alpha and use thereof in cancer treatment: Methods and pharmaceutical compositions for the treatment of cancer or acute ischemia are provided. Also provided are methods of identifying agents capable of preventing the formation of or dissociating the MSF-A-HIF-1alpha protein complex, and methods of determining the prognosis of an individual having cancer by identifying the presence or absence... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090098132 - Composition and method for treating lupus nephritis: The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in... Agent: Wyeth Patent Law Group

20090098131 - Compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090098130 - Glucagon-like protein-1 receptor (glp-1r) agonist compounds: The present invention provides GA targeting compounds which comprise GA targeting agent-linker conjugates linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.... Agent: Perkins Coie LLP

20090098129 - Member of the tnf ligand family: The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprising: i) a polypeptide having the amino acid sequence of figure (1); or ii) a variant of the polypeptide of i).... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090098126 - Method and kit for the detection of adenoviruses: A method for the simultaneous detection of adenoviruses of subgenera A, B, C, D, E and F in a sample comprising contacting said sample with at least one forward primer and at least one reverse primer for a hexon gene of an adenovirus of subgenera A, B, C, D, E... Agent: Fulbright & Jaworski L.L.P.

20090098128 - Npc1l1 orthologues: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090098135 - Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment... Agent: Viksnins Harris & Padys Pllp

20090098137 - Combinations of therapeutic agents for treating cancer: A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease.... Agent: Novartis Corporate Intellectual Property

20090098134 - Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies: The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.... Agent: King Spalding LLP

20090098138 - Detection of proteins from circulating neoplastic cells: The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated... Agent: Wellstat Management Company. LLC

20090098133 - Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer: e

20090098136 - Use of tnf receptor antagonists for treating dry eye: Methods of treating dry eye by administering inhibitors of tumor necrosis factor α (TNFα) are disclosed.... Agent: Alcon

20090098139 - Combination therapy for the treatment of neovascular disorders: The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a combination of VEGF antagonists to the patient. The invention also features a pharmaceutical composition containing a first VEGF antagonist and a second VEGF antagonist for the treatment or prevention... Agent: (osi) Eyetech, Inc.

20090098140 - Monoclonal antibodies and their use: Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human... Agent: Klarquist Sparkman, LLP

20090098141 - Il-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same: The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090098142 - Methods and compositions for treating and monitoring treatment of il-13-associated disorders: Methods and compositions for treating and/or monitoring treatment of IL-13-associated disorders or conditions are disclosed.... Agent: Lowrie, Lando & Anastasi, LLP W2023

20090098143 - Vaccine production for pathogenic bird viral diseases: The present invention is an improved method for the production of vaccines to transmittable viral pathogens where the virus is pathogenic to the chicken embryos. Bird embryos are selected for vaccine production from wild and domestic birds, and preferably waterfowl, that have increased resistant to the viral pathogen. The invention... Agent: Alston & Bird LLP

20090098144 - Immunogen presenting hiv gp120 v3 loop in a conformation that induces broadly neutralizing antibodies: Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090098145 - Methods and compositions for treating ophthalmic conditions via modulation of megalin activity: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. Provided are methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or... Agent: Wilson Sonsini Goodrich & Rosati

20090098146 - Methods to diagnose a required regulation of trophoblast invasion: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-β3, receptors of cytokines of the TGβ family, or HIF-1α.... Agent: Howson & Howson LLP

20090098147 - Antibody fragment-polymer conjugates and uses of same: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also... Agent: Goodwin Procter LLP

20090098148 - High efficiency tissue-specific compound delivery system using streptavadin-protein a fusion protein: The present invention relates to methods and compositions that can be employed to introduce toxins and nucleic acids into the cytoplasm or nucleus of a eukaryotic cell, particularly a cell of a higher vertebrate. The invention particularly concerns the use of a fusion protein of streptavidin and protein A sequences... Agent: Darby & Darby P.C.

20090098149 - Transgenic algae for delivering antigens to an animal: Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter. In... Agent: Barnes & Thornburg LLP

20090098151 - Als-specific peptide composition: The invention relates to a composition for eliciting an immune response in an animal to produce an antibody that binds selectively to an amyotrophic lateral sclerosis (ALS)-specific epitope.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090098150 - Anti-acetylated huntingtin antibodies and uses therof: This invention includes, in part, methods of preparing acetylated Huntingtin (Htt) polypeptides, acetylated Htt polypeptide antigens, and antibodies that specifically recognize acetylated epitopes on Htt polypeptides. The invention also relates, in part, to the preparation and use of antibodies that specifically recognize and bind to acetylated epitopes on acetylated Htt... Agent: Wolf Greenfield & Sacks, P.C.

20090098152 - Vaccines containing canine parvovirus genetic variants: Canine parvovirus vaccines and diagnostics and methods for their use are provided.... Agent: Fellers Snider Blankenship Bailey & Tippens

20090098153 - Activation of hcv-specific t cells: The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compositions containing the individual components of... Agent: Novartis Vaccines And Diagnostics Inc.

20090098154 - Yeast-based vaccines as immunotherapy: Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle... Agent: Sheridan Ross P.C.

20090098155 - Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease: The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form... Agent: Merck And Co., Inc

20090098156 - Regimens for immunisation with meningococcal conjugates: Multivalent meningococcal conjugate vaccines are administered according to a schedule in which at least one or two doses are administered to a patient aged between 0 and 12 months, and a further dose is administered to a patient aged between 12 and 24 months.... Agent: Novartis Vaccines And Diagnostics Inc.

20090098157 - Helicobacter pylori vaccination: A sterile immunogenic preparation of three purified H. pylori antigens (CagA, VacA and NAP) adjuvanted with alum in an isotonic buffer solution for intramuscular injection. The antigens may be administered in conjunction with antibiotics and/or antisecretories. Urease breath testing, stool antigen testing, and/or immunological analysis may be used as correlate(s)... Agent: Melodi Dice

20090098159 - Feline cell capable of being cultured without animal-derived protein, and method for producing virus and method for producing vaccine using thereof: The present invention provides a cell strain which is derived from an fcwf-4 cell that is a cell derived from a feline whole fetus and which is capable of being cultured without animal-derived proteins, a method for producing the cell strain, and a method for producing a virus by using... Agent: The Nath Law Group

20090098158 - Reduction of concomitant infections in pigs by the use of pcv2 antigen: The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090098160 - Method of developing an immunogenic response using psoralen inactivated hiv: A method of developing an immune response to HIV using a composition of inactivated HIV. Inactivation is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune... Agent: Williams Mullen

20090098161 - Method of making an immunogenic composition using psoralen inactivated hiv: A method of making an immunogenic composition using inactivated HIV. Inactivation of HIV is through psoraten and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the... Agent: Williams Mullen

20090098162 - Herpes simplex virus combined subunit vaccines and methods of use thereof: This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of vaccinating a subject against HSV and treating, impeding, inhibiting, reducing the incidence of, or suppressing an HSV infection or a symptom... Agent: Pearl Cohen Zedek Latzer, LLP

20090098163 - Mutant f. turlarensis strain and uses thereof: A mutant strain of Francisella tularensis has attenuated virulence and has a mutation in the gene coding for a putative peroxynitrite resistance protein A (prpA) which prevents normal function of the protein. The mutant is useful as a vaccine against type A and B virulent strains of F. tularensis, and... Agent: Cassan Maclean

20090098164 - Spore associated display: The present invention concerns spore display methods. More specifically, the invention concerns display of heterologous molecules, such as peptides and polypeptides, on spores of bacilli, such as, for example, Bacillus thuringiensis (Bt) or Bacillus cereus (BC), using externally exposed spore coat proteins or fragments or variants thereof.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090098165 - Methods and compositions for immunization against chlamydial infection and disease: The present invention provides Chlamydia proteins and compositions and methods of use in the treatment/prevention of chlamydial infection in a subject, for eliciting an immune response in a subject and for reducing the likelihood of infertility and reducing the incidence and/or degree of hydrosalpinx due to Chlamydia infection in a... Agent: Myers Bigel Sibley & Sajovec

20090098166 - Chimeric msp-based malaria vaccine: The invention provides an immunogenic composition comprising MSP-8 linked to an antigen. Methods of using the composition to induce an immune response in an animal are also provided.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090098167 - Phl p 1 allergen derivative: Method for producing derivatives of wild-type protein allergen Phl p 1 with reduced allergenic activity compared to the wild-type allergen, comprising the following steps: providing wild-type protein allergen Phl p 1, fragmenting said wild-type protein allergen into at least three fragments, wherein at least one fragment of said at least... Agent: Chalker Flores, LLP

20090098168 - Multiple-layer microbubble liposphere drug delivery vehicle and system: A multiple layer microbubble drug delivery system, multiple layer microbubble drug delivery vehicle, method thereof and fabrication method is disclosed. The microfluidic drug delivery system for producing multiple layer microbubbles includes a first inlet which receives a gas and directs the gas into a central stream, a second inlet which... Agent: VistaIPLaw Group LLP

20090098170 - Cosmetic composition comprising solid entrapping particles for sustained release of volatile materials: The invention relates to a cosmetic composition comprising (a) solid entrapping particles having an average particle size from 5 to 200 micrometers and comprising (i) a copolymer obtainable by copolymerization of monomers of ethylene with at least one class of co-monomers comprising at least one heteroatom, (ii) a plasticizer comprising... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090098171 - Cosmetic composition in the form of an emulsion comprising a continuous aqueous phase and a dispersed fatty phase, and method for its preparation: e

20090098169 - Modified clay mineral: Modified clay minerals obtained by treating a clay mineral with a particular acylarginine derivative are useful for stabilizing emulsion compositions, inter alia, W/O emulsion composition, while hardly causing skin irritation, and providing moisture retention properties.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090098172 - Surfactant, and emulsion cosmetic and liposome each containing the same: wherein R represents a saturated or unsaturated acyl group having 8-22 carbon atoms, and may have a hydroxyl group or other substituents, and an emulsion-type cosmetic composition comprising said surfactant and a water-soluble polymer. The surfactant of the invention has excellent surface activity and safety. Also, the emulsion-type cosmetic composition... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090098173 - Topical pain relief product: The present invention is directed to a topical composition comprising a counterirritant active ingredient and a sensate that provides a cooling sensation to the skin that is topically perceptible to an adult human subject for greater than about 90 minutes, e.g. greater than about 120 minutes, say greater than about... Agent: Philip S. Johnson Johnson & Johnson

20090098174 - Heparin coating of biological tissue: The present invention discloses an in vitro method to provide biological tissue with a heparin coating comprising the following steps; linking a biotin reagent to biological tissue, linking an avidin reagent to the biotinylated biological tissue, and linking a heparin reagent to the formed layer of avidin on the biological... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090098176 - Medical devices with triggerable bioadhesive material: Described herein are implantable medical devices comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue. The triggerable bioadhesive property of the polymer can be triggered or activated by exposure to a stimulus. Also, the present invention pertains to methods of making... Agent: Mayer & Williams PC

20090098175 - Methods and compositions for delivery of growth factor to fibrous connective tissue: The presently disclosed subject matter relates to a peptide composition for non-covalently localizing fibrous connective tissue-inducing growth factor to a surface of an implant, the composition comprising a peptide having binding affinity for a surface material of an implant coupled to a peptide having binding affinity for a fibrous connective... Agent: Affinergy, Inc.

20090098177 - Methods and devices for tissue repair: Methods for treating diseased or damaged tissue in a subject are disclosed, involving administering to said subject at a site wherein diseased or damaged tissue occurs, cells of a type(s) normally found in healthy tissue corresponding to the diseased or damaged tissue, and/or suitable progenitor cells thereof, in association with... Agent: Mcdermott Will & Emery LLP

20090098179 - Fluid equilbrated absorbent polymeric materials, devices including same and packaging for same: Disclosed are methods and devices for the engineering, formation, and post-formation handling of absorbent polymeric materials. Devices intended for use in a fluid environment that include an absorbent polymeric material can be formed and processed to ensure that upon installation of the device, the polymeric material can not only have... Agent: Dority & Manning, P.A.

20090098180 - Functionalized amino acids and absorbable polymers therefrom: s

20090098182 - Long term drug delivery devices with polyurethane based polymers and their manufacture: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients... Agent: Foley And Lardner LLP Suite 500

20090098185 - Method for treating thrombotic disorders using sulfated polysaccharides: Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.... Agent: Robins & Pasternak LLP

20090098183 - Microsphere-based materials with predefined 3d spatial and temporal control of biomaterials, porosity and/or bioactive signals: A tissue engineering scaffold for growing cells can include a plurality of biocompatible microspheres linked together to form a three-dimensional matrix. The matrix can include a plurality of pores for growing cells. The biocompatible microspheres can include first and second sets of microspheres. The first set of microspheres can have... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090098178 - Porous coating loaded with a liquid or a solid substance: The present invention relates to a process for manufacturing a porous coating with structures in the micro or nano-size domain characterized by the following steps: -providing a support having a surface, -depositing on said surface one mono-layer of temporary particles, -depositing a coating on said temporary particles in such a... Agent: Nixon & Vanderhye, PC

20090098184 - Processes and systems for loading medical implants with simulative growth agents: Methods and systems for providing an improved apparatus and packaging system to more expeditiously hydrate or reconstitute medical grafts and to effectively and uniformly seed the medical grafts with biological components and cells. The systems generally comprise a container comprising entry port, at least one substrate cavity, and top, side... Agent: Knobbe Martens Olson & Bear LLP

20090098181 - Triazolopyridazines as kinase modulators: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression... Agent: Philip S. Johnson Johnson & Johnson

20090098186 - Method and system for coating a surface of a medical device with a therapeutic agent and drug eluting medical devices made thereby: A multi-layer drug coated medical device such as for example an expandable vascular drug eluting stent is formed by vacuum pulse spray techniques wherein each layer is irradiated to improve adhesion and/or drug elution properties prior to formation of subsequent layers. Layers may be homogeneous or of diverse drugs. Layers... Agent: Burns & Levinson, LLP

20090098187 - Composition and its use for the manufacture of a medicament for treating, prophylactically treating, preventing cancer and/or infections in the urinary tract: A composition is provided that allows for treatment of cancer, prophylactic treatment, and treatment of infection in the urinary tract. The composition comprises a nitric oxide (NO) eluting polymer that elutes nitric oxide (NO) in a therapeutic dose. The nitric oxide (NO) eluting polymer may be integrated with a carrier... Agent: Inskeep Intellectual Property Group, Inc

20090098188 - Method for delivery of medication using a dissolvable device: A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of films made of a safe polymer material incorporating a medication that is released by dissolution of the film over time, and more particularly a treatment method for controlling or regulating the... Agent: Evelyn M. Sommer

20090098189 - Azaindoles as inhibitors of soluble adenylate cyclase: The present invention relates to azaindoles of general formula I, a method for the production thereof, and to the use thereof for the production of pharmaceutical compositions.... Agent: Millen, White, Zelano & Branigan, P.C.

20090098191 - Use of bases to stabilize transdermal formulations: Stabilized transdermal acid sensitive drug formulations and their associated methods of production and use are described. The formulations containing acid sensitive drugs can also an acrylic adhesive, and a pharmaceutically acceptable base. The formulations can further contain other adhesives, permeation enhancers, and other stabilizing compounds such as free radical inhibitors.... Agent: Hedman And Costigan PC

20090098190 - Use of lactobacillus for increasing the absorption of a metal chosen from fe, zn, ca and ions thereof: The present invention relates to the use of at least one strain of Lactobacillus plantarum chosen from the group comprising Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum '299, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, Lactobacillus plantarum HEAL 99, DSM 15316, and a... Agent: Buchanan, Ingersoll & Rooney PC

20090098192 - Extrudable and extruded compositions for delivery of bioactive agents, method of making same and method of using same: A nonaqueous, extrudable composition includes at least one thermoplastic polymer in an amount of more than 20 wt % of the whole composition and tobacco. An extruded bioactive product in the form of a sheet can be made by extruding or hot melt shaping a nonaqueous composition comprising at least... Agent: Antonelli, Terry, Stout & Kraus, LLP

20090098193 - Hemostatic compositions and methods for controlling bleeding: The disclosure provides hemostatic compositions useful to promote hemostasis at active bleeding wound sites. The hemostatic compositions include an article containing cellulose, e.g., cotton gauze, and a cross-linked polysaccharide ionically linked to the cellulose. Methods of making and using the hemostatic compositions are also provided.... Agent: Fish & Richardson P.C.

20090098194 - Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same: The present invention provides a method of treating a skin ailment including administering to a subject in need thereof, a therapeutically effective amount of a composition including (i) a primary diamine; (ii) a secondary aromatic diamine; (iii) a polyisocyanate; and (iv) optionally, a polyol. The present invention also provides a... Agent: Myers Bigel Sibley & Sajovec

20090098197 - Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome: A cancer vaccine comprising a cancer antigen which comprises, as an active ingredient, the product of a tumor suppressor gene WT1, a partial peptide or a modified version thereof, and a cationic liposome.... Agent: Morrison & Foerster LLP

20090098195 - Influenza virus infection suppressor: The present invention is directed to providing influenza virus infection suppressors which contain a sialylgalactose-binding peptide, for example, a ganglioside GM3-binding peptide, as an active ingredient. Specifically, the invention provides influenza virus infection suppressors which contain the sialylgalactose-binding peptide of the following (a) or (b): (a) a peptide having the... Agent: Richard S. Wesorick Tarolli, Sundheim, Covell & Tummino

20090098196 - Lipid carrier compositions with reduced poly-dispersity: The invention relates to a method for reducing the polydispersity of a population of gel-phase lipid-based delivery vehicles.... Agent: Morrison & Foerster LLP

20090098199 - Methods of treating gastrointestinal disorders independent of the intake of food: The present invention relates to a method of treating a gastrointestinal disorder by administering to a patient in need of treatment thereof a pharmaceutical composition, wherein said pharmaceutical composition can be administered to the patient independent of the intake of food.... Agent: Dykema Gossett PLLC

20090098198 - Satiety: b) a plurality of elements inside the shell, which elements expand inside the stomach, after the shell dissolves, to form a connected mass with an envelope volume greater than the total volume of the elements, and at least 3 times the volume of the capsule.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090098200 - Compositions comprising lipophilic active compounds and method for their preparation: Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090098201 - Composition and method for treatment and prevention of atherosclerosis: This invention relates to an oral composition for treatment or prevention of atherosclerosis comprising a low-dose aspirin and a low-dose of statin wherein the aspirin and statin are in a slow-release formulation. The invention also relates to a method of treatment or prevention of atherosclerosis using such a composition.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20090098202 - Extended release formulation: The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090098203 - Mucoadhesive tetracycline formulations: Mucositis is treated and/or prevented by administrating to a patient a formulation containing a tetracycline and at least one cationic polymer and/or mucoadhesive material. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090098204 - Tissue implants and methods for making and using same: The invention provides biocompatible, biodegradable calcium sulfate matrices containing calcium sulfate activated platelets for use in tissue formation. The matrices are particularly useful in stimulating hard tissue, for example, bone formation. The matrices may also further include a growth factor and/or a transfectable gene, the inclusion of which may be... Agent: Nixon Peabody LLP - Patent Group

20090098210 - Combinations and modes of administration of therapeutic agents and combination therapy: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations... Agent: Morrison & Foerster LLP

20090098206 - Particulate metal oxide: A particulate metal oxide having a median volume particle diameter in the range from 24 to 42 nm, a photogreying index in the range from 0.05 to 3 and/or and a yellowing index of less than 6. The dispersion can be used in a sunscreen product which is transparent, exhibits... Agent: Jones Day

20090098205 - Ph sensitive nanoparticle formulation for oral delivery of proteins/peptides: The present invention provides a pH sensitive nanoparticulate delivery system for the administration of peptide hormones and drugs. In particular it provides a pH sensitive nanoparticulate for oral insulin administration. The nanoparticles developed by this process are fatty acid nanoparticles and a polymer is used as a stabilizer and also... Agent: Faegre & Benson LLP Patent Docketing

20090098208 - Pharmaceutical compositions based on porous zeolites as release means of pharmacologically active molecules and relative use: The present invention relates to pharmaceutical compositions for the oral administration of pharmacologically active molecules, comprising a release means consisting of porous zeolite in powder form, incorporating pharmacologically active molecules inside the pores and/or on its surface, the relative use for the preparation of drugs for oral administration, in particular... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090098209 - Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration: The present invention is directed to methods of delivering propofol derivative compounds via pulmonary administration to a mammal in order to induce or maintain anesthetized, sedated and sub-hypnotic states.... Agent: Birch Stewart Kolasch & Birch

20090098207 - Technology for the preparation of microparticles: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.... Agent: Fish & Richardson, PC

20090098211 - Solid dosage forms: Pharmaceutical dosage forms comprising tadalafil are described. Preferred dosage forms are bioequivalent to Cialis® notwithstanding a large particle size.... Agent: Kenyon & Kenyon LLP

20090098212 - Acoustically sensitive drug delivery particle: Disclosed are ultrasound sensitive drug carrying particles, uses and methods thereof, wherein the drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon ultrasound exposure.... Agent: Birch Stewart Kolasch & Birch

20090098213 - Pain relief and soothing cream and method for making same: emollient and methyl salicylate, where said methyl salicylate comprises between 10 and 30 percent by weight of said cream; a skin stimulant comprising menthol crystals and two or more reactants selected from a group of camphor, cinnamomum cassia, diclofenac, eucalyptus, and ginger to cause a hot and cool stimulus on... Agent: Fulwider Patton LLP

20090098214 - Skin-revitalizing cosmetic composition: The invention provides a skin-revitalizing cosmetic composition for alleviating or eliminating skin problems such as dry skin, wrinkles, and age spots, the composition containing a skin-revitalizing agent at high concentration. The skin-revitalizing cosmetic composition contains a skin-revitalizing agent selected from the group consisting of aloe extract, placenta extract, hydrolyzed elastin,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090098215 - Dialysis solutions containing pyrophosphates: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high... Agent: Baxter Healthcare Corporation

20090098216 - Arsenic therapy for apls-type autoimmune lymph-oproliferative syndrome in mice and humans: The invention relates to the use of an arsenic compound for the preparation of a medicament that is used to treat autoimmune diseases.... Agent: Foley And Lardner LLP Suite 500

20090098217 - Compositions and methods for promoting thicker hair: The invention provides compositions for thickening hair comprising a celery product and optionally zinc. The invention also provides a method of thickening hair by administering to a person a composition containing a celery product, such as celery seed, celery powder, or celery extract.... Agent: Cyr & Associates, P.A.

20090098218 - Tetracyclic lactame derivatives: e

20090098219 - Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith: Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among is allantoin, divalent strontium salts, divalent zinc salts, monovalent sodium salts and the hydrated derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to... Agent: Buchanan, Ingersoll & Rooney PC

20090098222 - Accelerating agent of calcium absorption: The present invention provides an accelerating agent for calcium absorption comprising Gum Arabic, which is daily available while simultaneously taking dietary fiber.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090098221 - Creatine ascorbyl derivatives and methods of use thereof: The present invention provides methods of treating creatine responsive states, such as a neurological disorder (i.e., Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, muscular dystrophy, Charcot Marie Tooth syndrome, Alzheimer's disease, or creatine transporter defect) or a skin disorder, by administering a creatine-ascorbyl derivative.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090098220 - Liquid pharmaceutical preparation comprising forskolin for promoting lean body mass: A liquid pharmaceutical preparation comprising forskolin in an amount of about 0.025 mg/ml to about 1 mg/ml of the liquid pharmaceutical preparation for promoting lean body mass in a human subject. Further, an effective amount of the liquid pharmaceutical preparation comprising forskolin is administered subcutaneously in the human subject.... Agent: Jay M. Schloff Intellipex PLLC

20090098223 - Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tea containing the same as active ingredient and method for preparing the natural tea: A natural plant extract composition for the recovery and prevention of hyperlipidemia and stroke, a natural tea comprising the same as an active ingredient, and a method for preparing the natural tea. The natural plant extract composition contains a Cassia tora extract and an Albizzia julibrissin extract. The natural plant... Agent: Iphorgan, Ltd.

20090098224 - Metabolic enhancing properties of theaflavins and thearubigins: Naturally occurring or synthetically derived theaflavins and thearubigins are disclosed which are orally active and have novel and specific metabolic enhancing effects in humans. The inventors have discovered that theaflavins and thearubigins decrease appetite, reduce adipose tissue, increase metabolism and energy levels and protect and enhance lean body mass.... Agent: Derek W. Cornelius

20090098225 - Compositions and methods for reduction of ldl oxidation: Dicot, and especially Brassicaceae sprout preparations are employed as a dietary agents that significantly reduce oxidized species in human serum. In one especially preferred aspect, contemplated compositions are employed to reduce serum oxLDL and to increase serum HDL levels.... Agent: Fish & Associates, PC Robert D. Fish

20090098226 - Composition for cosmetic or pharmaceutical-dermatological use: Composition in the form of a cosmetic formulation or dermatological medicament, suitable for maintaining skin cells at, or helping to restore skin cells to, their basal physiological state, enabling them to effect a regeneration of the dermis and the epidermis, comprising: —curcumin—a phosphosaccharide and possibly—a metal or basic oxide, or... Agent: Squire, Sanders & Dempsey L.L.P.

20090098227 - Tto-based wide spectrum therapeutics, disinfectants & anesthetics for use in aquaculutre: The invention discloses a novel wide spectrum aquaculture pharmaceutical, comprising a therapeutic, disinfective and/or anesthetize effective amount of a preparation comprising TTO in a stable water-in-oil emulsion of alkali or ammonium salts of organic fatty acid; said emulsion is also stable when converted into an oil-in-water emulsion, wherein the preparation... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20090098228 - Agent and method for improvement of impairment of learning and memory: An improving agent for impairment of learning and memory containing yokukansan is provided as an easy and simple means for enhancing memory of aged people, etc. and for improving the impairment of learning and memory.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090098229 - Method of treating osteoporosis with extract of dioscorea sp.: A method for treating osteoporosis in a subject in need of such treatment includes administering orally to the subject an effective amount of an extract product of a Dioscorea species capable of promoting proliferation and differentiation of bone marrow cells in the subject. Particularly, the Dioscorea species is Dioscorea alata... Agent: Panitch Schwarze Belisario & Nadel LLP

20090098230 - Nutraceutical moringa composition: The present invention incorporates portions from the Moringa plant into a nutraceutical beverage to provide a therapeutic effect in a person. The leaves, seeds, and fruit of the Moringa plant are used in the present invention to provide a biologically metabolized nutritional composition for health, well-being, and for treatment of... Agent: BatemanIPLaw Group

20090092542 - Bioinert tissue marker: This invention relates to a safe, effective, bioinert microporous radiopaque microparticles or spheres as a method and means to mark or provide “localization” of various tissues within the body and to reduce the incidence of adverse tissue reaction. Further, these same microporous particles or spheres comprising the tissue marker(s) are... Agent: Stuart K.j. Smyth

20090092543 - Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells: The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule... Agent: National Institute Of Health C/o Ballard Spahr Andrews & Ingersoll, LLP

20090092545 - Antibodies that bind both bcma and taci: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane... Agent: Zymogenetics, Inc. Intellectual Property Department

20090092546 - Carrier molecules: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even... Agent: Robins & Pasternak

20090092544 - Tumor diagnostic agent used in pet comprising anti-robo1 antibody: It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above... Agent: Greenblum & Bernstein, P.L.C

20090092547 - Injectable particles: According to an aspect of the invention, injectable polymeric particles are provided which contain branched poly(vinyl alcohol). Other aspects of the invention pertain to methods of making such particles. Still other aspects of the invention pertain to injectable compositions that comprise such particles and to methods of treatment that employ... Agent: Mayer & Williams PC

20090092548 - Methods and compounds for targeting tissues: The present invention relates to peptides which home to cells, e.g. heart cells, with high selectivity and which can be useful in the form of compositions. Such compositions can be used, e.g., for selectively targeting a systemically administered therapeutic agent or imaging agent to a cell or tissue in a... Agent: Fenwick & West LLP

20090092549 - Miniaturized liquid surface reactions using nanomolar amounts of concentrated [11c]carbon dioxide in a stationary gas-phase: Methods and reagents for miniaturized carboxylation with carbon-isotope labeled carbon dioxide using Grignard reagents or other organometallic reagents in a closable reaction loop or reactor are provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals or precursors for radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits... Agent: Ge Healthcare, Inc.

20090092551 - Increasing lifespan by modulation of pha-4: The roles of the pha-4 and daf-16 genes in diet-restricted induced longevity are described and characterized. Pha-4 acts, e.g., in the absence of daf-16, to increase lifespan, e.g., in nematodes. Given the role that pha-4 and daf-16 play in the mediation of longevity, they represent targets for modulation of life... Agent: Quine Intellectual Property Law Group, P.C.

20090092552 - Light stablized in vivo stain composition and method of manufacture: Photochemical demethylation reactions in solutions of thiazine dyes, in which the dye molecules act as both sensitizer and substrate, are reduced by quenching triple-state dye molecules, returning them to the unreactive ground state.... Agent: Jeffer, Mangels, Butler & Marmaro, LLP

20090092550 - Porphyrin linked metronidazole against gum disease: porphyromonas gingivalis: The present invention relates generally to targeted molecular agents (TMAs) directed to a particular organism or group of organisms and uses thereof. More particularly, the present invention provides TMAs having a targeting moiety which comprises a natural or induced auxotrophic requirement of the particular organism as a vehicle for directing... Agent: Knobbe Martens Olson & Bear LLP

20090092553 - Monocarboxylate transporters expressed in cancer cells: MCT1 and MCT4 are expressed at higher levels in many cancer cells than comparable normal cells of the same tissue. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the MCT1 and/or MCT4, as well as inhibitors and substrates of... Agent: Townsend And Townsend And Crew, LLP

20090092554 - Encapsulated contrast agents: The present invention relates to the field of polymer chemistry and more particularly to encapsulated contrast agents and methods for using the same.... Agent: Choate, Hall & Stewart LLP

20090092555 - Octameric protein for use in bionanotechnology applications: The present invention relates to purified multimeric proteins, comprising PlyCB monomers or functional fragments or variants thereof, which self-assemble into a ring like structure. The present invention also encompasses such multimeric proteins that comprise an integrin-binding sequence. The present invention further discloses contrast reagents, implant coatings, bone implants, and complexes... Agent: Fox Rothschild LLP

20090092556 - Azeotrope-like compositions of difluoromethane and trifluoroiodomethane: Provided are azeotrope-like compositions comprising difluoromethane and trifluoroiodomethane and uses thereof, including use in refrigerant compositions, refrigeration systems, blowing agent compositions, and aerosol propellants.... Agent: Honeywell International Inc.

20090092559 - Aerosol suspension formulations with tg 227 ea or tg 134 a as propellant: The invention relates to pressurized gas formulations for dosage aerosols, in which a medicament is formulated suspended in TG 227 ea (1,1,1,2,3,3,3-heptafluoropropane) and/or TG 134 a (1,1,1,2-tetrafluoroethane) as a propellant, and to their use for producing a medicament. The aerosol is preferably an inhalation aerosol.... Agent: Micheal P. Morris Boehringer Ingelheim Usa Corporation

20090092557 - Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use: An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at... Agent: Leydig, Voit & Mayer, Ltd.

20090092558 - Medicaments for the treatment of chronic obstructive pulmonary disease:

20090092560 - Trivalent chromium compounds, compositions and methods of use: The present invention provides chromium compounds, specifically chromium dinicocysteinate, which possess the ability to improve insulin sensitization, glucose tolerance, bioavailability, efficacy, and safety, and methods for their use.... Agent: Marshall, Gerstein & Borun LLP

20090092561 - Body-care and household products and compositions comprising specific sulfur-containing compounds: Disclosed are stabilized body care products, household products, textiles and fabrics which comprise specific sulfur containing compounds. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products, household cleaners... Agent: Joann Villamizar Ciba Corporation/patent Department

20090092562 - Oral care composition to reduce or eliminate dental sensitivity: The invention includes an oral care composition that reduces and/or eliminates the perception of tooth sensitivity. The composition includes an adherent material and particles having an average particle size of about 8 microns or less. The particles are present in the composition in an amount of about 5% by weight.... Agent: Colgate-palmolive Company

20090092563 - Activating brush tip applicators for dental bleaching compositions: A brush tipped applicator includes an applicator tip having a body defining an external surface and an internal conduit. The applicator tip body can have a proximal end defining a proximal opening of the internal conduit and a distal end. The proximal end of the applicator tip body can have... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090092564 - Tooth whitening products: A tooth whitening product is provided. The tooth whitening product has a backing layer and a tooth whitening composition. The tooth whitening composition includes first and second polymers, water, and a tooth whitening agent. The first polymer is a water soluble polymer and the second polymer is polyvinyl alcohol.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090092565 - Dental enamel recalcification accelerator and containing the same, oral composition and food or beverage: A dental enamel recalcification accelerator that even when used in oral compositions and food or beverage, poses no safety problem, and that is capable of effectively promoting the recalcification of decalcified dental enamel to thereby positively suppress any dental caries; and containing the same, an oral composition and food or... Agent: Young & Thompson

20090092566 - Self-tanning cosmetic compositions and methods: A self tanning composition containing at least one self tanning agent and at least one kinase inhibitor operable to inhibit the kinase induced phosphorylation of the self tanning agent; a method for increasing the efficacy of self tanning agents, and a method for tanning skin.... Agent: Julie Blackburn

20090092567 - Oil-containing compositions exhibiting reduced feathering: The invention relates to compositions containing at least one oil, at least one silicone elastomer, at least one wax, at least one filler, and at least one coloring agent as well as to methods of making and using such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090092568 - Deodorizing composition and method of forming thereof: An odor absorbing composition is provided comprising zinc salt of ricinoleic acid, a solubility promoter including sodium iminodisuccinate, water and optionally, other ingredients such as perfumes and antifungal agents or bactericides. The zinc ricinoleate can be completely solubilized in water, yet the solution will exhibit low foaming and friability. In... Agent: Fay Sharpe LLP

20090092569 - Deodorant compositions: This invention relates to deodorant compositions containing polytrimethylene ether glycol homo- and copolymers and/or polytrimethylene glycol ester(s) in a variety of physical forms. In at least one embodiment, the polytrimethylene ether glycol homo- and copolymers and/or polytrimethylene glycol ester(s) are derived predominantly from monomers (e.g., 1,3-propanediol) obtained from renewable resources,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090092571 - Liquid deodorant composition and deodorizing method: The present invention relates to a double component type deodorant which comprises a first deodorant component A containing a liquid mixture containing a polyphenol and an acid agent and a second deodorant component B containing an alkali agent and an aqueous solvent. These deodorant components A and B may be... Agent: Fitzpatrick Cella Harper & Scinto

20090092572 - Modification of cellulosic substrates to control body odor: A finish for cellulosic fibrous substrates containing tertiary amine-containing polymers for providing durable control of body odors and the cellulosic materials treated with the finish, which materials exhibit little or no discoloration and little or no degradation of physical strength as a result of the treatment.... Agent: Jacqueline S Larson

20090092570 - Odor-controlling composition: A composition for odor reduction and odor elimination and methods for reducing and eliminating odors and preparing the composition.... Agent: Smith, Gambrell & Russell

20090092574 - Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof: The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.... Agent: Pepper Hamilton LLP

20090092575 - Ophthalmic compositions with a disuccinate: wherein R1 is selected from hydrogen, alkyl or —C(O)alkyl, the alkyl having one to twelve carbons and optionally one or more oxygen atoms, A is a methylene group or an oxyalkylene group, and n is from 2 to 8. The ophthalmic composition also includes a cationic antimicrobial component and a... Agent: Bausch & Lomb Incorporated

20090092576 - Antifungal treatment of nails: A fungus treatment composition used to deliver active drugs trans-nail as well as a method for producing the fungus treatment composition, which may contain up to 50% additive ingredients. Preferred embodiments of the invention may include fungus treatment compositions which provide high nail penetrating power, which have antifungal agents, which... Agent: Jackson Walker LLP

20090092573 - Method of manufacturing a nicotine delivery product: A method of manufacturing a nicotine delivery product comprising nicotine and a cation exchange resin. More precisely, to a method for preparing a nicotine delivery product said method comprising (a) mixing nicotine, a cation exchange resin, an organic polyol and water to form a mixture wherein the total amount of... Agent: Edwards Angell Palmer & Dodge LLP

20090092577 - Male produced pheromone in tetropium fuscum (f.) and tetropium cinnamopterum (kirby) (coleoptera: cerambycidae): Described herein is (E)-6,10-dimethyl-5,9-undecadien-2-ol (geranyl acetol), termed here fuscumol, which has been identified as a male-produced pheromone emitted by Tetropium fuscum (F.) and Tetropium cinnamopterum. Also described are novel derivatives thereof e.g. esters, methods for the synthesis thereof and to a composition comprising fuscumol plus host volatiles e.g. a synthetic... Agent: Ade & Company Inc.

20090092580 - Dialkyl ether delivery agents: The present invention provides dialkyl ether compounds and pharmaceutically acceptable salts thereof, compositions containing the same and one or more active agents, and methods of administering active agents with the same.... Agent: Emisphere Technologies, Inc

20090092578 - Methods of selecting and producing modified toxins, conjugates containing modified toxins, and uses thereof: Methods for selecting and identifying modified toxins and conjugates thereof are provided. The methods are select for toxins that exhibit reduced toxicity to the host cell in which they are expressed. Methods of increasing production of toxins, such as the modified toxins, or conjugates thereof, also are provided. In particular,... Agent: Bell, Boyd & Lloyd LLP

20090092579 - Novel method for down-regulation of amyloid: Disclosed are novel methods for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing... Agent: Stroock & Stroock & Lavan LLP

20090092581 - Interferons of rhesus and cynomolgus origin and uses thereof: Disclosed are interferons of Rhesus and Cynomolgus origin and methods of production and use thereof.... Agent: Ropes & Gray LLP

20090092582 - Compositions and methods for modifying properties of biologically active polypeptides: The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical... Agent: Wilson Sonsini Goodrich & Rosati

20090092583 - Brain-localizing cells and uses thereof: It was discovered that cells expressing brain-localizing polypeptides on the cell surface can pass through the blood-brain barrier and therefore have the activity of translocating to the brain. By introducing desired substances into such brain-localizing cells, the substances can also be translocated to the brain. For example, by intravenously administering... Agent: Foley And Lardner LLP Suite 500

20090092588 - Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease: Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090092589 - Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains: A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the cells, particularly hematopoietic cells including committed progenitors and primitive hematopoietic stem... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20090092584 - Bio degradation of oxyanions such as perchlorate on ion exchange resins: Systems and methods for removing perchlorate load off of ion exchange resins are disclosed. The systems and methods rely upon direct contact between the resin and a liquid product formed by the culturing of perchlorate-destroying microorganisms. These methods can be incorporated into methods for removing perchlorate from aqueous streams. A... Agent: Foley & Lardner LLP

20090092585 - Canine probiotic bifidobacteria pseudolongum: According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria pseudolongum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria pseudolongum of the present invention are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090092590 - Method for improving stool characteristics in infants: In accordance with the present invention, a novel method for improving the stool characteristics, reducing the incidence of diarrhea, and firming the stool of a formula-fed infant of a formula-fed infant has been discovered. The method comprises administering to the infant at least one prebiotic and hydrolyzed pectin.... Agent: Bristol-myers Squibb Company - Mead Johnson

20090092586 - Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype: The invention provides methods for differentiating non-embryonic multipotent stem cells along the pancreatic lineage. The present invention further provides non-embryonic multipotent stem cells and progeny derived therefrom to provide pancreatic cells to a subject.... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090092587 - Laminins, derivatives, and compositions including same and methods for their therapeutic use: In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The... Agent: Board Of Regents, Nevada System Of Higher Education, On Behalf Of Universtiy Of Nevada, Reno

20090092591 - Use of a mixture of superoxide dismutase and catalase for treating inflammatory skin lesions: The invention concerns the use of a mixture of superoxide dismutase and catalase for preparing a topical composition for treating inflammatory skin lesions, said lesions being selected among the group consisting of dermal fibroses, epidermal keratoses, cheloid scars or hypertrophic eschars. The inventive compositions are formulated to obtain all galenic... Agent: Oliff & Berridge, PLC

20090092596 - Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an... Agent: Osi Pharmaceuticals, Inc.

20090092594 - Mammalian genes involved in viral infection and tumor suppression: The present invention provides methods of identifying cellular genes necessary for viral growth and cellular genes that function as tumor suppressors. Thus, the present invention provides nucleic acids related to and methods of reducing or preventing viral infection or cancer. The invention also provides methods of producing substantially virus-free cell... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090092592 - Methionyl trna synthetase polynucleotides: The invention provides metS polypeptides and DNA (RNA) encoding metS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing metS polypeptides to screen for antibacterial compounds.... Agent: Swanson & Bratschun, L.L.C.

20090092595 - Suppression of spla2-integrin binding for treating an inflammatory condition: The present invention relates to the discovery that a secretory phospholipase A2 (sPLA2-IIA) plays an active role in mediating inflammatory signaling by way of its specific binding with integrin, especially integrin αvβ3 or α4β1. More specifically, the invention provides a method for identifying inhibitors of inflammatory signaling by screening for... Agent: Townsend And Townsend And Crew, LLP

20090092593 - Therapeutic drug for heart disease and virus disease: The present invention is related to provide a therapeutic drug for heart diseases and viral diseases. The invention provides a therapeutic drug for heart diseases and viral diseases, comprising a free immunoglobulin light chain or a constitutive polypeptide thereof as an active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090092598 - Antibody therapy: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.... Agent: Immunomedics, Inc.

20090092605 - Compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090092603 - Early diagnosis and treatment of drug resistance in muc1-positive cancer: A method of determining likelihood of acquiring drug resistance of a tumor or cancerous cells, cancer metastasis, cancer recurrence, or decreased life expectancy, comprising measuring the level of MUC1 or MUC1-associated factor expressed in the cancerous cells or tumor.... Agent: Jhk Law

20090092601 - Humanized anti-lt-beta-r antibodies: Humanized antibodies to LT-β-R and methods of use thereof are provided.... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20090092597 - Mammalian cell surface antigens; related reagents: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090092604 - Method for the treatment of multiple sclerosis by inhibiting il-17 activity: Provided are methods of treatment for inflammatory and autoimmune disorders of the central nervous system and gastrointestinal tract. Also provided are methods of diagnosis.... Agent: Dnax Research Inc. Legal Department

20090092600 - Methods and compositions relating to the regulation of muc1 by hsf1 and stat3: This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or inflammatory cell growth and/or activation. The invention provides methods of inhibiting interactions between MUC1 and a heat shock factor, method of inhibiting interactions between transcription factors and the MUC1 promoter, and... Agent: Fulbright & Jaworski L.L.P.

20090092599 - Optimized fc variants and methods for their generation: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Xencor

20090092602 - Use of anti-tissue factor antibodies for treating thromboses: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue... Agent: Morrison & Foerster LLP

20090092606 - Antibacterial treatments: s

20090092607 - Fc-erythropoietin fusion protein with improved pharmacokinetics: The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the invention are also provided.... Agent: Goodwin Procter LLP Patent Administrator

20090092608 - Human tumor necrosis factor receptor-like 2: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090092609 - Monoclonal antibodies to respiratory syncytial virus and uses therefor: The present invention is directed to particular human monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of respiratory syncytial virus infections. In particular, these antibodies may neutralize RSV. Also disclosed are improved methods for producing monoclonal antibodies.... Agent: Fulbright & Jaworski L.L.P.

20090092611 - Antibodies that bind both bcma and taci: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane... Agent: Zymogenetics, Inc. Intellectual Property Department

20090092610 - Fcgammariib specific antibodies and methods of use thereof: The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to... Agent: Edell, Shapiro & Finnan, LLC

20090092614 - Anti-igf-1r antibodies and uses thereof: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090092612 - Anti-platelet membrane glycoprotein vi monoclonal antibody: e

20090092617 - Erbb receptor-derived peptide fragments: The invention relates to new peptide compounds capable of modulating cell proliferation, differentiation, survival and/or motility. The peptide compounds of the invention comprise short peptide fragments of the ErbB receptor and are capable of binding to ErbB and modulating activity of the receptor. The invention also relates to antibodies capable... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090092613 - Novel tnf receptor death domain ligand proteins and inhibitors of ligand binding: Novel TNF receptor death domain (“TNF-R1-DD”) ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090092618 - Peptide-based immunization therapy for treatment of atherosclerosis: The present invention relates to a fragment of apolipoprotein B, for immunization for prophylactic or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, in particular myocardial infarction or stroke, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing ischemic... Agent: Gauthier & Connors, LLP

20090092615 - Targeting of notch3 receptor function for cancer therapy: The present invention involves the use of peptides from Notch3, and antibodies that recognize epitopes represented by those peptides, as anti-cancer agents. Methods of combination therapy using standard anti-cancer protocols in conjunction with Notch3 peptides and antibodies also are provided.... Agent: Fulbright & Jaworski L.L.P.

20090092616 - Znf206: a novel regulator of embryonic stem cell self-renewal and pluripotency: We have identified ZNF206, a novel repressor of human embryonic stem cell (hESC) differentiation. Repressing extra-embryonic endoderm development preserves the pluripotent state of human embryonic stem cells, and, conversely downregulating expression of ZNF206 in hESCs causes them to upregulate the expression of genes associated with the extra-embryonic endodermal lineage, down-regulate... Agent: Biotechnology Law Group C/o Portfolioip

20090092619 - Methods and compositions for malaria prophylaxis: A composition for preventing malaria infection including a steric inhibitor of circumsporozoite protein cleavage. A pharmaceutical composition for preventing malaria infection including a steric inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention.... Agent: Kohn & Associates, PLLC

20090092620 - Flu virus hemagglutinin specific monoclonal antibodies: The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090092621 - Antibodies for preventing and treating attaching and effacing escherichia coli (aeec) associated diseases: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein... Agent: Myers Bigel Sibley & Sajovec

20090092622 - Molecules, compositions, methods and kits for applications associated with flaviviruses: A method for controlling a flavivirus entry into a cell, kits for assaying the flavivirus entry into the cell, and methods of treating and preventing flaviviruses infections are disclosed, together with vaccine and pharmaceutical compositions.... Agent: Seed Intellectual Property Law Group PLLC

20090092624 - Antiinfective flavononol compounds and methods of use thereof: m

20090092625 - Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion: The invention relates to methods for manipulating hematopoietic progenitor cells and related products In one aspect the invention relates to the use of agents that activate a PTH/PTHrP receptor to enhance the growth and maintenance of hematopoietic progenitor cells in vivo and in vitro, to enhance mobilization of hematopoietic stem... Agent: Edwards Angell Palmer & Dodge LLP

20090092623 - Promoter: The present invention provides a novel polynucleotide vectors and their use in the production of biological material in host cells, and also in medical therapy or polynucleotide vaccination. The novel vectors of the present invention comprise a promoter normally associated with the US3 gene of Human Cytomegalovirus (HCMV).... Agent: Glaxosmithkline Corporate Intellectual Propewrty Uw2220

20090092626 - Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1: A self-adjuvanting immunogenic composition comprising multiple immunogens, each immunogen comprising a lipopeptide cap, a universal T helper sequence and an immunodominant HIV-1 Tat B cell epitope. The immunogen also comprises one or more linker sequences and/or polar charged amino acid sequences. The HIV-1 Tat B cell epitope of each immunogen... Agent: Howson & Howson LLP

20090092627 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham Mccutchen LLP

20090092628 - Conserved-element vaccines and methods for designing conserved-element vaccines: Embodiments of the present invention include conserved-element vaccines and methods for designing and producing conserved-element vaccines. A conserved-element vaccine (“CEVac”) is a recombinant and/or synthetic vaccine that incorporates only highly conserved epitopes from an observed set of pathogen variants. The conserved epitopes are identified computationally by aligning biopolymer sequences, such... Agent: Olympic Patent Works PLLC

20090092629 - Vaccine for nontypeable haemophilus influenzae infection: This invention provides a method for identifying strains of nontypeable Haemophilus influenzae that can be used as immunogenic compositions having specificity against a plurality of Haemophilus influenzae strains. The invention also provides compositions comprising whole cell bacteria or outer membrane protein P2 obtained from the strains for use as vaccines.... Agent: Hodgson Russ LLP The Guaranty Building

20090092630 - Chimeric recombinant antigens of toxoplasma gondii: A method for treatment or prevention of Toxoplasma gondii infections pharmaceutical composition comprising an antigen fragments of Toxoplasma gondii in the form of a chimeric fusion product or a nucleotide sequence coding for the chimeric fusion product and a method of using the chimeric fusion product or nucleotide sequence coding... Agent: Steinfl & Bruno

20090092631 - Glycosylated specificity exchangers that induce an antibody dependent cellular cytotoxicity (adcc) response: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.... Agent: Knobbe Martens Olson & Bear LLP

20090092632 - Methods for preparing complex multivalent immunogenic conjugates: Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other... Agent: Klarquist Sparkman, LLP

20090092633 - Polyamino acid for use as adjuvant: Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090092634 - Chicken virus vaccine and diagnostic: A novel astrovirus designated chicken astrovirus type 3 has been isolated and characterised. Nucleotide sequences and polypeptide sequences of this astrovirus are provided with uses of the same and the isolated astrovirus in assay kits and vaccines.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090092635 - Heterologous prime-boost immunization regimen: The present invention is directed to a method for generating an antigen-specific immune response in a subject in general and in particular to administering a priming dose of an immunogenic composition of a recombinant mumps virus (rMuV) that encodes an antigen followed by administering a boosting dose of recombinant vesicular... Agent: Wyeth Patent Law Group

20090092636 - Multivalent pcv2 immunogenic compositions and methods of producing such compositions: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090092637 - Medicaments and methods to treat autoimmune disease and cancer:

20090092638 - Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use: This invention provides a new approach to the design of a virus with a defective replication cycle, which can be rescued by wild type virus co-infection, and which expresses foreign antigenic epitopes that contribute to the elimination of virus infected cells and then to viral clearance. The vector of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090092639 - Immunogenic composition: Methods and compositions for increasing antibody titer in egg yolks and for using the antibodies are disclosed.... Agent: Quarles & Brady LLP

20090092640 - Increased t-cell tumor infiltration and eradication of metastases by mutant light: Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.... Agent: Barnes & Thornburg LLP

20090092641 - Uses of natural immunobiotic extract: The present invention provides a method of improving disease management in an animal by administering an effective amount of β-glucan composition to the animal. The β-glucan composition comprises at least about 70% β-(1,3/1,6)-D-glucan by dry weight and a biological activity of at least 20 μg Bb released per mg of... Agent: Brinks, Hofer, Gilson & Lione

20090092643 - Foam strip for the delivery of oral care compositions: The present invention relates to a polyurethane foam strip (1), shaped for the application to the labile surface of the front teeth and/or gums of a subject, which strip is provided with one or more oral care compositions for delivery to the teeth and/or gums of the subject. It further... Agent: Dykema Gossett PLLC

20090092644 - Locked-in type powder: The present invention relates to a locked-in type powder comprising polyphenols, the locked-in type powder which is excellent in long-term stability, substantially does not show decrease in color tone and discoloration even after long-term storage, also does not result in change in odor quality and decrease in deodorizing and antioxidizing... Agent: Fitzpatrick Cella Harper & Scinto

20090092642 - Skin and/or hair products, containing compounds with an isoprenoid structure: e

20090092645 - Radiation method for fabrication of nano-sized compound antibacterial fabric textile: The invention discloses an innovative process to produce highly antibacterial nano-composite fabric textile containing silver metal compound. The process mainly uses high-energy D-ray radiation to modify silver type of bactericides and graft or crosslink them onto Nylon or PET fiber surface to produce excellent antibacterial textile products. The mechanism uses... Agent: Michael Lin

20090092646 - Effigy and compound to affect bird behavior: An exemplary device is an effigy of a bird predator treated with a compound that irritates birds via the avian trigeminal pathway. Another exemplary device is an effigy of a bird predator that includes a supply of a compound that irritates birds via the avian trigeminal pathway. An exemplary method... Agent: Lee & Hayes, PLLC

20090092647 - Polyurethane foams for wound management: The invention relates to a process for producing polyurethane foams for wound management wherein a composition containing a polyurethane dispersion and inorganic, cationic coagulants is frothed and dried.... Agent: Connolly Bove Lodge & Hutz, LLP

20090092648 - Antimicrobial polymer compositions and the use thereof: wherein: R1═H, Alkyl, Aryl, HO—(CH2CH2-O—)n-, MeO—(CH2CH2-O—)n-, HO—(CH2)n-; R2═H, Alkyl, Aryl, HO—(CH2CH2-O—)n-, MeO—(CH2CH2-O—)n, HO—(CH2)n-; R3═H, Alkyl, Aryl, —(CH2CH2—O—)—(CH2—)n; R4,5═H, Alkyl, Aryl, —(CH2CH2—O—)—(CH2-)n-CH3, —O—CH3, —O—C2H5, —O—C3H7; and n=1-30; and the anionic polyester is selected from the group consisting of an anionic polyester having at least one carboxylic group, a sulfonic acid polymer,... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20090092649 - Method and apparatus for imparting a biocidal agent: A method and an apparatus is disclosed for using a biocidal agent associated with a sheet of material on a food item subsequent packaging of the item to maintain product properties in packaged beverages and foods. The method includes providing a sheet for imparting a biocidal activity to a food... Agent: Lathrop & Gage Lc

20090092651 - Absorbable adhesives and their formulation for use in medical applications: Described are medical products including an adhesive containing a polypeptide component such as gelatin and a tackiness-providing polyhydroxy compound, such as at least one compound selected from the group consisting of glycerin and fructose. Such medical products can find use as a bolster material for use in conjunction with a... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20090092650 - Sustained delivery formulations of octreotide compounds: The present invention relates to an octreotide sustained release delivery system for treatment of diseases relating to somatotropin and/or somatostatin. The sustained release delivery system of the invention includes a flowable composition containing an octreotide compound, and an implant containing the octreotide compound. The flowable composition may be injected into... Agent: Schwegman, Lundberg & Woessner, P.A.

20090092652 - Method for the inhibition of angiogenesis or cancer using protective antigen related molecules: The present invention is based on the discovery that protective antigen related molecules (PARMs) without anthrax lethal factor have antiangiogenic or anticancer properties. The invention is directed to a method of inhibiting an angiogenic disease/disorder or cancer. Additionally, the invention can be applied to those at risk for developing cancer... Agent: David S. Resnick

20090092653 - Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells: Methods for treating a patient having a disease or damage to at least one kidney are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. When administered, the cells promote and support the repair and... Agent: Patton Boggs LLP

20090092654 - Drug delivery methods, structures, and compositions for nasolacrimal system: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within... Agent: Schwegman, Lundberg & Woessner, P.A.

20090092655 - Novel prepolymerizable surface active monomers with both fluorine-containing groups and hydrophilic groups: Provided are surface modified contact lenses formed from one or more fumaric- or itaconic-containing prepolymers having reactive functionality that is complimentary to surface modifying polymers.... Agent: Bausch & Lomb Incorporated

20090092656 - Method of treating atrophic vaginitis: The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.... Agent: Wilmerhale/boston

20090092657 - Amino acid combinant omega oil aphrodisiac: A method of enhancing the libido in an adult human comprising the administering of a composition, comprising an effective amount of the amino acids tryptophan and phenylalanine and an effective amount of omega oils.... Agent: Douglas Burke

20090092658 - Novel formulations of proton pump inhibitors and methods of using these formulations: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed... Agent: Wilson Sonsini Goodrich & Rosati

20090092659 - Devices for improved wound management: The present invention provides devices and compositions for the management of infection of topical lesions, each of the devices and compositions containing protonated/acidified nucleic acids either on its surface, or integrated into the device. These modified nucleic acids are effective as bactericidal and/or bacteriostatic agents without regard to the class... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090092661 - Liposome compositions for in vivo administration of boronic acid compounds: Liposome formulations for administration of a boronic acid compound are described. The liposomes are comprised of a phospholipid having two acyl chains with between 20-22 carbon atoms in each chain and a boronic acid compound entrapped in the liposomes. In a preferred embodiment, the boronic acid compound is in the... Agent: Philip S. Johnson Johnson & Johnson

20090092662 - Liposome formulations of boronic acid compounds: A liposome composition comprised of liposomes having a peptide boronic acid proteasome inhibitor compound entrapped in the liposomes is described. More specifically, liposomes having a compound of Formula I or II entrapped in the interior aqueous compartment are loaded with a peptide boronic acid compound, to form a boronate ester... Agent: Philip S. Johnson Johnson & Johnson

20090092660 - Methods and compositions for needleless delivery of particles: Methods and compositions for needleless delivery of particles to the bloodstream of a subject are provided herein. In one aspect, the invention provides a delivery construct, comprising a receptor binding domain, a transcytosis domain, a particle to be delivered to a subject, and, optionally, a cleavable linker. In other aspects,... Agent: Jones Day

20090092665 - Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors: The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor;... Agent: Greenberg Traurig, LLP

20090092664 - Polymer-metal chelator conjugates and uses thereof: The present invention provides prodrugs comprising a polymer conjugated to a metal chelator via a disulfide bond. For example, D-penicillamine may be conjugated to a polymer (e.g., gelatin, chitosan, polyglutamic acid) via a linker, such as SPDP. Thus, the cellular delivery and pharmacokinetics of D-penicillamine can be substantially improved. Methods... Agent: Fulbright & Jaworski L.L.P.

20090092663 - Tumor-targeted drug delivery systems and uses thereof: The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a... Agent: Clark & Elbing LLP

20090092666 - Vaccines with enhanced immune response and methods for their preparation: The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20090092667 - Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer: The present invention provides methods for reducing Aβ deposition, Aβ neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine, also known as (−)-nilvadipine, to the animal or... Agent: King & Spalding

20090092668 - Acetaminophen formulation for joint pain relief: The invention relates generally to a formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for joint pain relief. The formulation may comprise supplements such as glucosamine, hyaluronic acid and methylsulfonylmethane (MSM) and acetaminophen for acute joint pain. The invention also encompasses methods... Agent: Frommer Lawrence & Haug

20090092669 - Stable imatinib compositions: Formulations containing imatinib, preferably imatinib mesylate, with high polymorphic stability and the processes for the preparation thereof are disclosed.... Agent: Kenyon & Kenyon LLP

20090092670 - Long acting dual release product containing carbinoxamine and pseudoephedrine: Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090092671 - Cerium oxide nanoparticles for treatment and prevention of alzheimer's disease, parkinson's disease, and disorders associated with free radical production and/or mitochondrial dysfunction: Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP

20090092673 - Biocide: A two part biocide composition containing metal ions and bromine donor for killing microorganisms in a body of water and a method of killing microorganisms in a body of water by placing both metal ions and a bromine in the body of water to allow use of lower concentrations of... Agent: Carl. L. Johnson Jacobson And Johnson

20090092672 - Orally disintegrating tablet compositions of lamotrigine: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090092674 - Flowable wound matrix and its preparation and use: This invention relates to a flowable collagen/glycosaminoglycan (GAG) material including particles of collagen/GAG matrix that, when hydrated, can be effectively delivered to wounds having varying depths and geometries. The flowable collagen/GAG matrix allows a more intimate contact between the wound matrix and the wound bed, and provides a structural framework... Agent: Banner & Witcoff, Ltd.

20090092675 - Compositions containing multiple polymers and particles made using the compositions: The compositions described herein include a first polymer that is either a polyvinyl alcohol or a polyvinyl formal, and a second polymer that is one of a polyvinyl alcohol, a polyvinyl formal, polyvinylpyrrolidone, a polysaccharide, or a polymethacrylate. The first polymer and the second polymer in the composition are different.... Agent: Fish & Richardson PC

20090092676 - Cross-linked polymer particles: Cross-linked polymer particles, as well as related compositions and methods, are disclosed.... Agent: Fish & Richardson PC

20090092677 - Multi-component particles for injection and processes for forming the same: In accordance with one aspect of the invention, novel compositions containing injectable particles are provided in which the injectable particles contain at least two polymeric components that differ in composition from one another (e.g., because at least one polymeric component contains a polymer that is not present in another polymeric... Agent: Mayer & Williams PC

20090092679 - Particle/cell separation device and compositions: A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted.... Agent: Knobbe Martens Olson & Bear LLP

20090092678 - Universally applicable blood plasma: A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.... Agent: Jacobson Holman PLLC

20090092680 - Preparation for treatment of mineral deficiency: The invention relates to a preparation having an improved taste, as well as to the use of said preparation for treatment of mineral deficiency. In accordance with the invention, it has been found possible to effectively mask the bad taste of even such notorious minerals as iron. As a result,... Agent: Morrison & Foerster LLP

20090092681 - Artificial cerebrospinal fluid: The present invention provides an artificial cerebrospinal fluid containing 120 to 160 mEq/L of sodium ion, 1 to 6 mEq/L of potassium ion, 75 to 155 mEq/L of chloride ion, and 5 to 45 mEq/L of bicarbonate ion, and provides an artificial cerebrospinal fluid further containing at least one component... Agent: Sughrue Mion, PLLC

20090092682 - Fungicidal composition for through periderm bark application to woody plants: A fungicidal composition for topical application to woody plant periderm, the composition comprising (a) a systemic fungicide, (b) an organosiloxane surfactant, and (c) water.... Agent: Arthur M. Reginelli Renner, Kenner, Greive, Bobak, Taylor & Weber

20090092683 - Micronized wood preservative formulations: The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090092684 - Small molecule antagonists of bcl-2 family proteins: The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds... Agent: Casimir Jones, S.c.

20090092685 - Wound and ulcer treatment with super-oxidized water: Super-oxidized water based on hypochlorous acid, such as is obtained by the electrochemical treatment of a saline solution, may be used in the treatment of leg ulcers or other open wounds. Preferably, the pH of the super-oxidized water is in a range of 4 to 7, and the water has... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090092686 - Process for the recovery of a phytolipid composition: Disclosed is a process for the recovery of a phytolipid composition from a vegetable oil by-product. The phytolipid composition produced comprises squalene, phytosterols, mixed tocopherols and tocotrieneols, and vegetable wax and is useful as an emollient. The phytochemical composition may be applied directly to the skin to provide emolliency. Alternatively,... Agent: Brett L. Nelson Eastman Chemical Company

20090092689 - Composition and method for supporting female sexual health: The present invention relates generally to a composition and method for supporting female sexual wellness by providing a nutritional supplement comprising of acanthopanax gracilistylus, glycyrrhiza glabra, chrysanthemum morbifolium, corydalis ambigua, and ligusticum in combination, and more preferably, comprising of acanthopanax gracilistylus, chrysanthemum morbifolium, and ligusticum in combination. The invention synergistically... Agent: Sylmark, Inc.

20090092688 - Ointment for topical treatment of hot flashes and method of use: A composition and method of use therefor that provides for the objective topical treatment of hot flashes that is clinically shown to objectively reduce skin temperature, with the effective ingredients including menthol and peppermint oil which can be substituted with spearmint oil. The method involves application of the composition, which... Agent: Sandra Lee Lipkin A Law Corporation

20090092687 - Prhormone composition and method of use thereof: The invention provides methods and compositions for maintaining a state of sexual wellness in a healthy human by providing a dietary supplement comprising one or more sexual steroid prohormones.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090092690 - Process of making theaflavins enriched tea extract: This invention provides various products and processes such as a process of making a theaflavins enriched extract of tea having a low content of high molecular weight thearubigins which comprises extracting theaflavins from tea using ethanol to produce an extract having a high theaflavins content and a low content of... Agent: Cooper & Dunham, LLP

20090092691 - Formulation based on marigold, aloe, and centellae: The formulation includes between 1 and 98 parts of glycolic extract of marigold officinalis, between 1 and 98 parts of glycolic extract of aloe vera and between 1 and 98 parts of glycolic extract of centellae asiaticae. The formulation conforms an emulsion from the use of between 4 and 8%... Agent: Bachman & Lapointe, P.C.

20090092693 - Platelet manipulation to prevent and treat endovascular disease and its sequelae, to prevent and treat arrhythmias and to prevent malignancy: Reduction of platelet counts to below 150 thousand per cubic millimeter by pharmacologic, mechanical, combined mechanical and pharmacological, or other means for the purpose of reducing the incidence and severity of vascular disease in at risk populations, for the stabilization and reversal of said disease in patients already known to... Agent: Attila Mady

20090092692 - The use of onion extracts to prevent and treat acute and chronic cardiac and vascular complications and their sequelae, as well as to resolve hematomas: Onions (Allium Cepa and its close relatives, as opposed to Allium Sativum) contain potent coagulation modulators, as well as platelet inhibitors. Clinical, in vivo and in vitro testing confirms that the efficacy of commonly consumed quantities of onions in terms of the efficacy of its impact on coagulation and platelet... Agent: Robert A. Parsons

20090092694 - Method of producing blood type checking reagent containing lectin: Lectin is extracted from seeds of bitter gourd (also known as balsam pear or Momordica charantia). A blood type checking reagent for checking a blood type includes the lectin. The lectin extracted from seeds of bitter gourd preferably has a molecular weight between 100,000 and 170,000 measured with polyacrylamide gel... Agent: Kubotera & Associates, LLC

20090092695 - Health supplement for lowering plasma glucose and plasma triglyceride: A kind of health supplement for lowering plasma glucose and plasma triglyceride is prepared from a mixture of dried grape skins with the flesh removed, dried grape seeds and dried grape stems, and the mixture is ground into fine powder (termed 3SG powder) according to a ratio of volume between... Agent: Bacon & Thomas, PLLC

20090092697 - Extracts of polygonum multiflorum thunb., and preparation process and uses of the same: Disclosed herein are processes for preparing extract products from the root of Polygonum multiflorum Thunb. and the extract products thus obtained, which are biologically active in promoting the proliferation, growth and/or differentiation of hematocytes and bone marrow cells in vitro and in vivo.... Agent: Panitch Schwarze Belisario & Nadel LLP

20090092696 - Herbal combination omega oil aphrodisiac: A method of enhancing the libido in an adult human comprising the administering of a composition, comprising an effective amount of an herbal aphrodisiac selected from the group consisting of those herbs, which are purported to enhance the libido in humans, and an effective amount of omega oils.... Agent: Douglas Burke

20090092698 - Compositions and methods for altering alpha- and beta-tocotrienol content using multiple transgenes: Preparation and use of isolated nucleic acids useful in altering the oil phenotype of plants are described. Isolated nucleic acids and their encoded polypeptides are described that alter alpha- and beta-tocotrienol content in transformed seeds and oil obtained from the transformed seeds. Expression cassettes, host cells and transformed plants are... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090087375 - Actriib fusion polypeptides and uses therefor: Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis.... Agent: Wyeth/finnegan Henderson, LLP

20090087377 - Compositions for targeted imaging and therapy: The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.... Agent: Fulbright & Jaworski, LLP

20090087376 - Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer's disease: The present invention relates to the identification of compounds that are suitable for imaging amyloid deposits in living patients. The invention relates, in part, to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease. The present invention also relates to therapeutic uses... Agent: Wolf Greenfield & Sacks, P.C.

20090087378 - Positron tomography method and positron-emitting compound to be used therein: e

20090087379 - Radiofluorinated compounds and their preparation: The present invention provides a process for [18F]-fluorination of biomolecules containing a primary amino group such as proteins and peptides and in particular of peptides. The invention further provides reagents for this process, in particular 18F-labelled prosthetic groups for use in the preparation as well as non-labelled intermediates useful in... Agent: Ge Healthcare, Inc.

20090087380 - Polymer devices for therapeutic applications: Multi-layered polymer devices having three-dimensional containers for holding a therapeutic and/or imaging agent are provided. The devices have a high loading ratio of agent to polymer material for effective treatment. Delivery wings or regions with channels connected to the containers are also incorporated in the devices. The delivery wings can... Agent: Lumen Patent Firm

20090087381 - Chelator-functionalized nanoparticles: Provided herein are chelator-functionalized nanoparticles comprising a passive core; and an active coating that demonstrate T1 magnetic resonance pattern upon exposure to a magnetic field. Also provided are methods of making such chelator-functionalized nanoparticles as well as imaging methods using the nanoparticles.... Agent: General Electric Company Global Research

20090087382 - Contrast agents and methods for preparing contrast agents: Contrast agents comprising a scaffold protein having at least one operative integrated metal ion binding site.... Agent: Bryan Cave Powell Goldstein

20090087383 - Nanoparticle-based imaging agents for x-ray/computed tomography and methods for making same: The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such... Agent: General Electric Company Global Research

20090087384 - Medicine and method for treatment of prostate cancer: The invention concerns a medicine for treatment of prostate cancer and a corresponding treatment method. The medicine can be supplied to a prostate tumor through the bloodstream, contains an active component and a binding component as well as ultrasound microbubbles. The binding component includes coupling molecules that specifically bind to... Agent: Schiff Hardin, LLP Patent Department

20090087386 - Effervescent composition and method of making an effervescent composition including a viscous component: Disclosed is an effervescent composition and a method of making an effervescent composition that includes a viscous component and is a free flowing granulation.... Agent: Allison Johnson, P.A.

20090087385 - Intranasally administering curcumin in a bolus of helium gas to treat alzheimers disease: Intranasally administering curcumin prodrugs and curcumin hybrids in a bolus of helium gas to the brain to treat Alzheimer's Disease... Agent: Philip S. Johnson Johnson & Johnson

20090087387 - Acetals of nepetalic acid and method of preparation: Disclosed are acetals of nepetalic acid. They may be prepared by reaction of an alcohol with nepetalic acid, and are useful as repellents for insects and arthropods, in addition to other uses.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090087389 - Dehydroepiandrosterone sulfate dihydrate inhalation compositions and methods: The invention relates to inhalation compositions derived from dehydroepiandrosterone sulfate. The compositions of the invention involve liquid nebulizer formulations prepared from dehydroepiandrosterone sulfate dihydrate. The compositions of the invention comprise water and chloride ion. The liquid nebulizer formulations can be used to treat patients suffering from asthma or COPD.... Agent: Wilson Sonsini Goodrich & Rosati

20090087388 - Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an... Agent: Keown & Zucchero, LLP

20090087390 - Fluidized slurry of water soluble and or water-swellable polymer and mixture thereof (fps) for use in dentifrice and household applications: An oral care or household cleaner system contains a fluid polymer suspension (FPS) thickening agent. The FPS thickening agents comprises a water soluble/water swellable polymer, a polyol, and a hydrated thickening silica. The water soluble/water swellable polymer is selected from the group consisting of acrylic acid polymer, salts of acrylic... Agent: Hercules Incorporated Hercules Plaza

20090087392 - Acid-neutralizing agent: Acid-neutralizing agent contains substantial amount of calcium of an acid-neutralizing ability against various acid chemicals substance for humans, animals, agricultural produces, meat and poultry. And the method of producing the same are provided. An environmental friendly high speed and high press scraping treatment is applied to a calcium-containing substance represented... Agent: Gary C. Honeycutt

20090087393 - Dental treatment compositions and conformable dental treatment trays using the same: The present invention is a formable dental treatment tray utilizing poly(2-ethyl-2-oxazoline) and a gelatinous active. Blending of the active is accomplished by mixing the Poly(2-ethyl-2-oxazoline) with an active ingredient, such as a peroxide like hydrogen peroxide, carbamide peroxide, sodium perborate, or sodium percarbonate, usually also with water or an appropriate... Agent: Geoffrey E. Dobbin, Patent Attorney

20090087391 - Foamable fluoride oral care composition: A dental fluoride foam composition comprising an aqueous solution of a water soluble fluoride ion releasable salt, a surfactant selected from the group consisting of nonionic surfactants, zwitterionic surfactants, betaine surfactants and mixtures thereof; and an orally compatible acidifying agent in an amount sufficient to adjust the pH of the... Agent: Colgate-palmolive Company

20090087395 - Compositions for use in darkening the skin: The present invention features a polymer for darkening the skin. The polymer comprises repeating units derived from melanin precursors and amine-comonomers. The polymer may be combined with a cosmetically acceptable carriers to form topical compositions. Methods of darkening the skin are also provided.... Agent: Philip S. Johnson Johnson & Johnson

20090087394 - Photostabilization of octyl triazone: Methods and compositions useful in enhancing protection from UV radiation, the compositions containing octyl triazone and diethylthexyl syringylidene malonate in an amount effective to photostabilize octyl triazone.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090087396 - Sweat-absorbing cosmetic product and method for the production thereof: The sweat-absorbing complex in the base formulation is present in the form of emulsified particles. The particles consist of a three-dimensional, water-swellable network of said at least one water-absorbing component and are at least partially covered with said at least one surface-active agent.... Agent: Norris, Mclaughlin & Marcus, P.A.

20090087398 - Method for treating damaged hair: The present invention relates to a method for treating damaged hair, where the hair is chemically treated, comprising the steps of: a) contacting the hair with a shampoo composition, the shampoo comprising: from about 5% to about 50% of an anionic surfactant; from about 0.025% to about 5% by weight... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090087399 - Polysiloxane block copolymers: The invention relates to polysiloxane block copolymers of the formula A[LB(S)Q]m, where A is a polysiloxane block, L is a divalent organic linker, B is a polymer block composed of radically polymerizable monomers, S is a sulfur atom and Q is a monovalent organic radical and m is an integer... Agent: Frommer Lawrence & Haug

20090087400 - Breathable polyurethanes, blends, and articles: e

20090087397 - Mascara composition: Mascara compositions containing a keratin conditioning agent, alone or in combination with an emollient/moisturizing agent, provide increased resistance of eyelash hair fibers to breaking. Low viscosity mascara composition of the invention containing low concentrations of surfactant and wax are easily removable from the eyelashes. Mascara compositions of the invention reduce... Agent: Avon Products, Inc.

20090087402 - Cyclopropanated macrocyclic ketones and lactones: s

20090087401 - Deodorant composition: It is intended to provide a novel deodorant composition which is excellent in the deodorizing effect, is capable of affording a deodorant composition by a convenient method, and shows no decrease in the deodorizing performance even after a long period of time, once the deodorant being prepared. Specifically, there is... Agent: Sughrue-265550

20090087403 - Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20090087404 - Methods of treating cancer using il-21 and monoclonal antibody therapy: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with... Agent: Zymogenetics, Inc. Intellectual Property Department

20090087405 - Use of lck inhibitors for treatment of immunologic diseases: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090087407 - Methods for the treatment of scleroderma using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline: Methods of treating, preventing, correcting and/or managing skin diseases or disorders characterized by overgrowths of the epidermis, keratoses, scleroderma, cutaneous vasculitis, acne or wrinkles are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in... Agent: Jones Day

20090087406 - Reverse micelles based on phytosterols and acylglycerols and therapeutic uses thereof: The present invention relates generally to reverse-mice liar system comprising a hydrosoluble therapeutically active agent. Reverse micelles according to the invention are particularly useful to deliver drugs. The present invention also relates to pharmaceutical composition comprising said reverse micelles and methods for preparing the same.... Agent: Hunton & Williams LLP Intellectual Property Department

20090087408 - Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device: The present invention provides a suspension vehicle and suspension formulations deliverable from an implantable delivery device. In particular, the suspension vehicle of the present invention allows the formulation of beneficial agent suspensions that are stable over time at ambient and physiological temperatures. In addition, the beneficial agent suspensions formed using... Agent: Intarcia Therapeutics, Inc. Attn: Barbara G. Mcclung

20090087409 - Viral polymerase inhibitors: R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, all of which optionally substituted with R90; or R9 is covalently bonded to either of R7 or R8 to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, as an inhibitor of HCV NS5B... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090087411 - Long-acting interferons and derivatives thereof and methods thereof: A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.... Agent: Pearl Cohen Zedek Latzer, LLP

20090087410 - Treatment of hypersensitivity: The present invention relates to a method for inhibiting a hypersensitivity reaction in a subject, wherein said method comprises administering an effective amount of chaperonin (10).... Agent: Townsend And Townsend And Crew, LLP

20090087412 - Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression: The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+ stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of... Agent: Fulbright & Jaworski L.L.P.

20090087413 - Self-complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders: The invention provides methods for delivering interfering RNA molecules to an eye of a patient to treat ocular disorders. In particular, the methods of the invention comprise the use of a self-complementary adeno-associated (scAAV) viral vector that can deliver an interfering RNA molecule to an eye of a patient to... Agent: Alcon

20090087416 - B7-h3 and b7-h4, novel immunoregulatory molecules: The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.... Agent: Fish & Richardson P.C.

20090087417 - Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands: Methods for promoting dopaminergic neuronal development and producing neural cells having a dopaminergic phenotype. Dopaminergic neural cells may be used for treating individuals having a neurodegenerative disease such as Parkinson's disease. Dopaminergic cells may be implanted into the brain of the individual, and/or dopaminergic neural development may be induced or... Agent: Morrison & Foerster LLP

20090087418 - Method for the preparation of anallergic probiotic bacterial cultures and related use: The aim of the present invention is a method for the preparation of anallergic probiotic bacterial cultures.... Agent: Pearne & Gordon LLP

20090087414 - Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs: Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse... Agent: K&l Gates LLP

20090087415 - Treatment of cardiovascular disorders using the cell differentiation signaling protein nell1: It has been identified in accordance with the present invention that Nell1 is essential for normal cardiovascular development by promoting proper formation of the heart and blood vessels. The present invention therefore provides therapeutic methods for treating cardiovascular disorders by employing a Nell1 protein or nucleic acid molecule.... Agent: Scully Scott Murphy & Presser PC

20090087419 - Licorice polyphenol preparation: This invention provides a highly concentrated licorice polyphenol preparation with high bioavailability. Further, this invention is intended to maintain high transparency of a composition without deterioration of the indigenous properties of an aqueous substance, even when such composition is added thereto. Such licorice polyphenol preparation comprises a hydrophobic licorice extract... Agent: Sughrue Mion, PLLC

20090087420 - Stable solution of reduced coenzyme q: The present invention provides a composition of a practically usable solution capable of stably maintaining, against oxidation, reduced coenzyme Q, which has not been employed in practice so far because of being liable to undergo oxidation and hydrophobic, a method of preparing the solution and a method of storing the... Agent: Sughrue Mion, PLLC

20090087421 - Novel recombinant staphylokinase derivatives and the preparations and applications thereof: The present invention relates to the biotechnology field, more particularly, to novel recombinant staphylokinase (RGD/KGD-Sak) derivatives and the preparation the thereof. The derivatives, have a low polymerizing ability, low immunogenicity and a bifunctionality of thrombolytics and anticoagulant. Based on the line, structural analysis of the monomer and dimer of recombinant... Agent: Cook Alex Ltd

20090087422 - Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same: The present invention relates to pharmaceutical compositions for treating diseases and conditions caused by ischemia. The pharmaceutical compositions contain a conjugate of a phospholipase (PL) polypeptide and a protein transduction domain (PTD). PLC-δ plays a major role in the regulation of cytosolic calcium levels. During myocardial ischemia, cytosolic calcium accumulation... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090087425 - Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease: There is provided a pharmaceutical composition for treating respiratory disease comprising an NO-donating steroid and at least one bronchodilator. Also provided is a method for treating respiratory diseases associated with inflammation comprising administering an NO-donating steroid with at least one bronchodilator. Method of use of the combination of an NO-donating... Agent: Davidson, Davidson & Kappel, LLC

20090087426 - Methods for treatment of allergic asthma: Methods of treatment of allergic asthma with IgE antagonists, including anti-IgE antibodies, IgE variants, peptide antagonists, peptidomimetics and other small molecules, are described.... Agent: Genentech, Inc.

20090087424 - Modulating retinal pigmented epithelium permeaion by inhibiting or activating vegfr-1: Described is a method for use of an agonist or an antagonist of VEGFR-1 in the treatment or prevention of diseases wherein disorders of the retinal pigment epithelium permeation are involved.... Agent: Young & Thompson

20090087423 - Novel protein complex and use thereof: The present invention provides a novel binding protein, a preventive/therapeutic agent for cancer or neurodegenerative diseases, etc. Specifically, the substance that inhibits the binding of (a) a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 26, a... Agent: Edwards Angell Palmer & Dodge LLP

20090087427 - Biological materials and uses thereof: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and... Agent: Fish & Richardson P.C.

20090087428 - Anti-fc-gamma riib receptor antibody and uses therefor: The present application describes antibodies that selectively bind human FcγRIIB, with little or no binding to other human FcγRs, e.g., human FcγRIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds FcγRIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic... Agent: Genentech, Inc.

20090087429 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090087431 - Methods of treating bone disorders with modulators of axl: The invention provides methods for treating or preventing bone and cartilage disorders comprising administering to a mammal an inhibitor of Axl gene expression or an inhibitor of Axl protein activity.... Agent: Wyeth Patent Law Group

20090087430 - Selective inhibition of toll-like receptor-2: It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere... Agent: Fish & Richardson PC

20090087432 - Treating prostate cancer with anti-erbb2 antibodies: The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.... Agent: Goodwin Procter LLP

20090087433 - Actriib fusion polypeptides and uses therefor: Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis.... Agent: Wyeth/finnegan Henderson, LLP

20090087434 - Nfia in glial fate determination, glioma therapy and astrocytoma treatment: Disclosed herein are compositions comprising NFIA inhibitors, as well as methods of using the same to treat glioma and astrocytomas.... Agent: Knobbe Martens Olson & Bear LLP

20090087438 - Anti-tsg101 antibodies and their uses for treatment of viral infections: The present invention provides methods of using antibodies that bind a TSG101 protein to inhibit or reduce viral production. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV infection. The invention further provides methods of detecting viral infected cells using TSG101... Agent: Jagtiani + Guttag

20090087439 - Compositions and methods for diagnosing or treating psoriasis: In one aspect, the present invention provides isolated nucleic acid molecules that encode a CAN-1 polypeptide, or an STG polypeptide. In another aspect, the present invention also provides isolated STG polypeptides, isolated CAN-1 polypeptides, and isolated SEEK-1 polypeptides. In another aspect, the present invention provides isolated antibodies that bind specifically... Agent: Davis Wright Tremaine, LLP/seattle

20090087436 - Compositions and methods for treating diseases: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20090087435 - Isolated chimeric proteins of modified lumazine synthase: isolated chimeric proteins including up to ten copies of peptides, polypeptides or protein domains inserted in the amino termini of the Brucella spp. Lumazine synthase enzyme. Isolated nucleotide sequences codifying the chimeric proteins. Vectors, plasmids and transformed cells used for expressing the proteins. Monoclonal and polyclonal antibodies induced by the... Agent: Sughrue Mion, PLLC

20090087437 - Methods and compositions relating to the regulation of apoptosis by muc1 and bh3-containing proapoptotic proteins: This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or immune cell growth. The invention provides methods of inhibiting interactions between MUC1 and BH3-containing proapoptotic proteins, methods of inhibiting MUC1 expression, and methods of promoting apoptosis. Also provided are screening methods... Agent: Fulbright & Jaworski L.L.P.

20090087440 - Methods for treating cancer: Dendritic cells (DC) play a critical role in antigen-specific immune responses. Materials and Methods are provided for treating disease states, including cancer, by activating dendritic cells from the host which are rendered hypo-responsive to activation stimuli by the disease. In particular, methods are provided for treating cancer in a mammal... Agent: Dnax Research Inc. Legal Department

20090087441 - Wortmannin analogs and methods of using same in combination with chemotherapeutic agents: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.... Agent: Pepper Hamilton LLP

20090087442 - Antibodies that recognize hyperproliferative cells and methods of making and using same: The invention relates to antibodies that bind to antigens, such as antigens associated with hyperproliferating cells, and methods of treating hyperproliferative disorders. The invention antibodies are useful for treating hyperproliferative disorders, such as neoplasia.... Agent: Wilson Sonsini Goodrich & Rosati

20090087443 - Pharmacological adjunctive treatment associated with glaucoma filtration surgery: A composition for controlling or preventing progression of glaucoma comprises a material that reduces or inhibits production of a TGF-β isoform or a chemokine or cytokine that stimulates expression of a TGF-β isoform. The material can comprise a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt... Agent: Bausch & Lomb Incorporated

20090087444 - Pharmaceutical composition comprising polysaccharides from angelica gigas nakai for activation of dendritic cells: The present invention relates to a pharmaceutical composition for activating dendritic cells having polysaccharides from Angelica gigas Nakai as valid component. The angelan, polysaccharides separated from Angelica gigas Nakai, can improve the revelation of surface molecule of dendritic cells, the secret of cytokine of dendritic cells, the proliferation capability of... Agent: Jones Day

20090087446 - Combination motif immune stimulatory oligonucleotides with improved activity: Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5′ TCGTCGTTTTCGGCGCGCGCCGT 3′ (SEQ... Agent: Pfizer Inc

20090087445 - Method for the redox potential-dependent detection of target molecules by interacting polypeptides: The invention primarily relates to an amino acid sequence EKKEQKEKEK KEQEIKKKFK LTGPIQVIHL AKACCDVKGG KNELSFKQGE QIEIIRITDN PEGKWLGRTA RGSYGYIKTT AVEIDYDSLK LKKD (=SEQ ID NO 1), a protein recognition domain comprising said amino acid sequence, the use of said amino acid sequence or protein recognition domain for identifying redox-dependent protein-protein or protein-lipid interactions,... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090087447 - Novel hcv non-structural polypeptide: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are... Agent: Novartis Vaccines And Diagnostics Inc.

20090087448 - Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production: The present invention generally relates to the field of immunology and provides immunoprotective compositions and methods for preparing such compositions from transgenic plant cells. The present invention also relates to the field of protein production (e.g., the recombinant production of enzymes, toxins, cell receptors, ligands, signal transducing agents, cytokines, or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090087449 - Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus: The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least... Agent: Clark & Elbing LLP

20090087450 - Combination therapy of hybrid cells with bcg injection for treating cancer patients: The present invention relates to cancer treatment compositions and methods for a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation in combination with Mycobacterium bovis bacillus Calmette-Guerin (BCG).... Agent: David W. Clough Howrey LLP

20090087451 - Methods and compositions for vaccination: The invention provides kits, methods and compositions of matter which improve the safety of vaccination. By combining the administration of antiviral drugs, particularly ester derivatives of cidofovir, with the administration of viral vaccines, particularly the variola vaccine DryVax, side effects of the vaccine are diminished without significantly affecting the effectiveness... Agent: Husch Blackwell Sanders LLP

20090087452 - Methods and apparatus for the production of viral vaccines: A viral vaccine in the dried state is described. Methods for drying viral vaccine in the liquid state into viral vaccine in the dried state are presented. The methods may include introducing the viral vaccine in the liquid state into a gas stream and recovering viral vaccine in the dried... Agent: Cyr & Associates, P.A.

20090087453 - Virosome particles comprising antigens from influenza virus and hepatitis b virus: The present invention provides a virosome comprising a virosomal membrane comprising at least one lipid and envelope proteins of an enveloped virus and of the virosome and attached to said envelope proteins. Furthermore, the invention provides a vaccine comprising the virosome of the invention and, a method for the production... Agent: Trask Britt

20090087454 - Method for therapeutic, clinical and veterinary use poly-iclc: We disclose here a method for using Poly-ICLC to prevent and/or treat certain human and veterinary infectious, neoplastic and autoimmune disorders, as well as for regulating a broad variety of genes in humans, consisting of use of poly-ICLC repeatedly and at low doses, alone or in combination with other drugs... Agent: Mr. Max Stuhl Oppenheimer

20090087455 - Adipogenic adenoviruses as a biomarker for disease: A vaccine may be administered to a subject to prevent-related disease due to an adipogenic adenovirus. The vaccine may stimulate the production of adipogenic adenovirus neutralizing antibodies in the subject such that the adipogenic adenovirus neutralizing antibodies prevent obesity-related disease due to an adipogenic adenovirus.... Agent: Townsend And Townsend And Crew, LLP

20090087456 - Adjuvanted vaccine: This invention relates to new immunogenic compositions and vaccines suitable for preventing or treating tularemia.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090087458 - Activatable recombinant neurotoxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Allergan, Inc.

20090087457 - Compositions and methods for topical application and transdermal delivery of botulinum toxins: Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations... Agent: King & Spalding

20090087459 - Methods for treating eye disorders: The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis,... Agent: Allergan, Inc.

20090087460 - Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these: In a dissolving step, in a container 13, a poorly soluble drug and a dispersion stabilizer (polyvinylpyrrolidone and sodium lauryl sulfate) are dissolved in a volatile organic solvent. In a solid composition forming step following the dissolving step, the organic solvent contained in the solution is removed by evaporation, and... Agent: Drinker Biddle & Reath (dc)

20090087461 - Anti-bacterial pyrocatechols and related methods: wherein m is an integer of 0 to 100, R is independently selected from a first hydrocarbon structure having from 1 to 50 carbon atom and R1 and R2 are independently chosen from a hydrogen atom and a second hydrocarbon structure having 1 to 10 carbon atoms. Related methods are... Agent: Colgate-palmolive Company

20090087463 - Cosmetic containing glass flakes: A cosmetic of the present invention contains glass flakes. The glass flakes have a composition including at least 52 mass % of silicon dioxide and 5 mass % or less of alkali metal oxides. The glass flakes have an average thickness of 0.1 to 1.0 μm, an average particle diameter... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090087464 - Particle stabilised emulsion composition: The present invention relates to emulsifier system comprising food-grade gelled particles and the preparation of particle stabilised emulsions with this emulsifier. The emulsifier system can be used in any fields of applications, such as food products, home and personal care applications and pharmaceutical applications.... Agent: Unilever Patent Group

20090087462 - Use of pyrimidine derivatives for cosmetic purposes: The present invention is directed to the use of certain pyrimidine derivatives for cosmetic purposes, i.e. for the preparation of a composition for providing a cosmetic effect. It was found that said pyrimidine derivatives are particularly useful for treating wrinkles but also for thickening the epidermis, for improving hair growth... Agent: Nixon & Vanderhye, PC

20090087465 - Saline nose wipe and methods of manufacture and use: The present invention generally relates to a wet wipe or sheet that is suitable for contacting the skin and removing mucus from the skin. More specifically, the present invention relates to a wet wipe having an aqueous saline component suitable for dissolving and removing mucus in combination with the fabric... Agent: Kolisch Hartwell, P.C.

20090087466 - Process for providing antimicrobial surfaces: Processes for providing durable antimicrobial surfaces are disclosed that comprise treating a polymer substrate surface with formaldehyde followed by treatment with an antimicrobial peptide. Further embodiments include articles, including medical devices, characterized by a durable antimicrobial surface provided by the processes of the invention.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090087468 - Semi-rigid gel article for disinfecting a surface: The present invention relates to a semi-rigid gel article which contains an antibacterial agent and can be used for disinfecting and/or cleaning a surface. More particularly, the article comprises water, a gelling agent, an antibacterial agent and wherein the article is capable of disinfecting a surface by contacting the surface... Agent: The Clorox Company

20090087467 - Solid formulations of hydrogen cyanamide for agricultural applications: Agricultural crops are protected from the growth of weeds and other undesirable organisms by the application of hydrogen cyanamide in a granular formulation.... Agent: Townsend And Townsend And Crew, LLP

20090087469 - Alginate-based nanofibers and related scaffolds: Alginate nanofibers, scaffolds that include alginate nanofibers, implantable devices that include alginate nanofibers, and methods for making the alginate nanofibers by electrospinning.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090087470 - Controlled release formulations of octreotide: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a... Agent: Foley And Lardner LLP Suite 500

20090087472 - Controlled release of biopharmaceutical growth factors from hydroxyapatite coating on bioresorbable interference screws used in cruciate ligament reconstruction surgery: Controlled release of biopharmaceutical growth factors from a hydroxyapatite coating on a bioresorbable interference screw used in cruciate ligament reconstruction surgery on a human. Biologically active scaffolds, such as interference bone screws used for ligament fixation, made by growing calcium phosphate-based hydroxyapatite coatings on bioresorbable poly(α-hydroxy ester) scaffolds that provide... Agent: Quarles & Brady LLP

20090087471 - Method of treating tissue: In one embodiment, the method comprises providing tissue, preparing the tissue, and treating the tissue to improve remodeling characteristics of the tissue. The tissue may be, for example, cortical bone. Treating the tissue to improve remodeling characteristics may comprise heating the tissue, treating the tissue with a chemical, or other.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090087473 - Osteoinductive bone graft material and manufacturing method: In order to promote a bone regeneration, atelocollagen, collagen or metal to be utilized as a biomaterial is immersed in an organic solvent solution containing dissolved silanol polyhedral oligomeric silsesquioxane or silanol, then the immersed material is taken out of the solution and dried, and the dried silanol polyhedral oligomeric... Agent: Jacobson Holman PLLC

20090087474 - Therapeutic use of growth factors,nsg29 and nsg31: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on secreted therapeutic proteins, NsG29 and NsG31. NsG29 and Ns31 are members of a newly identified family of growth factors with a specific cystein pattern and characterised by expression... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090087475 - Non-wovens with high interfacial pore size and method of making same: A Nonwoven fibrous structures with a high interfacial pore size and substrates made therefrom are provided. The substrates may be used, for example, in wipes. In one embodiment, the wipes include a hydromolded pattern on one side. The hydromolded pattern has an average pore-size of the interface between two stacked... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090087477 - Methods for preparing reverse micelles based on sterols and acylglycerols for the delivery of metal ions: The present invention relates to a method for the preparation of reverse micelles based on sterols, acylglycerols and metal salt and to reverse micelles obtained thereby. They are advantageously useful in the pharmaceutical and dietetic fields.... Agent: Hunton & Williams LLP Intellectual Property Department

20090087481 - Methods of treating neurological conditions with hematopoeitic growth factors: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090087479 - Orally bioavailable lipid-based constructs: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetucic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090087478 - Orally deliverable and anti-toxin antibodies and methods for making and using them: The invention provides antibodies with superior therapeutic efficacy and related methods of engineering such antibodies to increase their stability and resistance to proteases, e.g., in the digestive tract. Protease cleavage motifs are identified and subsequently modified to reduce or eliminate cleavage at that site. Methods of employing these orally deliverable... Agent: Kelley Drye & Warren LLP

20090087480 - Pharmaceutical composition and method using antifungal agent in combination: (wherein R1 represents an amidino group that may be substituted with a hydroxyl group that may be protected with an acyl group, an amidino group that may be substituted with an alkoxy group that may be substituted, or an amidino group that may be substituted with an aralkyloxy group that... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090087476 - Prosaposin as a neurotrophic factor: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.... Agent: Kenyon & Kenyon LLP

20090087482 - Temperature-sensitive liposomal formulation: A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090087483 - Oral dosage combination pharmaceutical packaging: Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation from a secondary module. In a preferred embodiment the first and second pharmaceutical formulations are separated from one another in a... Agent: Hayes Soloway P.C.

20090087484 - Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules: A formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules includes a permeation enhancer, a hydrophilic macromolecule, and a carrier such as a nonionic surfactant that exhibits in-situ gelling properties. The formulation is delivered within the GI tract as a liquid having at least some affinity... Agent: Philip S. Johnson Johnson & Johnson

20090087485 - Orally disintegrating tablets: The present invention describes a directly compressible composite excipient prepared by coating calcium silicate with a carbohydrate. The present invention further describes the incorporation of the composite excipient into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity.... Agent: Mallinckrodt Inc.

20090087486 - Foam wafer containing a polyvinyl alcohol-polyethyleneglycol-graft copolymer: Sheet-like dosage forms dissolving or disintegrating in an aqueous medium for releasing at least one active substance in a body orifice or body cavity. The sheet-like dosage forms comprise a polymer matrix in the form of a solidified foam containing spaces or cavities, as well as at least one pharmaceutical... Agent: D. Peter Hochberg Co. L.p.a.

20090087487 - Paliperidone sustained release formulation: The present invention provides sustained release dosage forms comprising Paliperidone and processes for preparing the same.... Agent: Kenyon & Kenyon LLP

20090087488 - Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use of the manufacture of a medicament: The present invention relates to controlled release oral dosage forms of galantamine or acceptable salts thereof and processes for the preparation thereof.... Agent: Ranbaxy Inc.

20090087489 - Imatinib compositions: The invention relates to a pharmaceutical composition, preferably a tablet, containing about 23-29% w/w imatinib and processes for its preparation.... Agent: Kenyon & Kenyon LLP

20090087490 - Extended release formulation and method of treating adrenergic dysregulation: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of... Agent: Myers Bigel Sibley & Sajovec

20090087491 - Method for preparing particles from an emulsion in supercritical or liquid co2: The present invention relates to a method for preparing particles, notably particles encapsulating an active substance. It also relates to particles obtainable by this process, dispersion thereof, and their use as a vehicle for pharmaceutical, cosmetic, diagnostic, veterinary, phytosanitary active substances or processed foodstuff.... Agent: Stites & Harbison PLLC

20090087492 - Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use: The present invention relates to a process, for the production of crystalline particles of an active organic compound The process includes the steps of generating a micro-seed by a wet-milling process and subjecting the micro-seed to a crystallization process. The resulting crystalline particles have a mean particle size of less... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090087493 - Supramolecular functionalization of graphitic nanoparticles for drug delivery: Disclosed are nanoparticles, such as carbon nanotubes or other materials having extended aromatic surfaces (e.g., graphene sheet or nanotube), which are used to deliver active agents such as drugs, labels or dyes (termed for convenience a “drug”) to the interior of cells. The nanoparticles are functionalized by a hydrophilic polymer... Agent: Peters Verny , L.L.P.

20090087494 - Methods and compositions for targeted delivery of therapeutic agents: Compositions and methods for targeted delivery of therapeutic agents, and particularly for mucosal, oral, nasal, or parenteral delivery of therapeutic agents. The compositions comprise carrier particles containing or encapsulating a therapeutic agent or agents, which have been modified on their surface to contain one or more targeting moieties that enable... Agent: Edell, Shapiro & Finnan, LLC

20090087495 - Food for improving motor function: A food for improving motor function comprising as effective components carnosine and/or anserine and a material for improving motor performance (a material for motor energy source, a material for promoting conversion into energy and/or an antioxidant) is provided. In the invention, by synergistic effect of these components, the motor function... Agent: Birch Stewart Kolasch & Birch

20090087496 - Process for preparing mixed metal oxide powders: Process for preparing a mixed metal oxide powder, in which oxidizable starting materials are evaporated and oxidized, the reaction mixture is cooled after the reaction and the pulverulent solids are removed from gaseous substances, wherein as starting materials, at least one pulverulent metal and at least one metal compound, the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090087497 - Compositions and methods for treating symptoms of aging: Compositions and methods are provided that are based on a discovery that a combination of three compounds, doxycycline, selenium, and zinc, retards physiological age-related changes (for example cardiac aging and the decline in exercise capacity) and can also prolong survival.... Agent: Bio Technology Law Group C/o Portfolioip

20090087498 - Shampoo formulation for treatment of hair loss and method of use: A shampoo formulation comprising a shampoo, bicarbonate soda, and onion skins used alone or in combination with a conditioner comprising acetic acid for the treatment of hair loss and promotion of hair growth.... Agent: Cislo & Thomas LLP

20090087499 - Depilatory product: The invention comprises a depilatory product based on a complexing gel. The product will remove the hair via reduction and hydrolysis as do chemical depilatories. Despite the peeling nature of the product, the hair is not removed by pulling it out like a wax depilatory. The product is to be... Agent: Schweitzer Cornman Gross & Bondell LLP

20090087500 - Guava leaf extract powder and method for production thereof: The invention provides a method for producing a guava leaf extract powder, including extracting guava leaves with hot water at 90 to 98° C.; concentrating the obtained extract to a Brix level of 20 to 30; and lyophilizing the concentrated extract, and a guava leaf extract powder produced through the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090087501 - Oral compositions containing botanical extracts: The disclosure provides oral compositions having at least two botanical active ingredients derived from plants. The oral composition also includes an orally acceptable vehicle to deliver an effective amount of the at least two active ingredients in vivo. The botanical active ingredients provide particularly efficacious antimicrobial (antibacterial, antiviral, and/or antifungal),... Agent: Colgate-palmolive Company

20090087502 - Non-toxic antimicrobial composition: Disclosed herein are non-toxic antimicrobial compositions for cleaning, reducing the bioburden and substantially killing gram negative and positive bacteria on hard surfaces. The antimicrobial compositions comprise about 0.01% to about 4.0% by weight of one or more oils selected from the group comprising rosemary oil, tea tree oil, spearmint oil,... Agent: Ashok Tankha

20090087504 - Method for treating diabetic complications: The present invention relates to a method for treating diabetic complications, which comprises administering an extract obtained by: crashing and drying any one selected from Euphorbiae radix, gingered Magnolia bark, parched Puerariae radix and Glycyrrhizae radix; extracting the dried herbal material with alcohol or aqueous alcohol solution; filtering the extract;... Agent: Birch Stewart Kolasch & Birch

20090087503 - Use of anabolic agents, anti-catabolic agents, antioxidant agents and analgesics for protection, treatment and repair of connective tissues in humans and animals: The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine,... Agent: Covington & Burling, LLP Attn: Patent Docketing